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The Glu-Leu-Arg (ELR)(+) chemokine C-X-C ligand 1 (CXCL1) is widely 
known to be involved in the recruitment of neutrophils to sites of inflammation by 
binding to the receptor C-X-C receptor 2 (CXCR2) expressed on the surface of 
neutrophils. The role of neutrophils in central nervous system (CNS) diseases has not 
been well characterized. Thus, we wanted to better understand the role of the 
CXCL1/CXCR2 signaling axis in the context of mouse models of the human 
demyelinating disease multiple sclerosis (MS), including infection with the JHM strain of 
mouse hepatitis virus (JHMV) and the myelin oligodendrocyte glycoprotein (MOG) 
peptide from amino acid 35 to 55 (MOG35-55)-induced Experimental Autoimmune 
Encephalomyelitis (EAE) model. In both models, the doxycycline (Dox)-inducible 
expression of CXCL1 from astrocytes selectively increased the recruitment of neutrophils 
into the spinal cord, correlating with an increase in both morbidity and demyelination. 
Antibody-mediated depletion of neutrophils during the overexpression of CXCL1 in the 
CNS correlated with a decrease in the severity of demyelination, indicating a role for 
neutrophils in white matter disease in JHMV-infected mice and MOG35-55-induced EAE.  
During CNS development, proliferation and migration of oligodendrocyte 
progenitor cells (OPCs) was dependent upon surface expression of the chemokine 
receptor CXCR2; genetic ablation of Cxcr2 resulted in misalignments in oligodendrocyte 
lineage cells (OLCs), decreased white matter in the spinal cord, and decreased myelin 
iv 
sheath thickness. Subsequent studies have determined that CXCR2 signaling has 
important roles on both hematopoietic and non-hematopoietic cells in remyelination in 
different models of demyelination. To better determine the role the CXCR2 signaling on 
OLCs during the pathogenesis of JHMV and MOG35-55 EAE, mice were engineered in 
which CXCR2 expression was inducibly ablated on oligodendroglia upon treatment with 
tamoxifen. Using both the JHMV infection and EAE models, we observed no significant 
changes in clinical disease, demyelination, or leukocyte infiltration into the CNS 
following tamoxifen-induced ablation in oligodendrocytes, indicating that CXCR2 in 
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1.1 Multiple sclerosis 
Multiple sclerosis (MS) is a chronic inflammatory and demyelinating autoimmune 
disease that affects the central nervous system (CNS) (1, 2). Diagnosis of the disease 
typically ranges between 20 and 40 years of age and similar to most other autoimmune 
diseases, affects more women than men at a 2-3:1 ratio (3, 4). To date, over 2.5 million 
people have MS and this number continues to rise (3, 5). MS is considered to be a 
misguided T cell attack to proteins embedded within the myelin sheath in the CNS. 
Nonetheless, both the innate and adaptive immune response have been shown to be 
involved in the pathogenesis of MS, including infiltrating macrophages, activated 
microglia, natural killer (NK) cells, dendritic cells (DCs), T helper 1 (Th1) and T helper 
17 (Th17) CD4+ T cells, CD8+ T cells, B cells, and plasma cells (3). In addition, 
emerging evidence has begun to show that neutrophils may also be involved in the 
pathogenesis of MS, by both studies in preclinical animal models of MS e.g. 
Experimental Autoimmune Encephalomyelitis (EAE) and indirect evidence in MS 
patients (4, 6-11). While there is no cure for MS, there are many approved therapies that 
can dampen disease and decrease relapses (12). Current disease modifying therapies 
(DMTs) that have been effective for MS have mainly been developed to dampen the 
adaptive immune response, indicating that B and T cells play a large role in the 
pathogenesis of the disease by dampening new lesion formation and rate of relapse in 
relapsing remitting MS (RR-MS) patients (5, 13, 14). Symptoms of MS can still occur in 
patients on these DMTs, arguing that both B and T cells are not the only cell types 
involved in MS pathogenesis, thus new DMTs for the innate immune response need to be 
studied and developed to dampen MS symptoms (5, 13, 14).  
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Environmental factors that may contribute to development of MS include 
prepubescent development in latitudes higher than 40o, vitamin D deficiency, Epstein-
Barr virus (EBV) infection as a child, and cigarette smoke (15-17). In addition to EBV, 
other pathogens have been identified to be linked to the development and/or exacerbation 
of MS, including human herpesvirus 6 (HHV-6), and human endogenous retroviruses 
(HERV) that may lead to induction of MS through molecular mimicry (18-20). Bacterial 
infections by Mycoplasma pneumoniae, Chlamydia pneumoniae, Streptococcus 
pneumoniae, and the production of superantigens from Staphylococcus aureus, as well as 
infection by the protozoa Acanthamoeba castellanii have also been suggested to be risk 
factors associated with development of MS (18). In contrast, many species of helminthes 
infections have been associated with a decrease in risk for the development of MS and 
this has been suggested to be associated with elevated T helper 2 (Th2) immune 
responses (18). The fact that autoimmune diseases, such as MS, have risen in the past 3 
decades in developing countries has given evidence to the hygiene hypothesis, which 
states that the decrease in the incidence of infectious diseases due to clean water, 
improved hygiene, antibiotics, and vaccinations leads to an increase in autoimmune 
diseases (21, 22).  
During the early stage of MS pathology, there are acute regions of inflammation 
within the white matter of the CNS resulting in demyelination (23). Oligodendrocytes 
will then become destroyed and/or damaged; in addition, axonal conduction will become 
impeded due to the loss of myelin. This is why many patients will have the following 
common symptoms that can impair their quality of life, including walking difficulties, 
sensory disturbances, vision problems, cognitive issues, depression, and intestinal and 
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sexual dysfunctions (2, 4, 24). In RR-MS patients, episodic focal attacks correlating with 
many of these common symptoms typically occur, varying in duration from 24 hours to 
many weeks, which typically completely resolve (25). The remission in these patients is 
related to decreases in inflammation and partial remyelination to restore some of the lost 
axonal conduction (26, 27). While oligodendrocyte progenitor cells (OPCs) are typically 
dispersed throughout a healthy CNS, in subacute lesions within the CNS in MS patients, 
they can be enriched (28). In addition, perivascular infiltrates into the CNS that migrate 
and accumulate within subacute lesions of demyelination include activated CD4+ T cells, 
CD8+ T cells, and macrophages interacting with local reactive microglia to release 
various proinflammatory cytokines dysregulating oligodendrocytes (23, 29). In addition, 
CD8+ T cells that are clonally expanded and major histocompatibility complex (MHC) 
class I restricted appear close to demyelinated axons during MS, thought to interact with 
myelin protein epitopes (30). Patients will form what are known as shadow plaques in 
previously demyelinated areas; these are remyelinated white matter areas due to the 
maturation of OPCs and produce very thin myelin sheath surrounding axons (28, 31-34). 
There are two main forms of MS with which patients can be diagnosed; 85% of 
diagnosed patients have the RR-MS form, while 15% of patients are diagnosed with the 
primary progressive form (PP-MS) (4). After 30 years with RR-MS, approximately 66% 
of patients will develop a more progressive form of the disease termed secondary 
progressive MS (SP-MS) (4). Progressive forms of MS do not have stages of remission 
and instead, symptoms will progressively get worse. The progressive form of disease 
does not consist much of the adaptive immune system, although axonal degeneration and 
grey matter neuropathy persist (35-38). Microglial activation within the CNS, plus 
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macrophages, T cells, and B cells, are observed near the border of preformed MS lesions 
(39, 40). While OPCs are known to aid in the remyelination process, OPCs ultimately fail 
at remyelinating damaged areas of the CNS, resulting in an inability to recover (26, 41).  
 
1.2 Introduction to mouse hepatitis virus 
Mouse hepatitis virus (MHV) is a member of the family Coronaviridae, a virus 
family of enveloped positive-sense single-stranded ribonucleic acid (RNA) (26-32kb) 
viruses (42). MHV has many different strains that can cause various pathologies in mice 
depending on both strain and age. These include the enterotropic strain MHV-Y, which is 
highly contagious and can lead to outbreaks in housed lab mice colonies causing enteritis; 
the hepatotropic strain MHV-2, causing hepatitis by intraperitoneal (i.p.) injection or 
neurotropic after intracranial (i.c.) injection leading to minor meningitis; and the MHV 
A59 strain, which is both neurotropic and hepatotropic following i.c. injection that infects 
neurons and glia in the CNS giving the mice mild encephalomyelitis and some 
demyelination, while only i.p. injection gives rise to hepatitis (43-46). In addition, the 
well-studied neurotropic strain of MHV is the neuroattenuated J2.2v-1 variant of the John 
Howard Mueller strain, termed JHMV, causes acute encephalitis that leads to chronic 
demyelination in susceptible adult mouse strains (47-50). Demyelination and chronic 
neuroinflammation in JHMV-infected mice occurs due to the chronic persistence of viral 
RNA in the white matter tracts (51). Lab strains of mice susceptible to JHMV infection 
within the CNS are used as a model of viral-induced demyelination and 
encephalomyelitis to study the human demyelinating disease MS (52). There are many 
preclinical models that recapitulate clinical and histological symptoms of MS. An 
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environmental trigger that is proposed to contribute to inducing MS clinical symptoms in 
genetically susceptible people is viral infection; thus, studying JHMV will give insights 
into viral-induced demyelination/remyelination during persistent neurotropic viral 
infection. 
JHMV was derived from the highly lethal JHM-DL laboratory strain using a 
monoclonal antibody (mAb) (49, 50). JHMV is a model to study aspects of viral infection 
within the CNS for both viral-induced encephalomyelitis and mechanisms regarding 
neuroinflammation. It is also used as a model for the human demyelinating disease MS to 
study immunological mechanisms contributing to viral-induced demyelination as well as 
to study remyelination during in the chronic stage of disease. 
The route of infection of JHMV is by direct i.c. infection that first leads to 
infection and replication of ependymal cells of the lateral ventricles and subsequently 
infects astrocytes, oligodendrocytes, and microglia by binding to the surface-expressed 
receptor carcinoembryonic antigen cell adhesion molecule 1 (CEACAM1a) (47-49, 53). 
Viral titers analyzed by plaque assay within the CNS peak around day 5-7 post-infection 
(p.i.) and by 14 days post-infection (d.p.i.), no viral replication is detectable, although 
viral RNA persists within the CNS and leads to a continued neuroinflammation, immune 
cell infiltration, and demyelination that does not completely resolve (42, 48, 54, 55). 
Following i.c. infection with JHMV, the innate antiviral response is rapidly 
initiated within 48 hours with localized expression of proinflammatory cytokines and 
chemokines including interleukin-1α (IL-1α), IL-1β, IL-6, IL-12, and tumor necrosis 
factor-α (TNF-α) and the production of matrix metalloproteinases (MMPs) (47, 56-58). 
Similar to almost all viral infections, the type I interferon response is an important 
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immune response for host defense to JHMV infection through the production of 
interferon-α (IFN-α) early during disease (57, 58). The first cell types infiltrating into the 
CNS are part of the innate immune response and these include neutrophils, NK cells, and 
infiltrating monocytes/macrophages (42, 48). During JHMV infection, 
monocytes/macrophages expressing the chemokine C-C receptor 2 (CCR2) are recruited 
to the CNS by responding to its C-C ligand 2 (CCL2) (59-61). Extensive research into 
aspects of the innate immune response have shown that both neutrophils and 
monocytes/macrophages are important for breaking down the blood brain barrier (BBB) 
by the production of MMPs and this facilitates CNS entry of virus-specific T cells that 
aid in controlling viral replication (56, 61-64). NK cells have been shown to not be 
important for viral clearance (65).  
Ultimately, the adaptive immune response is required for control of JHMV within 
the CNS. This is done primarily by virus-specific CD4+ and CD8+ T cells, which first 
expand in the draining cervical lymph nodes, and then traffic through the BBB and into 
the CNS by responding to the chemokines CCL5, CXCL9, and CXCL10 (66-71). CCR2 
ablation, but not its ligand CCL2, impeded recruitment of virus-specific T cells to the 
CNS, resulting in an increase in mortality following JHMV infection of the CNS and it is 
believed to be due to CCR2 expression on endothelial cells to aid in the breakdown of the 
BBB (59, 72). In addition, CCL2 signaling is involved in the recruitment of 
monocytes/macrophages to the CNS during JHMV infection by binding to CCR2 
expressed on the surface of these cells (59-61). To help control viral replication during 
JHMV infection, antigen presenting cells (APCs) will increase MHC class I and II 
molecules and by the recruitment of virus-specific CD4+ and CD8+ T cells into the CNS 
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limiting replication within astrocytes, oligodendrocytes, and microglia via production of 
IFN-γ; in contrast to perforin secretion by CD8+ viral-specific T cells for the control of 
replicating virus from astrocytes and microglia (42, 54, 73-76). 
Although virus-specific T cells help control JHMV replication within infected 
cells, sterile immunity is not achieved and virus persists primarily within white matter 
tracts. During chronic JHMV infection, viral recrudescence is controlled by antibody-
secreting cells (ASCs) and ablation of these cells results in the reappearance of 
replicating virus (54, 55, 77-80). While infiltrating T cells and macrophages are 
important in controlling viral replication during acute disease, these cells are also 
responsible for the demyelination observed in the spinal cord of JHMV-infected mice 
(48). In addition, during both the acute and chronic stages of disease, chemokine and 
chemokine receptor production within the CNS leads to chronic neuroinflammation and 
demyelination (42, 48). 
 
1.3 Neutrophils, BBB breakdown, and CXCR2 signaling during  
acute JHMV-induced disease 
Neutrophils are part of the innate immune system and are well studied in the 
context of killing of invading pathogens by releasing toxic factors, including the release 
of microbicidal granules, neutrophil extracellular traps (NETs), reactive oxygen and 
nitrogen species, and the ability to phagocytize invading pathogens to digest them (81-
84). However, how neutrophils aid in host defense in response to viral infection of the 
CNS has been less well characterized. Some examples of how neutrophils are involved in 
CNS viral infection include promoting vascular leakage and lethality in the acute phase 
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of disease during lymphocytic choriomeningitis virus (LCMV) and enhancement of the 
expression of the neutrophil attracting chemokine, CXCL5, during human 
immunodeficiency virus 1 (HIV-1) that contributes to neuronal death (85, 86). 
Furthermore, neutrophil depletion during West Nile virus (WNV)-induced neurologic 
disease in mice has shown to play either a beneficial or detrimental role, depending on 
when neutrophils were depleted (87). 
In other preclinical CNS models of neurodegenerative disease, the depletion of 
neutrophils was beneficial. Decreased recruitment of neutrophils into the CNS by 
CXCR2 antagonism during middle cerebral artery occlusion resulted in a reduction in 
neurological deficits and infarct volume (88). In addition, when neutrophils were 
depleted in a model of aneurysmal subarachnoid hemorrhage, the mice showed memory 
improvements (89, 90). Lastly, in a model for Alzheimer’s disease (AD), targeting 
neutrophil recruitment to the CNS reduced gliosis and cognitive decline (91). Neutrophils 
have been shown to aid in breakdown of the BBB early during disease/injury, leading to 
the enhancement of CNS inflammation in animal models of spinal cord injury, 
autoimmune demyelination, and viral-induced demyelination (56, 92-95). Together, these 
data show that neutrophils within the CNS can act as a double-edged sword and that early 
during infection, they can help open the BBB to allow for clearance of infectious virus, 
although it is possible that neutrophils can amplify disease due to the secretion of toxic 
factors and new studies will be needed to better understand the role of prolonged 
neutrophil infiltration into the CNS during JHMV infection.  
 Chemokines and chemokine receptors are important for the recruitment of 
leukocytes to sites of inflammation (96-99). Chemokines have been shown to be 
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important during different biological processes, including organogenesis, maturation and 
migration of stem cells, formation of secondary lymphoid tissues, and angiogenesis (98-
105). Of particular interest is the chemokine receptor CXCR2, which is present mainly on 
neutrophils and is important for neutrophil chemotaxis out of the bone marrow and to 
sites of inflammation (84). The chemotaxis of the CXCR2+ neutrophils occurs when 
ELR(+) CXC chemokines e.g. CXCL1, 2, 5, and 7 are expressed in inflamed tissue (84, 
96). In addition to neutrophil chemotaxis, signaling through CXCR2 is important in 
oligodendrocyte precursor positioning during CNS development, can be anti-apoptoic, 
enhance the production of growth factors, and can modulate synaptic transmission (96). 
In humans, these ELR(+) CXC chemokines will bind the receptors CXCR1 and CXCR2, 
(96, 106).  
In the cerebrospinal fluid (CSF) of MS patients, CXCL8 was elevated and 
neutrophils were observed in the CSF correlating with clinical relapse (8, 96, 107). In 
addition, Segal and colleagues have recently shown that in the plasma of RR-MS 
patients, there is an increase in CXCL1, CXCL5, and neutrophil elastase in patients with 
new lesion formation and an increase in plasma levels of CXCL1, neutrophil elastase, 
CCL11, and granulocyte-colony stimulating factor (G-CSF) in SP-MS patients correlated 
with overall CNS tissue damage by T2 lesion volume analysis (6, 11). Transcriptional 
profiling studies of lesions from MS patients showed an increase of IL-6, IFN-γ, and IL-
17 (10). Thus, the elevated levels of ELR(+) CXC chemokines in MS patients may be 
due to the production of IL-17 from Th17 cells, which are known to be recruited to the 
CNS and can signal through the IL-17 receptor, potentially enhancing expression of these 
chemokines (108-114).  
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In an early study of transgenic mice in which CXCL1 was constitutively 
expressed from oligodendrocytes, adult mice showed an increase in neutrophil infiltration 
into the CNS, causing an increase in mortality (115). We wanted to expand on the 
understanding of how ELR(+) CXC chemokines played a role in preclinical disease 
models of MS when overproduced from a natural source within the CNS, specifically 
CXCL1 from astrocytes. We designed transgenic mice utilizing the reverse tetracycline-
controlled transcriptional activation system to allow for controlled overexpression of 
CXCL1 from astrocytes in response to doxycycline (Dox) treatment (116). Utilizing this 
“tet-on” system, we used a doxycycline-inducible reverse tetracycline-controlled trans 
activator (rtTA) protein termed rtTA2s-M2, which will bind more efficiently to the 
tetracycline-responsive promoter element (TRE) in the presence of Dox, allowing for 
overexpression CXCL1 (117-119). How inducible expression of CXCL1 affects host 
defense and disease following JHMV infection of the CNS will be covered in Chapter 3.  
 
1.4 Experimental autoimmune encephalomyelitis: A model of  
autoimmune inflammatory demyelination 
In addition to the JHMV model of neurologic disease and demyelination, EAE is 
another animal model used to study immune-mediated demyelination and serves as a 
well-accepted preclinical model of MS. There are many different variations of EAE that 
can be induced in animal models that can vary depending on the antigen used in 
immunization, age, sex, and genetic strain of animal (120). EAE has been used for 
decades as a model for MS and has helped in the understanding of neuroinflammation, 
immune-mediated tissue damage, and immune surveillance of the CNS (12). A few 
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commonly studied models of EAE include the use of Lewis rats, DA rats, SJL mice, and 
C57BL/6 mice (1). The underlying protocol for inducing EAE involves an administration 
of an encephalitogenic peptide from a myelin-specific protein emulsified in Complete 
Freund’s Adjuvant (CFA) and subsequently injected with pertussis toxin (121-123). For 
example, SJL mice can be immunized with the proteolipid peptide from amino acids 139 
to 151 (PLP139-151), causing a relapsing remitting form of disease (120-123). Another 
example utilizes the MOG35-55 injected into the C57BL/6 mouse strain, causing an acute 
neuroinflammation and demyelination that does not completely resolve (121-123). 
Mechanistic studies of EAE pathogenesis and drug development have employed both 
EAE models due to the large array of transgenic mice available on these backgrounds (1, 
12). Thus, EAE has been used as a proof of concept model for MS, aiding in the 
development of Food and Drug Administration (FDA)-approved therapies, including 
glatiramer acetate, mitoxantrone, natalizumab, fingolimod, fumarate, and teriflunomide, 
as well as drugs that are under clinical trials for MS patients, including rituximab and 
laquinimod (12, 124, 125). 
In EAE, autoreactive T cells in the CNS will interact with CNS resident antigen 
presenting cells (APCs), including resident microglia, macrophages, DCs, and B cells, 
that cause an inflammatory cascade leading to white matter damage (124, 126). 
Infiltrating monocytes/macrophages can migrate into the CNS by an inflammatory 
cascade through production of cytokines and chemokines produced from these 
autoreactive T cells (124, 126). These monocytes/macrophages, in combination with 
autoreactive antibodies produced from plasma cells, lead to myelin destruction and 
axonal damage through mechanisms, including antibody-dependent cell-mediated 
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cytotoxicity (ADCC), phagocytosis, and the production of toxic factors (124, 126). It has 
also been shown that myelin-loaded macrophages can drain back into cervical and lumbar 
lymph nodes and the spleen where new autoreactive T cells specific for additional 
myelin-specific proteins can arise (126). Lastly, MOG-specific CD8+ T cells, B cells, 
microglia, astrocytes, and even neutrophils have been shown to play a role in EAE 
pathogenesis (4, 124, 127-129). For instance, Th17+ T cells produce many 
proinflammatory cytokines, including granulocyte-macrophage colony-stimulating factor 
(GM-CSF), IL-2, IL-9, IL-17, and IL-21 that can all disturb glial cell survival (130, 131). 
 
1.5 Neutrophils and EAE pathogenesis 
During EAE, ELR(+) CXC chemokines are elevated in the CNS during the acute 
stage of disease (132, 133). Neutrophils have been implemented in the pathogenesis of 
EAE and depletion of neutrophils by anti-Ly6G and/or anti-CXCR2 has shown to delay 
onset or decrease exacerbation of clinical disease as well as decreased demyelination 
(132-135). Both G-CSF and CXCL1 drive the migration/recruitment of neutrophils out of 
the bone marrow and into the blood within 48 hours after MOG35-55 peptide 
immunization (11). There is a significant increase from the preclinical to the onset of 
symptoms of the ELR(+) CXC chemokines CXCL1, CXCL2, and CXCL5, in the brain 
and spinal cord of mice immunized with MOG35-55 EAE (133). When neutrophils from 
wild type mice are adoptively transferred into Cxcr2 -/- mice, it results in the re-
establishment of clinical symptoms, although the clinical scores do not return to wildtype 
levels, indicating a role for CXCR2+ neutrophils during EAE pathogenesis (132). When 
MOG35-55 EAE mice were treated with anti-CXCL1, onset of clinical disease was delayed 
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by approximately 3 days, correlating with a decrease in Ly6G+ neutrophils being 
recruited to the cerebral cortex (133). During MOG35-55, previous studies by Friese and 
colleagues showed by anti-Ly6G studies that neutrophils are important contributors early 
during pathogenesis likely by aiding in BBB breakdown and maturing APCs within the 
perivascular regions within the spinal cord (134). Cxcr2 -/- mice were resistant to 
demyelination in the cuprizone model, demonstrating that CXCR2+ neutrophils were 
important in inducing demyelination in this model (136).  
In atypical EAE, it has been shown that the neutrophil-chemoattractant 
chemokine CXCL2 is increased in the brainstem, resulting in increased neutrophil 
accumulation within the CNS and exacerbation of disease (137-139). When the 
suppressor of cytokine signaling 3 (SOCS3) gene is knocked out in neutrophils, mice are 
more susceptible to atypcial signs of EAE by allowing for increased recruitment of 
neutrophils to the cerebellum and brainstem (140). Adoptive transfer studies in EAE have 
shown that both IFN-γ-producing Th1 cells, and IL-17-producing Th17 cells can 
independently produce disease and potentially have independent mechanisms (141, 142). 
Specifically IL-17 has been shown to enhance the expression of ELR(+) CXC 
chemokines through the IL-17R and knockout studies of Il-17rc has shown a dampening 
of EAE disease correlating with a decrease in ELR(+) CXC chemokines (90). In addition, 
when Act1, part of the IL-17 receptor complex, is knocked out in the CNS - specifically 
in NG2+ OPCs and to a lesser extent astrocytes (but not in mature oligodendrocytes or 
neurons), there is a reduction in EAE pathogenesis correlating with a decrease in 
neutrophil recruitment and ELR(+) CXC chemokine production, including messenger 
ribonucleic acid (mRNA) of Cxcl1 and Cxcl2 in the spinal cord (130). This illustrates that 
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signaling through OPCs and astrocytes of the Th17 pathway increases ELR(+) CXC 
chemokines and overall neuroinflammation (130). Together these data indicate a role for 
ELR(+) CXC chemokines and their receptor, CXCR2, in neutrophils to aid in the 
pathogenesis of demyelinating mouse models, EAE and cuprizone. Thus, further studies 
will require determining the pathogenic role of neutrophils during MOG35-55 EAE 
pathogenesis following the breakdown of the BBB; to this end, we utilized the mice 
described previously that overexpress CXCL1 from glial fibrillary acidic protein 
(GFAP)+ astrocytes in a Dox-dependent manner and will be discussed in Chapter 4. 
 
1.6 ELR(+) CXC chemokine signaling during chronic  
JHMV-induced disease and EAE 
During chronic JHMV infection, oligodendrocytes serve as a reservoir for JHMV 
and these animals experience chronic neuroinflammation and demyelination (90). Direct 
viral-induced lysis does not appear to be a cause of demyelination as immunodeficient 
mice showed replication in oligodendrocytes with minimal demyelination (49, 53, 143). 
Adoptive transfer of splenocytes isolated from JHMV infected mouse into JHMV-
infected immunodeficient mice results in widespread demyelination, indicating that T 
cells are important in white matter damage (143-145). Similarly, JHMV infection of CD4 
or CD8 knockout mice resulted in demyelination, although the data indicated a more 
important role for CD4+ T cells in contributing to white matter damage (70). CD4+ T 
cells have been shown to secrete CCL5, a chemokine that attracts inflammatory 
macrophages enhancing demyelination in the CNS during JHMV, arguing this is one 
potential mechanism by which CD4+ T cells contribute to disease (70, 143, 146-148). 
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Nonetheless, the mechanisms of action of both CD4+ T cells and CD8+ T cells is 
somewhat controversial during JHMV infection in that, IFN-γ secretion by CD8+ T cells 
has been shown to enhance demyelination by recruiting macrophages/microglia to white 
matter tracts, while a different study showed CD4+ T cell secretion of IFN-γ was 
protective and aided in controlling of viral replication in the CNS (149-151). Activated 
bystander CD4+ T cells that were not viral antigen specific within the CNS did not 
appear to contribute to demyelination, arguing that white matter damage is mediated by 
virus-specific T cells (152). Adoptive transfer of CD4+CD25+FoxP3+ regulatory T cells 
(Tregs) into JHMV-infected mice resulted in muted clinical disease severity accompanied 
by reduced neuroinflammation and demyelination (153). Together this shows insights 
into the mechanisms of how T cells are required for clearance of JHMV from the CNS, 
although they also contribute to enhanced neuroinflammation and demyelination and into 
the chronic stage of disease. 
T cell production of IFN-γ has been observed out to 4 weeks following JHMV 
infection and this potentially contributes to dysregulation of oligodendrocytes and 
demyelination (58). IFN-γ production from CD8+ T cells contributes to demyelination 
and oligodendrocyte damage and destruction during an adoptive transfer study (149). 
OPCs have displayed more sensitivity to IFN-γ induced apoptosis compared to mature 
oligodendrocytes, although apoptosis still occurs in IFN-γ receptor knockout 
oligodendrocyte lineage cells (OLCs), suggesting the mechanism of demyelination is not 
only due to IFN-γ; release of chemokines such as CXCL10 by activated glia may cause 
dysregulation and/or death of oligodendrocytes whereas CXCL1 may be beneficial (74, 
154-160). Activated microglia and macrophages are involved in demyelination by 
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directly stripping myelin from axons (146, 161, 162). While defining the specific roles of 
microglia and macrophages in demyelination in JHMV-infected mice, recent studies in 
EAE argue that infiltrating macrophages are more pathogenic than microglia, suggesting 
this may be true in JHMV infection as well (163). The process of demyelination is 
multifaceted and many factors contribute to its mechanism, thus utilizing the mouse 
model of chronic JHMV infection will continue to give us insights into this process and 
how to combat it. 
Growing evidence has suggested that CXCR2 in neutrophils, as well as CXCR2 
on resident CNS cells, may play a role in the pathogenesis of MS (4). When MS and 
neuromyelitis optica (NMO) patients were administered the neutrophil-activating 
molecule G-CSF, symptoms of disease were exacerbated, arguing that neutrophils may 
play a role in the pathogenesis of MS and NMO (164, 165). In addition, neutrophils have 
been shown to be higher in MS patients and in a more primed state than healthy patients 
(34). In the CNS of MS patients, CXCL1 was upregulated in astrocytes within active 
lesions adjacent to proliferating CXCR2+ oligodendrocytes (166). Cultured mouse OPCs 
began to proliferate when given spinal cord astrocytes secreting CXCL1 and human fetal 
oligodendrocytes from early to mature showed expression of CXCR2, while fetal human 
astrocytes showed production of CXCL1 when induced by IL-1β, but not IFN-γ or 
transforming growth factor β (TGFβ) (166-168). It is also known that the 
CXCL1/CXCR2 signaling axis is important for spinal cord OPC proliferation and 
positioning during development (169). Adult Cxcr2 -/- mice have misaligned glial cells 
within the CNS including OPC numbers and positioning, as well as decreased white 
matter area and myelin sheath thickness in the spinal cord and OPCs derived from these 
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Cxcr2 -/- mice have a decreased capacity to differentiate into mature oligodendrocytes 
(170). Adoptive transfer of bone marrow transfer of wildtype mouse cells into Cxcr2 -/- 
mice revealed an increase in recovery that was attributed to OPCs increased replication 
and oligodendrocyte differentiation in demyelinated regions in both EAE and cuprizone 
models of demyelination (171). This indicated that resident glial cell expression of 
CXCR2 inhibits myelin repair after demyelination occurred. During both EAE and spinal 
cord injury, CXCR2 antagonism increased oligodendrocyte differentiation and aided in 
recovery, suggesting that CXCR2 increases clinical severity, although antagonistic 
studies are difficult to differentiate between decreased immune cell infiltration and on 
glial cells (172, 173). All together, this points to a clear role of CXCR2 in OPCs during 
development and potentially OPC differentiation in general. 
During the chronic stage of JHMV infection, our lab has previously determined 
that anti-CXCR2 treatment increased clinical disease severity that was associated with 
increased apoptosis of oligodendrocytes and demyelination (160). These data correlated 
with in vitro data from cultured OPCs derived from mouse neural progenitor cells (NPCs) 
in which CXCL1 administration blocked OPC apoptosis (160). Not only is OPC 
apoptosis decreased in the presence of CXCL1 during JHMV infection, but also when 
treated with IFN-γ, possibly by inducing CXCL10, which signals through the specific 
receptor CXCR3 (158). When cultured OPCs from Cxcr3 -/- mice were treated with IFN-
γ, there was also a reduction in apoptosis, further arguing that CXCL10 may augment 
demyelination by directly killing oligodendrocytes (158). Mechanisms of how CXCL1 
aids in CXCR2+ OPC protection from apoptosis include decreasing caspase 3, a pro-




Collectively, findings derived from in vitro and in vivo models advocate that 
CXCR2 signaling is involved in oligodendrocyte biology. However, all of these 
experiments have employed either Cxcr2 whole-body knockout mice or treatment with 
blocking antibodies or small molecule antagonists to assess how CXCR2 signaling 
controls these events. Therefore, accurate interpretation of how CXCR2 signaling 
modulates oligodendroglia biology is confounded by the fact that microglia, astrocytes, 
and neurons may express CXCR2, leading to potential off-target effects of CXCR2-
targeted therapies. To circumvent this issue, we have generated mice in which CXCR2 is 
ablated in a tamoxifen-inducible manner in oligodendroglia in adult mice in order to 
evaluate how signaling through this receptor affects disease progression in EAE and 
JHMV-induced neurologic disease. These findings are detailed in Chapter 5. 
 
1.7 Summary 
Chapters 3 and 4 examine how CXCL1 influences the pathogenesis of JHMV 
and MOG35-55-induced EAE. Transgenic mice were developed on a C57BL/6 background 
to overexpress the chemokine CXCL1, driven by a GFAP promoter when induced by the 
tetracycline derivative, doxycycline, to allow for controlled overexpression of CXCL1 in 
astrocytes (174). Increased expression of CXCL1 from GFAP+ astrocytes correlated with 
an enhancement recruitment of neutrophils, but not other immune cells, into the CNS, 
mainly into the spinal cord, enhancing clinical disease and demyelination in both JHMV 
and MOG35-55 EAE. When neutrophils were depleted by antibody treatment, there was a 




Chapter 5 evaluates the role of CXCR2 signaling on OLCs within the JHMV and 
MOG33-55 EAE mouse models of neuroinflammation/demyelination. To accomplish this, 
we designed transgenic mice in which Cxcr2 is selectively ablated within 
oligodendrocytes upon treatment with tamoxifen (175). Neuroinflammation and 
demyelination were not affected during both the JHMV and MOG35-55 EAE pathogenesis, 
suggesting that CXCR2 signaling on oligodendrocytes is not important in controlling 
disease progression. Future studies understanding the roles of chemokine and chemokine 
receptor signaling in glial cells will help us determine novel therapeutic targets for MS 
patients. Taken together, this indicates that blocking of neutrophil attracting molecules by 
the use of therapeutic agents may aid in decreasing neuroinflammation and demyelination 
in MS patients. 
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Infection of the central nervous system (CNS) by neurotropic viruses represents an increasing worldwide
problem in terms of morbidity and mortality for people of all ages. Although unique structural features of the
blood-brain-barrier (BBB) provide a physical and physiological barrier, a number of neurotropic viruses are
able to enter the CNS resulting in a variety of pathological outcomes. Nonetheless, antigen-speciﬁc lymphocytes
are ultimately able to accumulatewithin the CNS and contribute to defense by reducing or eliminating the invad-
ing viral pathogen. Alternatively, inﬁltration of activated cells of the immune systemmay be detrimental, as these
cells can contribute to neuropathology that may result in long-term cellular damage or death. More recently,
myeloid cells e.g. neutrophils have been implicated in contributing to both host defense and disease in response
to viral infection of the CNS. This review highlights recent studies using coronavirus-induced neurologic disease
as a model to determine how neutrophils affect effective control of viral replication as well as demyelination.







Intracranial infection of susceptible mice with the JHM strain of
mouse hepatitis virus (JHMV) causes an acute encephalomyelitis
followed by a chronic demyelinating disease similar to the human
demyelinating disease multiple sclerosis (MS). Early following JHMV
infection of the CNS, the virus targets ependymal cells lining the ventri-
cles, replicates, and rapidly disseminates into the brain parenchyma at
which point the virus infects and replicates within astrocytes, oligoden-
droglia, and microglia throughout the brain and spinal cord [45]. In
response to viral infection of glial cells, a rapid and orchestrated expres-
sion of chemokines occurs that contribute to attracting inﬂammatory
cells into the CNS. In terms of host defense, secretion of chemokines de-
rived from the CNS, including CXCL10 and CCL5, promote themigration
and accumulation of virus-speciﬁc CD4+ and CD8+ T cells that control
viral replication via secretion of IFN-γ and cytolytic activity. While in-
ﬂammatory T cells are effective in eliminating virus, sterile immunity
is not achieved; viral protein and/or RNA persist within astrocytes and
oligodendroglia resulting in chronic expression of chemokine genes
leading to chronic neuroinﬂammation and demyelination. Histological
features associated with viral persistence include the development of
an immune-mediated demyelinating disease similar to the human de-
myelinating diseaseMS in that both T cells andmacrophages are critical
mediators of disease severity and contribute to myelin damage [5,32].
Through the course of both acute and chronic JHMV-induced neuro-
logic infection, there is a coordinated expression of chemokines and
chemokine receptors that regulate inﬂammation contributing to
both host defense and disease exacerbation. Among the chemokines
expressed during infection are members of the ELR(+) chemokine
family CXCL1, CXCL2, and CXCL5. CXCL1 and CXCL2 are potent
chemoattractants for neutrophils via binding and signaling through
the receptor CXCR2 [28,39,48]. Moreover, PMNs have been shown to
enhance CNS inﬂammation by disrupting blood brain barrier (BBB)
integrity in various animal models of chronic neuroinﬂammation in-
cluding spinal cord injury (SCI) [9,44] and autoimmune demyelination
[4] while blocking or silencing of CXCR2 signaling mutes inﬂammation
and tissue damage inmousemodels in which PMN inﬁltration is critical
to disease initiation [2,4,9,18,24,25,43,47].
2. Neutrophils and acute viral-induced encephalomyelitis
Neutrophils represent a component of the innate immune response
and provide an essential role in killing invading pathogens through an
arsenal of defense mechanisms including release of microbicidal gran-
ules and release of reactive oxygen/nitrogen species [3,30]. While a
clear role for neutrophils in combating bacterial pathogens is docu-
mented [3,30], how these cells contribute to host defense and disease
in response to CNS viral infection is less well characterized. McGavern
et al. [19] employed two-photon microscopy to elegantly demonstrate
that neutrophils, along with monocytes, were responsible for vascular
leakage and acute lethality following lymphocytic choriomeningitis
virus (LCMV) infection of the CNS. Human immunodeﬁciency virus-1
(HIV-1) infection of monocyte-derived macrophages increases expres-
sion of CXCL5 that serves to attract neutrophils that may augment
neuropathology by contributing to neuron death [10]. Experimental
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infection of mice with West Nile virus (WNV) in which neutrophil traf-
ﬁcking to the CNS is impaired results in increased protection fromWNV
encephalitis by limiting immune cell access to the CNS thus diminishing
neuropathology [46]. With regards to JHMV-induced encephalomyeli-
tis, early work by Stohlman et al. [50] highlighted a previously unrecog-
nized role for neutrophils in effectively controlling viral replication
within the CNS. The underlyingmechanisms by which neutrophils con-
tribute to an effective host defense are related to neutrophil-mediated
permeabilization of the blood-brain-barrier (BBB) through release of
matrix metalloproteinase 9 (MMP-9) [50] although other factors inde-
pendent of MMP-9 may also be involved [37]. In addition, monocytes
can also enhance T cell accumulation within the CNS of JHMV-infected
mice through the glia limitans [37]. Neutrophils are rapidly mobilized
from the bone-marrow and into the blood in response to CNS infection
by JHMV and this most likely reﬂects the precipitous increase in expres-
sion of the neutrophil chemoattractants CXCL1, CXCL2, and CXCL5 that
all bind to their cognate receptor CXCR2with high binding [12]. Indeed,
treatment of JHMV-infected mice with a blocking antibody speciﬁc for
CXCR2 resulted impaired migration of CXCR2-bearing neutrophils to
the CNS and this resulted in increased mortality that was associated
with impaired ability to control viral replication within the CNS [12].
Blocking neutrophil accumulation within the CNS resulted in reduced
expression of MMP-9, limited permeabilization of the BBB, and dimin-
ished inﬁltration of virus-speciﬁc T cells [12]. Collectively, these ﬁndings
illustrate that neutrophils are an important component of an effective
host defense following CNS infection with a neurotropic virus.
3. Neutrophils and viral-induced demyelination
Neutrophil inﬁltration into the CNS has been associated with neuro-
logic disease in pre-clinical animal models [6,14,34,38,40]. Herz et al.
[11] have recently demonstrated that CXCR2 antagonization reduced
neurological deﬁcits and infarct volumes following middle cerebral
artery occlusion and this was associated with reduced neutrophil
inﬁltration into the CNS. Similarly, depletion of neutrophils following
subarachnoid hemorrhage was found to improve memory in a model
of aneurysmal subarachnoid hemorrhage (SAH) [33]. Additionally,
Zenaro et al. [49] have demonstrated a role for the adhesion molecule
lymphocyte function-associated antigen 1 (LFA-1) in promoting neu-
trophil accumulation within the CNS and amplifying AD-like pathology
in transgenic models of Alzheimer's disease (AD). Depletion of neutro-
phils and/or a deﬁciency in LFA-1 resulted in protection from cognitive
decline and reduced gliosis arguing that blocking neutrophil trafﬁcking
may be beneﬁcial in AD [49]. Within models of spinal cord injury/
trauma, neutrophils are among the ﬁrst cells to accumulate within the
site of injury and a number of studies argue for a pathogenic role for
these cells through limiting tissue sparing andmotor recoverywhile in-
creasing expression of pro-inﬂammatory cytokines [1,36]. Collectively,
these studies demonstrate that in animal models of chronic neuroin-
ﬂammation/neurodegeneration neutrophils can amplify the severity
histologic disease and argue that blocking entry into the CNS may
limit the severity of neurologic disease.
A role for neutrophils in immune-mediated demyelination remains
to be well characterized. Ransohoff et al. [22], have shown that
CXCR2-positive neutrophils are essential for cuprizone-induced demye-
lination and potentially contribute to oligodendrocyte cell loss.
Questions remain regarding the importance of neutrophils in the path-
ogenesis of MS given the paucity of these cells in active lesions; howev-
er, elevated neutrophil numbers within the cerebrospinal ﬂuid (CSF) of
MS patients have been correlated with clinical relapse [20]. Administra-
tion of granulocyte-colony-stimulating factor (G-CSF), a neutrophil
activatingmolecule, toMS and neuromyelitis optica (NMO) patients re-
sulted in disease exacerbation arguing for a role for these cells in ampli-
fying disease severity [16,31]. Additionally, neutrophils have been
reported to be more numerous and exhibit a more primed state in
MS patients [29]. Recent studies [15,35] highlight the importance
of CXCL1 as well as other myeloid-chemoattractant molecules as
having a possible role in potentiating disease in patients with either
relapsing-remitting or progressive forms of MS, suggesting that soluble
factors that attract neutrophils and/or neutrophil-related molecules
may be important therapeutic targets for MS patients. Support for this
notion is derived from studies employing experimental autoimmune
encephalomyelitis (EAE) as a model for MS in which disease onset is
mute when neutrophil trafﬁcking to the CNS is disrupted [4,27]. More
recently, Stoolman et al. [42] have expanded on these ﬁndings to
show that enriched expression of CXCL2 within the brainstem attracts
neutrophils that substantially contribute to atypical EAE. Similarly,
mice in which neutrophils lack suppressor of cytokine signaling 3
(SOCS3) exhibit an increase in susceptibility to the atypical EAE and
this correlates with preferential recruitment of neutrophils into the cer-
ebellum and brainstem [23]. The site of neutrophil recruitment may be
critical in terms of amplifying histopathology as neutrophil accumula-
tion within the brain, but to a limited extent in the spinal cord, contrib-
ute to tissue injury [41]. Collectively, these ﬁndings indicate that
neutrophils can affect the severity of clinical disease and neuroinﬂam-
mation in EAE.
4. A transgenic model to study viral-induced neutrophil-mediated
neuropathology
In attempt to better understandhowneutrophils inﬂuence both host
defense and disease following CNS viral infection, we have recently
engineered transgenic mice to utilize the tetracycline-controlled tran-
scriptional activation system in which the human glial ﬁbrillary acidic
protein (hGFAP) promoter drives expression of a modiﬁed version
of the reverse tetracycline transactivator protein (rtTA*M2) [26]
(Fig. 1A). Astrocytes were chosen for targeted expression of CXCL1 as
previous studies [7,8,17] have shown that JHMV-infected astrocytes ex-
press CXCL1 [13,21]. In the presence of doxycycline (Dox), transcription
initiates at a tet-operon and leads to production of recombinant CXCL1
mRNA transcripts. Double transgenic (tg) mice (pBI-CXCL1-rtTA) and
single tg mice (pBI-CXCL1) were generated; characterization of double
tg mice revealed Dox-dependent expression of CXCL1 from cultured
astrocytes as determined by ELISA (Fig. 1B) [26]. I.c. infection of Dox-
treated double tg mice with JHMV resulted in a selective increased
expression of CXCL1 mRNA transcripts and protein within the brain
and spinal cords when compared to Dox-treated single tg mice infected
with JHMV (Fig. 1C) [26]. Dox-induced overexpression of CXCL1 did not
enhance control of viral replication within the CNS as both infected
double and single tg mice exhibited similar viral titers at deﬁned
times post-infection (p.i.) norwere there differences in either frequency
or numbers of virus-speciﬁc CD4+ and CD8+ T cells within the CNS of
double tg mice compared to single tg mice [26]. However, Dox-
treatment of JHMV-infected double tgmice resulted in increased clinical
disease and mortality when compared to infected single tg mice [26].
In conjunction with increased expression of CXCL1 initiated within
the CNS of Dox-treated double tg mice infected with JHMV, there was
a rapid increase in CXCL1 protein levels in serum [26]. Correspondingly,
there is a rapid increase in neutrophils within the blood at days 4
(p b 0.05) and 7 (p b 0.001) in double tg mice compared to infected sin-
gle tg controls [26]. Dox-induced CXCL1 production in JHMV-infected
double tg mice also resulted in an increase in neutrophil frequency
within the brain at days 4 and 7 p.i. [26]. Similarly, therewas an increase
in neutrophil frequency within spinal cords of double tg mice at days 4
(p b 0.01) and 7 (p b 0.05) p.i. compared to single tg mice [26]. Immu-
noﬂuorescence staining for neutrophils (Ly-6B.2) supported the ﬂow
cytometric data and revealed increased numbers of neutrophils
accumulating within the meninges of double tg mice at day 7 p.i. [26].
The increased presence of neutrophils within the CNS of double tg
mice suggested that there would also be a corresponding increase in
blood-brain-barrier (BBB) permeability. Surprisingly, no differences
were observed in BBB permeability within the brain or spinal cord at
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day 4 p.i. as measured by sodium ﬂuorescein (NaF) uptake [26]. Exam-
ination of spinal cords from JHMV-infected Dox-treated double tg mice
revealed an overall increase (p b 0.05) in the severity of demyelination
when compared to infected single tg animals (Fig. 2A) [26]. The increase
in demyelination in double tg mice was associated with a signiﬁcant
(p b 0.05) loss of mature oligodendrocytes (as determined by expres-
sion of GST-π) within the spinal cords and increased numbers of
microglia in Dox-treated JHMV-infected double tg mice compared to
Fig. 1. Derivation and characterization of a mouse model in which CXCL1 expression within the CNS is under control of a Doxycycline promoter. (A) Cartoon depiction of experimental
strategy to generate double (dbl) transgenic (tg) mice in which expression of mouse CXCL1 is under control of the GFAP promoter upon doxycycline treatment. (B) Cortex tissue from
double tg and single tg post-natal day 1 (P1) mice was dissociated and enriched for astrocytes. Following 24-h of Dox (100 ng/ml) treated double tg astrocyte cultures,
immunoﬂuorescence conﬁrmed CXCL1 expression within GFAP-positive astrocytes while vehicle treatment yielded no CXCL1 ﬂuorescence. (C) Within the SC, dox-treated double tg











Fig. 2. Elevated CXCL1 expression is associated with increased demyelination. Histopathological analysis of spinal cords of double tg mice reveals an increase in demyelination.
(A) Representative luxol fast blue (LFB)-stained spinal cords reveals increased (p b 0.05) demyelination in JHMV-infected Dox-treated double tg mice compared to single tg controls.
(B) Flow cytometric analysis revealed a signiﬁcant increase in the frequency and total number of neutrophils within the spinal cord of JHMV-infected Dox-treated double tg mice
compared to single tg mice. Representative immunoﬂuorescence staining further demonstrated a signiﬁcant increase in the number of Ly6B.2-positive neutrophils (yellow
arrowheads) within the spinal cord parenchyma of JHMV-infected double tg compared to single tg mice; red arrowheads indicate neutrophils located within the spinal cord meninges.
Quantiﬁcation of neutrophils within the spinal cords indicated an overall increase (p b 0.05) in Dox-treated double tg mice compared to Dox-treated single tg mice. (C) Representative
LFB-stained spinal cord sections from JHMV-infected double tg mice treated with either control IgG2a or anti-Ly6G antibody between days 3–15 p.i. Quantiﬁcation of the severity of
demyelination revealed reduced white matter damage in mice treated with anti-Ly6G antibody compared to mice treated with isogenic IgG2a control antibody. Images adapted from
[26] with permission.
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infected single tgmice [26]. Flow cytometric data indicated that neutro-
phil frequencies within the spinal cords of infected double tg were
signiﬁcantly increased (p b 0.01) as well as their total numbers
(p b 0.001) at day 12 p.i. compared to single tg mice (Fig. 2B) [26].
Additionally, neutrophils were detected within the spinal cord paren-
chyma of double tg mice compared to single tg mice (Fig. 2B) [26].
Elimination of neutrophils via administration of anti-Ly6g monoclonal
antibody injection into JHMV-infected double tg mice treated with
Dox resulted in a reduction in the severity of demyelination when
compared to mice treated with isotype control antibody (Fig. 2C) thus
demonstrating that neutrophils are capable of augmenting the severity
of white matter damage [26].
5. Perspectives
Although a role for neutrophils in host defense following infection
with bacterial pathogens has been appreciated for a number of years,
how neutrophils affect host defense in response to viral infection of
the CNS has not been as well studied. However, it is now clear that
neutrophils are capable of enhancing control of viral replication within
the CNS through increasing the permeabilization of the BBB thereby
allowing antigen-speciﬁc lymphocytes access to sites of infection.
Equally interesting is how neutrophil inﬁltration into the CNS contrib-
utes to neuropathology e.g. demyelination. Compelling new informa-
tion derived from clinical studies from MS patients as well as
preclinical animal models of MS have emphasized a potential role for
these cells in amplifying white matter damage opening the possibility
of targeting neutrophil migration into the CNS as a therapeutic strategy
to limit CNS damage.
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Inducible Expression of CXCL1 within the Central Nervous
System Amplifies Viral-Induced Demyelination
Brett S. Marro,* Jonathan J. Grist,† and Thomas E. Lane†
The functional role of the ELR+ chemokine CXCL1 in host defense and disease following infection of the CNS with the neurotropic
JHM strain of mouse hepatitis virus (JHMV) was examined. Mice in which expression of CXCL1 is under the control of a
tetracycline-inducible promoter active within glial fibrillary acidic protein–positive cells were generated and this allowed for selec-
tively increasing CNS expression of CXCL1 in response to JHMV infection and evaluating the effects on neuroinflammation, control
of viral replication, and demyelination. Inducible expression of CNS-derived CXCL1 resulted in increased levels of CXCL1 protein
within the serum, brain, and spinal cord that correlated with increased frequency of Ly6G+CD11b+ neutrophils present within the
CNS. Elevated levels of CXCL1 did not influence the generation of virus-specific T cells, and there was no difference in control of
JHMV replication compared with control mice, indicating that T cell infiltration into the CNS is CXCL1-independent. Sustained
CXCL1 expression within the CNS resulted in increased mortality that correlated with elevated neutrophil infiltration, diminished
numbers of mature oligodendrocytes, and an increase in the severity of demyelination. Neutrophil ablation in CXCL1-transgenic
mice reduced the severity of demyelination in mice, arguing for a role for these cells in white matter damage. Collectively, these
findings illustrate that sustained CXCL1 expression amplifies the severity of white matter damage and that neutrophils can con-
tribute to this process in a model of viral-induced neurologic disease. The Journal of Immunology, 2016, 196: 000–000.
I noculation of susceptible mice with the neurotropic JHMstrain of mouse hepatitis virus (JHMV) into the CNS results inwidespread dissemination of virus, leading to infection and
replication within glial cells. This is followed by infiltration of
virus-specific T lymphocytes that control viral replication through
cytokine secretion and cytolytic activity (1). Sterilizing immunity
is not achieved, as viral Ag and viral RNA are detected within
white matter tracts of surviving mice, resulting in demyelination
that is amplified by inflammatory T cells and macrophages. In
response to infection, numerous cytokines/chemokines are se-
creted by inflammatory leukocytes and resident cells of the CNS,
generating an inflammatory milieu that contributes to host defense
while also promoting disease. Our previous work has evaluated
the functional roles for chemokines and chemokine receptors in
orchestrating leukocyte recruitment into the CNS in response to
JHMV infection that aid in host defense as well as their contri-
bution to demyelination (2–5).
Among the chemokines expressed during acute and chronic
JHMV-induced neurologic disease are the ELR+ CXC chemokines
CXCL1, CXCL2, and CXCL5 and its signaling receptor CXCR2
(4, 6). Following JHMV infection of the CNS, expression of CNS-
derived ELR+ ligands promote the migration of CXCR2-
expressing neutrophils (Ly6G/ChiCD11b+) to the blood–brain
barrier (BBB), where they can assist in breaking down structural
components of the glial limitans through release of matrix met-
alloproteinases (MMPs) from preformed granules. Indeed, Ab-
mediated neutralization of CXCR2 within JHMV-infected mice
prevented neutrophil migration to the CNS, and this was associ-
ated with a significant increase in mortality and inefficient control
of virus replication as a result of impaired parenchymal access of
virus-specific T cells (4). Anti-CXCR2 treatment was also found
to diminish macrophage recruitment to the CNS as well, making it
challenging to define the precise contributions of both immune
cell subsets in establishing host defense while also promoting
disease when CXCR2 signaling is neutralized (4). Other studies
have demonstrated that neutrophil depletion in JHMV-infected
mice in which monocyte trafficking to the CNS is compromised
does not alter early CNS inflammation, clinical disease severity, or
death, but rather it limits parenchymal access of leukocytes at later
times following infection, suggesting that neutrophils and mono-
cytes may act separately to shape adaptive immunity following
JHMV infection of the CNS (7, 8).
The present study was undertaken to expand our understanding
of how ELR+ chemokines influence host defense and disease
progression following JHMV infection of the CNS. To this end,
we have generated mice in which expression of CXCL1 is under
the control of a tetracycline-inducible promoter that is active
within glial fibrillary acidic protein (GFAP)+ cells that express an
enhanced version of the reverse tetracycline transactivator
(rtTA*M2) protein. The successful generation of these pBI-
CXCL1-rtTA mice has allowed us to selectively increase
CNS expression of CXCL1 in adult mice following JHMV-
induced disease and evaluate the effects on neuroinflammation,
control of viral replication, and demyelination.
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CXCL1 cDNA incorporating XhoI and NheI restriction site ends was
generated from the brains of C57BL/6 mice infected with 250 PFU JHMV.
CXCL1 cDNAwas cloned into a pBI-MCS-EGFP plasmid (9) downstream
of a bidirectional tetracycline responsive element. The purified pBI-
CXCL1 plasmid was linearized following an overnight incubation with
AatII and AseI restriction enzymes to generate a 3350-bp fragment con-
taining the pBI-CXCL1 construct.
Virus and mice
pBI-CXCL1 transgenic (tg) mice were generated by the University of
California, Irvine tg mouse facility through DNA microinjection of fer-
tilized C56BL/6 eggs using the linearized pBI-CXCL1 construct (9). The
five resulting founder tg mice where mated to wild-type C57BL/6 mice to
indentify F1 offspring containing the transgene. To generate double-tg
mice, hemizygous pBI-CXCL1 tgs were crossed to hemizygous GFAP-
rtTA*M2 mice (The Jackson Laboratory), resulting in double-tg mice
(pBI-CXCL1-rtTA), single-tg mice (rtTA-GFAP or pBI-CXCL1), or wild-
type mice. For evaluation of CXCL1 induction in experimental mice,
age-matched 5- to 6-wk-old single-tg or double-tg mice were infected
intracerebrally (i.c.) with 250 PFU JHMV strain J2.2v-1 in 30 ml sterile
HBSS; subsequently, animals were injected with doxycycline (Dox) (50 mg/kg
via i.p. injection) starting at day 2 postinfection (p.i.) and continuing through
day 12 p.i. SHAM-infected animals received 30 ml HBSS via i.c. injection.
For viral titer analysis, one half of each brain or whole spinal cord was ho-
mogenized and used in a plaque assay as previously described (10).
Primary astrocyte cultures
Cortices from postnatal day 1 pBI-CXCL1-rtTA (double-tg) and rtTA-
GFAP or pBI-CXCL1 (single-tg) mice were dissected and triturated
according to previously published protocols (11). In brief, following re-
moval of the meninges, cortical tissue was minced with a razor and placed
in prewarmed DMEM containing papain to completely dissociate the tis-
sue. Following further dissociation with a Pasteur pipette, single-cell
suspensions were added to poly-D-lysine–coated culture flasks and
grown for 9 d in DMEM supplemented with 10% FBS. Flasks were
then transferred to an orbital shaker in a 5% CO2 tissue culture incubator
and shaken for ∼16 h at 220 rpm to remove loosely adherent contami-
nating cells. Cells were passaged in 0.05% trypsin and replated. When
cells regained confluency, 10 mM Ara-C (Sigma-Aldrich, St. Louis, MO)
was added for 3 d to kill dividing cells. Cells were passaged again and
added to 24-well culture dishes or Nunc Lab-Tek II chamber slides
(Thermo Fisher Scientific, Waltham, MA).
Gene expression analysis
Total cDNA from brains and spinal cords of sham- and JHMV-infected
mice at days 4, 7, and 12 p.i. was generated via SuperScript III (Life
Technologies, Carlsbad, CA) following homogenization in TRIzol
(Life Technologies). To determine relative CXCL1 mRNA expression,
real-time SYBR Green analysis was performed using mouse b-actin
primers (forward, 59-GGCCCAGAGCAAGAGAGGTAT-39; reverse,
59-ACGCACGATTTCCCTCTCAGC-39) and mouse CXCL1 primers
(forward, 59-GGCGCCTATCGCCAATG-39; reverse, 59-CTGGATGTTCTT-
GAGGTGAATCC-39) using a Roche LightCycler 480 (12). CXCL1 ex-
pression was determined by normalizing the expression of each sample to
b-actin and then quantifying fold change relative to sham-infected double-tg
mice. Expression of defined mouse chemokine and cytokine genes within the
CNS of experimental mice was determined using a mouse cytokine and
chemokine RT2 Profiler PCR array (Qiagen, Valencia, CA).
ELISA
Assessment of CXCL1 protein within the supernatants of Dox-treated
astrocyte cultures was determined using a CXCL1 (KC) DuoSet sand-
which ELISA kit (R&D Systems, Minneapolis, MN) according to manu-
facturer specifications. To determine CXCL1 protein levels within the
spinal cords of double- and single-tg mice, spinal cords were homogenized
in RIPA buffer and clarified by high-speed centrifugation. Following
quantification of total protein, samples were diluted in RIPA buffer to a
standard protein concentration before performing the ELISA assay.
Flow cytometry
Flow cytometry was performed to immunophenotype inflammatory cells
entering the CNS using established protocols (3, 13). In brief, single-cell
suspensions were generated from tissue samples by grinding with frosted
microscope slides. Immune cells were enriched by a two-step Percoll
cushion (90 and 63%) and cells were collected at the interface of the two
Percoll layers. Before staining with the fluorescent Abs, isolated cells were
incubated with anti-CD16/32 Fc Block (BD Biosciences, San Jose, CA) at
a 1:200 dilution. Immunophenotyping was performed using either rat anti-
mouse IgG or Armenian hamster anti-mouse IgG Abs for the following
cell surface markers: F4/80 (Serotec, Raleigh, NC), MHV S510-tetramer
(National Institutes of Health), MHV M133-tetramer (National Institutes
of Health), CD4, CD8, Ly6g, CD11b, IFN-g (BD Biosciences), and Ly6c
(eBioscience, San Diego, CA). The following flow cytometric gating
strategies were employed for immunophenotyping inflammatory infil-
trates in the brain: neutrophils (CD45hiCD11b+Ly6G+), monocytes
(CD45hiCD11b+Ly6C+Ly6G2), macrophages (CD45hiCD11b+F4/80+),
microglia (CD45lo, CD11b+, F4/80lo), M133-specific CD4+ T cells
(CD45hi, CD4+, M133-tetramer+), and S510-specific CD8+ T cells
(CD45hi, CD8+, S510-tetramer+).
Sodium fluorescein BBB permeability assay
JHMV-infected double- or single-tg mice received 100 ml 10% sodium
fluorescein (NaFl) in PBS via i.p. injection. After 30 min, mice were
euthanized and perfused with 30 ml PBS to remove NaFl from the
vasculature. Brains and spinal cords were dissected, weighed, and
homogenized in PBS. Homogenates were clarified by centrifugation at
500 3 g for 10 min at 4˚C. A 1:1 ratio of supernatant was combined with
15% trichloroacetic acid and incubated for 24 h at 4˚C. Samples were
centrifuged and supernatants were neutralized with 5 N NaOH. Fluorescence
intensity was assessed with a Synergy H1 (BioTek, Winooski, VT) set at a 485
nm excitation, and NaFl concentrations were determined through extrapola-
tion from a standard curve generated from defined NaFl concentrations.
Clinical severity and histopathology
Clinical disease severity was assessed using a four-point scoring scale as
previously described (3). Mice were euthanized according to Institutional
Animal Care and Use Committee guidelines and perfused with 30 ml 4%
paraformaldehyde. Spinal cords were removed, fixed overnight in 4%
paraformaldehyde at 4˚C, and separated into eight 1.5-mm sections. Each
section was cryoprotected in 20% sucrose for 5 d before embedding in
OCT; 8-mm-thick coronal sections were cut and stained with Luxol fast
blue and H&E. The severity of demyelination for each mouse was deter-
mined using 6–12 spinal cord coronal sections per mouse using either a
previously described four-point scoring scale (14) and calculated as av-
erage 6 SEM or determining the percentage demyelination using ImageJ
software (National Institutes of Health).
Immunofluorescence
Spinal cord sections were processed as above. For immunofluorescence,
slides were first desiccated for at least 2 h and blocked with 5% normal
donkey serum with or without 0.3% Triton X-100. Primary Abs were in-
cubated overnight at 4˚C, including goat anti-CXCL1 1:50 (R&D Sys-
tems), rabbit anti-GFAP 1:500 (Life Technologies), rat anti-Ly6B.2 1:100
(Serotec, Raleigh, NC), rabbit anti-Iba11:500 (Wako Chemicals, Rich-
mond, VA), and rabbit anti–GST-p 1:1000 (MBL International, Woburn,
MA).
Neutrophil depletion
Mice received either 250 mg anti-Ly6g clone 1A8 or isotype control (Bio X
Cell, West Lebanon, NH) via i.p. injection every other day beginning
between days 3 and 15 p.i. Targeted depletion of neutrophils was con-
firmed by flow staining of circulating neutrophils at defined times after
treatment with Ly6g-specific Ab.
Statistical analysis
Flow cytometric data were analyzed with FlowJo (Tree Star), and statistical
analyses were performed using Prism (GraphPad Software)
Results
Dox treatment of pBI-CXCL1-rtTA double-tg mice elevates
CXCL1 mRNA and protein within the CNS
In response to CNS infection of C57BL/6 mice with JHMV,
the ELR+ chemokine CXCL1 is expressed at early times after
infection and serves to attract CXCR2-expressing neutrophils
to the CNS that aid in host defense by contributing to the
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permeabilization of the BBB (4). To better understand how
CXCL1 signaling affects host defense and disease progression
following viral infection of the CNS, tg mice were engineered to
use the tetracycline-controlled transcriptional activation system in
which the human GFAP promoter drove expression of a modified
version of the rtTA protein (rtTA*M2). Astrocytes were chosen for
targeted expression of CXCL1, as previous studies (15–17) have
shown these cells to be the primary source of CXCL1 in models of
neuroinflammation as well as following infection of astrocytes
with JHMV (5, 6). In the presence of Dox, transcription initiates at
a tetracycline operon and leads to production of rCXCL1 mRNA
transcripts. Double-tg mice (pBI-CXCL1-rtTA) were generated
and genotyped to confirm that they incorporated both constructs
(Fig. 1A). Characterization of double-tg mice revealed Dox-de-
pendent expression of CXCL1 from cultured astrocytes as deter-
mined by immunofluorescence staining and ELISA (Fig. 1B, 1C).
We tested whether treatment of tg mice with Dox resulted in
overproduction of CXCL1 within the brain and spinal cord of the
CNS of JHMV-infected mice. Double-tg or single-tg mice were
infected i.c. with JHMV (250 PFU) and subsequently treated daily
with Dox (50 mg/kg) via i.p. injection starting at day 2 p.i. and
continuing through day 12 p.i. (Fig. 2A). Dox treatment resulted in
increased mRNA transcripts specific for CXCL1 in the brains of
infected double-tg mice at days 4, 7, and 12 p.i. compared with
single-tg mice (Fig. 2B). Similarly, CXCL1 transcripts were ele-
vated in the spinal cords at days 4, 7 (p, 0.05), and 12 (p, 0.01)
p.i. when compared with single-tg mice (Fig. 2C). To confirm that
that CXCL1 mRNA was derived from the transgene and not from
germline-encoded CXCL1, we employed quantitative PCR primers
that specifically anneal to an untranslated region region specific
for endogenous CXCL1 mRNA and not tg CXCL1. As shown in
Fig. 2D, there was only a marginal increase in endogenously
produced CXCL1 mRNA transcripts when compared with
transgene-encoded CXCL1. These results confirm that increased
CXCL1 mRNA transcripts are derived from the CXCL1 trans-
gene. CNS-derived CXCL1 in Dox-treated double-tg mice resulted
in increased CXCL1 protein in both the spinal cord (Fig. 2E) and
serum (Fig. 2F) compared with single-tg mice at day 7 p.i. Im-
munofluorescence staining confirmed increased CXCL1 protein
present within the CNS and astrocytes as the primary cellular
source in Dox-treated double-tg mice (Fig. 2G). Finally, over-
production of rCXCL1 within the CNS of JHMV-infected mice
did not result in increased expression of other proinflammatory
cytokines and chemokines within the spinal cord (Fig. 2H) or
brain (data not shown). These data demonstrate that double-tg
mice are responsive to Dox treatment, resulting in increased
levels of CXCL1 derived within the CNS, and this corresponds
to elevated levels of circulating CXCL1 within the serum.
However, CXCL1 overproduction does not impact the expres-
sion of other proinflammatory factors involved in JHMV host
defense and disease.
CXCL1 overexpression increases morbidity/mortality in
double-tg mice
Dox-induced overexpression of CXCL1 within the CNS resulted
in a statistically significant increase in clinical disease sever-
ity (Fig. 3A) and this correlated with an increase in mortality
(Fig. 3B). This was not associated with impaired ability to control
viral infection in Dox-treated double-tg mice, as there were
comparable titers in the brains at days 4 and 7 p.i. whereas lower
viral titers (p , 0.05) were found in spinal cords at days 4 and
7 p.i. (Fig. 3C, 3D). Both double-tg and single-tg animals reduced
CNS viral titers to below detectable titers as measured by plaque
assay within the brain by day 12 p.i. (Fig. 3C) whereas viral titers
within the spinal cord at day 12 p.i. were near the limit of de-
tection (Fig. 3D). Moreover, no differences were observed with
viral RNA load between double-tg and single-tg mice at day 12 p.i.
(data not shown). Treatment of JHMV-infected astrocytes with
rCXCL1 did not decrease viral titers, ruling out that CXCL1 did
FIGURE 1. Generation and in vitro characterization of a Dox-inducible,
astrocyte-specific CXCL1 overexpressing mouse line. (A) Double-tg
mice utilizing the tetracycline operon–controlled Dox-inducible system
were generated by crossing hemizygous human GFAP-rtTA*M2 mice to
a tg mouse line incorporating a tetracycline responsive element driving
expression of CXCL1 (pBI-CXCL1). Shown are PCR results with ge-
nomic DNA from mice revealing amplicons specific for either pBI-
CXCL1 or GFAP-rtTa. The internal control was performed when
detecting GFAP-rtTa amplicons according to defined Jackson Laboratory
protocols. (B) Cortex tissue from double-tg and single-tg postnatal day 1
mice was dissociated and enriched for astrocytes. Following 24 h of Dox
(100 ng/ml)-treated double-tg astrocyte cultures, immunofluorescence
(original magnification 320) confirmed CXCL1 expression within GFAP+
astrocytes whereas vehicle treatment yielded no CXCL1 fluorescence. (C)
Supernatants from Dox-treated double-tg and single-tg astrocytes cultures
were collected and levels of CXCL1 were measured by ELISA. In the
presence of Dox, double-tg cultures yielded significantly elevated CXCL1
protein levels, whereas single-tg cultures did not. Data from (C) represent
supernatants pooled from triplicate wells derived from three separate
double-tg and single-tg mouse cultures. Data are presented as average 6
SEM; statistical significant was measured with an unpaired two-tailed
Student t test. **p , 0.01.
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not exert a direct antiviral effect on infected glial cells (data not
shown). Collectively, these data indicate that the augmented
clinical disease severity in Dox-treated double-tg mice is not a
result of an inability to control viral replication within the CNS.
Neutrophil migration to the CNS is increased in Dox-treated
double-tg mice
We have previously shown that neutrophils migrate into the CNS of
JHMV-infected mice through a CXCR2-dependent mechanism (4).
Therefore, we determined whether Dox-induced CXCL1 over-
expression within the CNS resulted in enhanced mobilization of
neutrophils to the CNS in response to JHMV infection. JHMV-
infected double-tg and single-tg mice were i.c. infected with
virus, treated with Dox, and mice were sacrificed at days 4 and 7
p.i. and neutrophil (Ly6GhiCD11b+) levels in blood were mea-
sured by flow cytometry. CXCL1 overexpression from the CNS
resulted in significantly increased frequency of neutrophils
within the blood at days 4 (p , 0.05) and 7 (p , 0.001) p.i. in
double-tg mice compared with infected single-tg controls
(Fig. 4A). Dox-induced CXCL1 production in JHMV-infected
FIGURE 2. CXCL1 is induced in vivo following administration of Dox into double-tg mice during acute JHMV infection. (A) To test the ability of Dox
to induce CXCL1 overproduction in vivo, double-tg and single-tg mice were infected with 250 PFU JHMV and treated daily with 50 mg/kg Dox between
days 2 and 12 p.i. (B) Administration of Dox to double-tg mice resulted in a significant increase in the expression of CXCL1 mRNA compared with Dox-
treated single-tg mice within the brain at days 4, 7, and 12 p.i. as measured by quantitative real-time PCR. (C) Within the spinal cord, dox-treated double-tg
mice had statistically significant increases in CXCL1 mRNA expression over Dox-treated single-tg mice at days 7 and 12 p.i. (D) CXCL1 transgene
expression within the brain and spinal cord did not impact endogenous CXCL1 production within Dox-treated double-tg mice compared with Dox-treated
single-tg mice. Overproduction of CXCL1 protein was observed within the spinal cord at day 7 p.i. within double-tg mice (E), and this correlated with an
increase in CXCL1 protein within the blood serum (F) at day 7 p.i. as measured by ELISA. (G) Immunofluorscence analysis (original magnification340) of
spinal cord tissue from Dox-treated double-tg mice confirmed that astrocytes were the source of CXCL1 production at day 7 p.i. (H) No significant changes
in proinflammatory gene expression between double-tg and single-tg mice were observed within the spinal cord at day 12 p.i. using an RNA superarray.
Data from (B) represent two experiments with a minimum of four mice per group. All quantitative real-time PCR samples were run in triplicate. (D) and (E)
represent a minimum of three mice per group. Superarray data were compiled used the average value of two mice per group run in duplicate. Data are
presented as average 6 SEM; statistical significance was measured using an unpaired two-tailed Student t test. *p , 0.05, **p , 0.01.
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double-tg mice also resulted in a significant increase in neutrophil
frequency within the brain at days 4 (p , 0.0001) and 7 (p , 0.01)
p.i. (Fig. 4B). Similarly, there was an increase in neutrophil fre-
quency within spinal cords of double-tg mice at days 4 (p , 0.01)
and 7 (p , 0.05) p.i. compared with single-tg mice (Fig. 4C).
Immunofluorescence staining for neutrophils (Ly6B.2) supported
the flow cytometric data and revealed increased numbers of
neutrophils accumulating within the meninges of double-tg
mice at day 7 p.i. (Fig. 4D). The increased presence of neu-
trophils within the CNS of double-tg mice suggested that there
would also be a corresponding increase in BBB permeability.
Rather, no differences were observed in BBB permeability
within the brain or spinal cord at day 4 p.i. as measured by
NaFl uptake (Fig. 4E) and at day 7 p.i. (data not shown). We
also determined whether Dox-induced expression of CXCL1
affected mobilization and migration of Ly6C+ monocytes to the
CNS, as previous studies revealed an important role for these
cells in amplifying the severity of autoimmune-mediated de-
myelination (18). There were no significant differences in
the frequency CD11b+Ly6C+Ly6G2 cells within the blood or
brains of Dox-treated double-tg mice as compared with single-
tg mice at defined times after infection with JHMV as deter-
mined by flow cytometric analysis (Fig. 4F, 4G). However,
there was a slight but significant (p , 0.05) decrease in
numbers of CD11b+Ly6C+Ly6G2 cells within the spinal cords
of Dox-treated double-tg mice at day 12 p.i. compared with single-
tg mice (Fig. 4G) There were no differences in numbers of CD11b+
Ly6C+Ly6G2 cells within the blood or CNS of Dox-treated double-
tg mice compared with single-tg mice (data not shown).
Demyelination is increased in response to elevated CNS
expression of CXCL1
Examination of spinal cords from JHMV-infected, Dox-treated
double-tg mice revealed an overall increase (p , 0.05) in the
severity of demyelination when compared with infected single-tg
animals (Fig. 5A). Analysis of defined spinal cord sections
revealed increased demyelination along the length of the spinal
cords of infected double-tg mice compared with single-tg mice,
although pathology was enhanced within the upper thoracic region
and to a lesser extent within the lower thoracic/lumbar regions
(Fig. 5A). The increase in demyelination in double-tg mice was
associated with a significant (p , 0.05) loss of mature oligo-
dendrocytes (as determined by expression of GST-p) within the
spinal cords (Fig. 5B). Additionally, there were increased numbers
of microglia (CD45loF4/80+) cells in Dox-treated, JHMV-infected
double-tg mice compared with infected single-tg mice within the
spinal cord as determined by flow cytometry as well as immu-
nohistochemical staining for Iba1 (Fig. 5C). Immunophenotyping
cells infiltrating into the brain via flow cytometry revealed no
differences in the frequencies or numbers of CD45hi cells at de-
fined times after infection (Supplemental Fig. 1). Within the spinal
cord, there was a significant increase in the frequency of CD45hi
infiltrates at day 4 p.i. and reflects the early enhancement of neu-
trophils in double-tg mice treated with Dox (Supplemental Fig. 1).
However, there were no differences in CD4+ T cells (Supplemental
Fig. 1), CD8+ T cells (Supplemental Fig. 1), or virus-specific CD4+
(Supplemental Fig. 1) or CD8+ T cells (Supplemental Fig. 1) in-
filtration into the brain or spinal cords of experimental mice.
Overexpression of CXCL1 in Dox-treated, JHMV-infected double-
tg mice did not increase numbers of infiltrating macrophages
FIGURE 3. CXCL1 overproduction amplifies JHMV-induced clinical disease and mortality but is not a result of delayed viral clearance. Double-tg and
single-tg mice were infected with 250 PFU JHMV and treated with 50 mg/kg Dox daily starting at day 2 p.i. through day 12 p.i. (A) Clinical severity was
assessed until day 30 p.i. using a four-point scale. (B) Dox treatment of double-tg mice led to significantly increased mortality compared with Dox-treated
single-tg controls. Viral titers of Dox-treated double-tg and single-tg mice were measured within both the brain (C) and spinal cord (D) by plaque assay.
Each symbol represents one individual mouse; solid black lines represent geometric means. Statistical significance was measured with the Mann–Whitney
U test. Clinical disease and mortality scoring represents an average of double-tg and single-tg mice. For (A) and (B), n = 23 single-tg mice and n = 12
double-tg mice. Statistical significance for the clinical scoring data was determined by a Student t test for each time point assessed. Statistical comparison of
the survival curves was measured using the Mantel–Cox test. *p , 0.05, **p , 0.01.
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(CD45hiF4/80+) in either the brains (Supplemental Fig. 2) or spinal
cords (Supplemental Fig. 2) as compared with infected single-tg
mice (Supplemental Fig. 2). Additionally, no differences were
detected in expression of activation markers MHC class II
(Supplemental Fig. 2) or CD80 (Supplemental Fig. 2), arguing
that overexpression of CXCL1 in response to Dox treatment was
not enhancing the activation state of inflammatory macrophages
that contributed to increased myelin destruction.
Neutrophil accumulation within the spinal cord correlates with
increased demyelination
We next determined whether neutrophil infiltration into the CNS
was associated with the increase in both clinical and histologic
disease in double-tg mice. Flow cytometric data indicated that
neutrophil frequencies within the spinal cords of infected double-tg
mice were significantly increased (p , 0.01) as well as their total
numbers (p , 0.001) at day 12 p.i. compared with single-tg mice
(Fig. 6A). CXCL1 expression, as determined by immunohisto-
chemical staining, was elevated within the spinal cords of Dox-
treated double-tg mice as compared with treated single-tg mice
(Fig. 6B). Correspondingly, in double-tg mice, a significant in-
crease in neutrophils (p , 0.05) was detected within the spinal
cord parenchyma of double-tg mice compared with single-tg mice
(Fig. 6C, 6D). Notably, neutrophils were enriched within the upper
thoracic region of the spinal cord undergoing demyelination
whereas these cells were relatively absent in demyelinating lesions
in single-tg mice (Fig. 6E). To determine whether the robust pa-
renchymal presence of neutrophils within the spinal cords of double-
FIGURE 4. CXCL1 overproduction from astrocytes mobilizes neutrophils and directs them to the CNS. Blood from Dox-treated, JHMV-infected
double-tg and single-tg mice was isolated at day 4 and day 7 p.i. and used for flow cytometric analysis. (A) The frequency of CD11b+Ly6G+ neutrophils
was significantly higher within the blood at days 4 and 7 p.i. Neutrophil migration to the brains (B) and spinal cords (C) of both groups was assessed by
flow cytometry at days 4 and 7 p.i. A significant increase in neutrophil frequency within the brain and spinal cord was observed in Dox-treated double-
tg mice at both time points. (D) Immunofluorescence analysis indicated that Ly6B.2+ neutrophils were primarily located at the ependymal lining and
perivascular space at the spinal cord, with minimal neutrophil presence within the parenchyma. Scale bars, 50 mM. (E) At day 4 p.i., brains and spinal
cords from Dox-treated single-tg and double-tg mice treated with NaFl were removed and total NaFl uptake was measured. No differences in the
frequency of CD11b+Ly6C+Ly6G2 cells were detected within either the blood (F) or brain and spinal cords (G) between Dox-treated double-tg or
single-tg mice at defined times after infection with JHMV. (A)–(C) represent three independent experiments with a minimum of three mice per group per
experiment at each time point analyzed; (F) and (G) represent two independent experiments with a minimum of three mice per group per experiment at
each time point analyzed. Data are presented as average 6 SEM; statistical significance was measured using an unpaired two-tailed Student t test. *p ,
0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001.
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tg mice was associated with the enhanced lesion load, neutrophils
were eliminated from the periphery using anti-Ly6g mAb injection
from days 3 to 15 p.i. (Fig. 7A). Flow analysis of immune cell in-
filtrates within the spinal cord confirmed neutrophil depletion fol-
lowing anti-Ly6g treatment (Fig. 7A). Supporting our previous
findings that double-tg mice display an increase in white matter
demyelination compared with single-tg mice was the observation
that isotype-treated double-tg mice displayed a significant increase
(p , 0.001) in the percentage of total white matter demyelination
compared with anti-Ly6g–treated single-tg mice (Fig. 7B).
Discussion
The ELR+ CXC chemokines (CXCL1–3 and CXCL5–8) are high-
affinity ligands for their cognate receptor CXCR2. This signaling
axis serves critical functions in host defense and disease, as it is
the dominant chemotactic pathway for neutrophil homing to sites
of inflammation. CXCL1, CXCL2, and CXCL5 are upregulated
within the CNS shortly following JHMV infection and control
neutrophil migration to the BBB, resulting in peak accumulation
by 3 d p.i (4). The importance of neutrophils in host defense to
JHMV infection has been investigated with the use of Abs that
either eliminate neutrophils from the periphery or prevent their
chemotaxis to the CNS. Many of these studies (4, 19, 20) have
implicated the short-lived neutrophils as a primarily cellular
source for the protease MMP9 during acute JHMV infection.
However, no studies have investigated how chronic ELR chemo-
kine overproduction from the CNS impacts neutrophil function as
well as host defense and disease following JHMV infection.
The successful generation of a Dox-dependent CXCL1-
expressing tg mouse has allowed for selective CXCL1 pro-
duction from astrocytes within mice infected with JHMV. Dox
administration resulted in elevated CXCL1 transgene expression
within the brains and spinal cords of double-tg mice, correlating
with rapid and selective neutrophil migration to the CNS
compared with Dox-treated controls. As a result of CXCL1
transgene expression, double-tg mice displayed a sustained
increase in clinical disease severity congruent with an increase in
mortality. This observation shares similarities to mice infected with
the lethal DM-JHMV variant that is characterized by a severe
disease whereby neutrophils dominate the immune cell composi-
tion early following infection (20). Overaccumulation of neutro-
phils in the CNS did not result in an increase in BBB permeability
or affect the expression of proinflammatory factors that could
potentially attract inflammatory leukocytes. Indeed, we observed
FIGURE 5. Elevated CXCL1 expression is associated with increased demyelination. Histopathological analysis of spinal cords of double-tg mice
reveals an increase in demyelination. (A) Representative Luxol fast blue–stained spinal cords (original magnification 34) reveal increased (p ,
0.05) demyelination in Dox-treated double-tg mice compared with single-tg controls. Assessment of demyelination in defined spinal cord sections
indicates white matter damage is more concentrated within the upper thoracic (T) regions (T3–T7) compared with lower T9–T13 as well as lumbar
(L) regions examined. (B) Increased demyelination was associated with a reduction in the number total GST-p+ oligodendrocytes within the white
matter. The dot plot presented in (A) represents the percentage demyelination at specific anatomical regions of the spinal cord. (C) Immunofluo-
rescence staining for Iba1 revealed increased numbers of positive cells within areas of demyelination in spinal cords of double-tg compared with
single-tg mice at day 12 p.i., and flow analysis indicated increased (p , 0.05) numbers of microglia (CD45loF4/80+). Scale bars, 50 mM. (A)–(C)
represent a minimum of four mice per group. Data are presented as average 6 SEM; statistical significance was measured using an unpaired two-
tailed Student t test. *p , 0.05.
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no statistical difference in the frequencies of macrophages or
T cells between double-tg and single-tg mice at day 12 p.i. as
measured by flow cytometry. These results are partially supported
by Savarin et al. (7, 8) who have provided evidence that neutro-
phils are not essential for promoting access of activated immune
cells into the CNS, as neutropenic mice or MMP9-deficient mice
infected with sublethal strains of JHMV do not show appreciable
differences in the early recruitment of activated leukocytes into
the parenchyma. Overall, these data indicate that the increased
presence of neutrophils within the CNS following JHMV infection
does not influence BBB integrity and has no impact on the re-
cruitment of other inflammatory cells from the periphery. Impor-
tantly, Dox-induced CXCL1 within the CNS did not affect
mobilization of CD11b+Ly6C+Ly6G2 monocytes within the
blood or migration into the CNS. Rather, there were decreased
numbers of these cells within the spinal cords of Dox-treated
double-tg mice compared with single-tg mice by day 12 p.i.
Whether CXCL1 modulates trafficking of CD11b+Ly6C+Ly6G2
monocytes in chronic stages of CNS inflammatory disease is not
known at this time.
An increase in the severity of white matter demyelination was
observed at day 12 p.i. in Dox-treated double-tg mice, and this
correlated with an overall decrease in the total number of GST-p+
mature oligodendrocytes. We do not think that CXCL1 had any
direct cytotoxic activity on oligodendroglia, as we have previously
FIGURE 6. Neutrophils are found within parenchymal regions of the
spinal cord in double-tg mice. (A) At day 12 p.i. brains and spinal cords
were isolated and single-cell suspensions were prepared from double-tg
and single-tg mice infected with JHMV. Flow cytometric analysis revealed
a significant increase in the frequency and total number of neutrophils
within the spinal cord of double-tg mice. (B) CXCL1 protein was detected
by immunohistochemical staining (red arrowheads) within spinal cords of
Dox-treated double-tg mice, and (C) immunofluorescence staining further
demonstrated a significant increase in the number of Ly6B.2+ neutrophils
(yellow arrowheads). Scale bars, 50 mM. (D) Quantification of neutrophils
within the spinal cords indicated an overall increase (p , 0.05) in Dox-
treated double-tg mice compared with Dox-treated single-tg mice. (E)
Quantification of neutrophils in defined anatomic regions of spinal cords
showed increased numbers of neutrophils (p , 0.05) within upper thoracic
(T) regions (T3–T9) and lower numbers at T11–T13 and lumbar (L) re-
gions in Dox-treated double-tg mice compared with Dox-treated single-
tg mice. (A) represents three independent experiments with a minimum
of three mice per group per experiment. (D) and (E) represent a minimum
of three mice per group. Data are presented as average 6 SEM; statis-
tical significance was measured using an unpaired two-tailed Student
t test. *p , 0.05.
FIGURE 7. Neutrophils amplify the severity of demyelination. (A) Dox-
treated JHMV-infected double-tg mice were treated with either anti-Ly6g
Ab or isotype-matched control starting between days 3 and 4 p.i. and
continuing every other day until day 15 p.i. Representative flow analysis of
spinal cords confirmed anti-Ly6G treatment successfully depleted neutro-
phils. (B) Representative Luxol fast blue–stained spinal cord sections from
JHMV-infected double-tg mice treated with either control IgG2a or anti-
Ly6G Ab between days 3 and 15 p.i. Quantification of the severity of
demyelination revealed reduced white matter damage in mice treated with
anti-Ly6G Ab compared with mice treated with isogenic IgG2a control
Ab; data are derived from two independent experiments with a minimum
of three mice per group per experiment. Data are presented as average 6
SEM; statistical significance was measured using an unpaired two-tailed
Student t test. *p , 0.001.
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shown that treatment of differentiating mouse oligodendrocyte
progenitor cells with recombinant CXCL1 does not kill these cells
(21). However, our findings revealed a significant parenchymal
presence of neutrophils associated with regions of severe de-
myelination in JHMV-infected double-tg mice, and ablation of
these cells limited the severity of white matter damage, arguing
for an important role for neutrophils in amplifying disease.
Although recent studies suggest that Ly6C+ myeloid precursor
cells play a pathogenic role during autoimmune demyelination
(17), our findings reveal that the increase in tissue damage was
not the result of enhanced migration of these cells to the CNS of
Dox-treated double-tg mice when compared with single-tg
mice. Neutrophils are known to possess an arsenal of prote-
ases and toxic factors that can impact cell survival, including
neutrophil elastase, cathepsin G, and MMPs (22). Moreover,
respiratory burst from the neutrophil phagosome and the gen-
eration NO as well as reactive oxygen species through the
NADPH oxidase complex can contribute to both vascular and
parenchymal damage, resulting in bystander destruction of
axons and oligodendrocytes within white matter tissue (23, 24).
This has been demonstrated in mouse models of ischemic injury
where inhibition of the NADPH complex results in less injury
to vascular endothelium and reduced cellular damage within
brain parenchyma (25). Furthermore, neutrophils are implicated
in exacerbating lesion development within spinal cords on pa-
tients with neuromyelitis optica (26), and inhibition of neutro-
phil elastase, a serine protease released from the primary
granules of neutrophils, within mouse models of neuromyelitis
optica resulted in reduced neuroinflammation and myelin loss
(27, 28). The potential destructive force of neutrophils has also
been demonstrated using neurovirulent JHM recombinant var-
iants, as neutrophil depletion or inhibition of NO synthase
correlated with reduced apoptosis of glial cells within the brain
(29). Another scenario is that neutrophils could be promoting
pathology by drawing in macrophages within more cervical and
upper thoracic regions of the spinal cord. Within the EAE
model of chronic neurologic disease, neutrophils have recently
been reported to have a role in maturating local APCs within
the CNS, thus potentially contributing to enhanced disease
severity by increasing numbers of autoreactive T cells (30). We
observed dense clusters of macrophages in heavily demyelin-
ated white matter regions that also contained significant neu-
trophil populations in double-tg mice. However, we think it
unlikely that the increase in disease severity is the result of
macrophages presenting viral Ag, as we did not detect elevated
numbers of virus-specific T cells within either the brain or
spinal cord.
Tani et al. (31) have shown that chronic overexpression of
CXCL1 from oligodendrocytes within naive mice results in a
neurologic disease associated with microglia and astrocytic reac-
tivity as a result of pronounced neutrophil accumulation within the
brain. Indeed, we observed increased numbers of microglia within
infected double-tg mice, and astrocytes displayed distinct pheno-
typic changes within heavily demyelinated regions, including
truncated morphologies and hypertrophy (unpublished observa-
tions). We are currently evaluating how microglia may augment
demyelination and whether this is dependent on the presence of
neutrophils. More importantly, these findings argue that sustained
neutrophil infiltration into the CNS enhances clinical disease se-
verity associated with an increase in white matter destruction.
Additionally, our observations are consistent with recent studies
from Segal and colleagues (32) and argue that therapies targeting
neutrophil accumulation within the CNS may offer novel alter-
native therapies for treating neuroinflammatory diseases.
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SUPPLEMENTAL FIGURE 1.  CXCL1 overproduction from the CNS does not affect 
T cell infiltration into the CNS.  Single cell suspensions from the brains and spinal cords 
from Dox-treated JHMV-infected double tg and single tg mice were isolated and 
immunophenotyped by flow cytometry.  (A) No statistical difference was observed in the 
frequency of CD45hi inflammatory infiltrates within the brain at day 4, 7 or 12 post-
infection (p.i.). (B) Within the spinal cord, CD45hi cells were elevated (p<0.05) at day 4 
p.i. in dox-treated double tg mice; however, this increase was no longer observed at day 7 
or 12 p.i. Furthermore, no changes were observed in the frequency of CD4+ (C,D) and 
CD8+ (E,F) T cells within the brain and spinal cord at day 4, 7 or 12 p.i.. The frequency 
and number of virus-specific CD4+ (G,H) and CD8+ (I,J) T cell also remained 
unchanged at all examined time-points.  Flow cytometric data represents 3 independent 
experiments with a minimum of 3 mice per group per experiment at each time-point. 
Data is presented as average+SEM. Statistical significance was measured using an 







































SUPPLEMENTAL FIGURE 2. Macrophage infiltration into the CNS is not affected by 
overproduction of CXCL1. Macrophage (CD45hiF480+) infiltration within the brain (A) 
and spinal cord (B) remained relatively unchanged in infected Dox-treated double tg mice 
compared to Dox-treated single tg mice. No differences were observed in the median 
fluorescence intensity (MFI) of MHC-II (C) and CD80 (D) within the brain or spinal cord 
of double tg and single tg mice. Flow cytometric data represents 3 independent 
experiments with a minimum of 3 mice per group per experiment at each time-point. 










INDUCED CENTRAL NERVOUS SYSTEM EXPRESSION OF CXCL1 AUGMENTS 
NEUROLOGIC DISEASE IN AN AUTOIMMUNE MODEL OF MULTIPLE 





The functional role of the chemokine CXCL1 in contributing to 
neuroinflammation and demyelination in EAE was examined. Through use of transgenic 
(tg) mice in which expression of CXCL1 is under the control of a tetracycline-inducible 
promoter active within GFAP+ cells, we have shown that sustained CXCL1 expression 
within the CNS increases clinical and histologic disease that is independent of an increase 
in either the frequency of encephalitogenic myelin-reactive Th1 or Th17 cells. Rather, 
increased disease was associated with enhanced recruitment of CD11b(+)Ly6G(+) 
neutrophils into the spinal cord. Neutrophil ablation resulted in a reduction in 
demyelination, arguing for a role for these cells in myelin damage. Collectively, these 
findings emphasize that CXCL1-mediated attraction of neutrophils into the CNS 




EAE is a T cell-driven autoimmune disease sharing many clinical and pathologic 
features with the human demyelinating disease MS (1-3). In EAE, CD4+ and CD8+ T 
cells specific for self-antigens expressed in CNS myelin initiate a localized inflammatory 
process that results in demyelination, axonopathy, and clinical deficits (4-6). The concept 
that the adaptive immune response is critical for new lesion development and disease 
progression in MS is emphasized in that FDA-approved disease modifying therapies are 
designed to limit infiltration of encephalitogenic lymphocytes into the CNS (7). Among 
the mechanisms by which myelin-reactive CD4+ T cells contribute to disease is through 
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localized secretion of cytokines e.g. IL-17 that increases expression of chemokines that 
attract myeloid cells into the CNS (8). Monocytes and macrophages amplify white matter 
damage through active stripping of the myelin sheath, leading to axonal damage, 
presentation of novel myelin epitopes to T cells, and amplifying neuroinflammation 
through secretion of proinflammatory molecules. In addition, IL-17 secretion increases 
expression of neutrophil chemoattractant chemokines CXCL1 and CXCL2, resulting in 
increased recruitment and accumulation of these cells within the CNS (9). 
 Increasing evidence in both preclinical models of MS as well as from MS patients 
have highlighted a potentially important role for neutrophils in demyelination (10-20). 
Neutrophil depletion delays the onset of clinical symptoms in EAE mice, arguing for a 
role for these cells in disease initiation and/or lesion formation (9, 13, 17, 19). Studies 
designed to decipher the mechanisms by which neutrophils augment disease progression 
point to increases in vascular permeability as well as secretion of reactive nitrogen and 
oxygen species (14, 18). In patients with relapsing-remitting MS, there are elevated 
systemic levels of neutrophil-activating chemokines, including CXCL1, CXCL5, and 
neutrophil elastase accompanied by increased numbers of neutrophils having a primed 
phenotype (10, 12). Collectively, these findings from preclinical models as well as MS 
patients strongly argue for a role for neutrophils in contributing to disease.  
 Given the transient nature of neutrophils in terms of having a short half-life, 
limited presence within lesions, and tightly regulated expression of chemotactic signals 
underscores the challenging aspects involved in understanding the role of these cells in 
autoimmune demyelination. To overcome some of these limitations, we have derived a 
transgenic mouse whereby expression of CXCL1 is under the control of a tetracycline-
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inducible promoter that is active within GFAP+ cells (21). Upon Dox treatment, these 
animals exhibit increased CXCL1 expression within the CNS, resulting in increased and 
sustained neutrophil infiltration into the spinal cord of mice infected with the neurotropic 
JHMV (21). Using these transgenic mice, we have recently shown that increased 
neutrophil infiltration into the CNS of mice infected with JHMV increased 
neuroinflammation and demyelination, emphasizing an important role for neutrophils in 
participating in white matter damage (21). Our present study was undertaken to assess 
how increased and sustained neutrophil recruitment into the CNS impacts EAE disease 
progression. Our findings indicate that increased expression of CXCL1 within the CNS 
results in more severe EAE as measured by both clinical disease and demyelination. The 
increase in disease was not dependent on an increase in myelin-reactive Th1 or Th17 
cells but correlated with increased numbers of neutrophil infiltration into the spinal cord. 
Indeed, depletion of neutrophils resulted in a reduction in the severity of white matter 
damage, highlighting a role for these cells in demyelination. 
 
4.3 Materials and methods 
4.3.1 Mice 
pBI-CXCL1-rtTA double transgenic mice (developed on the C57BL/6 
background) were developed as previously described (21). In brief, pBI-CXCL1 
transgenic mice were generated by the University of California, Irvine transgenic mouse 
facility through DNA microinjection of fertilized C56BL/6 eggs using the linearized pBI-
CXCL1 construct (22). The five resulting founder tg mice were mated to wildtype 
C57BL/6 mice to identify F1 offspring containing the transgene. To generate double tg 
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mice, hemizygous pBI-CXCL1 transgenics were crossed to hemizygous GFAP-rtTA*M2 
mice (JAX), resulting in double transgenic mice (pBI-CXCL1-rtTA), single tg (rtTA-
GFAP or pBI-CXCL1), or wildtype. Dox administration to double tg mice results in 
elevated CXCL1 transgene expression within astrocytes corresponding with increased 
CXCL1 protein and neutrophil accumulation whereas Dox treatment of single tg mice 
had no effect on CXCL1 expression nor neutrophil accumulation within the CNS (21). 
 
4.3.2 MOG35-55 EAE immunization 
For induction of EAE, experimental mice (aged 6-8 weeks old) were injected 
subcutaneously in the flanks with 200 µL of 1 mM MOG35- 55 peptide (DNA/Peptide 
Synthesis Core Facility, University of Utah) emulsified with reconstituted complete 
Freund’s adjuvant (Pierce Biotechnology, Waltham, MA, USA) containing 
Mycobacterium tuberculosis H37 Ra (2 mg/ml) (Difco Laboratories, Franklin Lakes, NJ, 
USA). Mice were injected intravenously with 100 µL Bordetella pertussis toxin (Ptx) 
(List Biological Laboratories Inc., Campbell, CA, USA) at 0.2 m g/mouse on days 0 and 2 
following sensitization. Double and single transgenic animals were injected with Dox 
(50mg/kg via i.p. injection) starting at day 9 following EAE induction and continuing 
through day 19 post-immunization. Experimental mice injected with MOG35- 55 were 
scored daily for clinical signs through day 21 following immunization using previously 






4.3.3 Flow cytometry 
Inflammatory leukocytes infiltrating into the CNS were isolated using an 
established protocol (3,4). In short, CNS tissue was minced and leukocytes were isolated 
using a two-step Percoll gradient (90% and 63%). The isolated cells were collected and 
then washed prior to staining. Cells were incubated in an anti-CD16/32 Fc Block (BD 
Biosciences, San Jose, CA) at a dilution of 1:200. Cells were stained with fluorescently 
tagged rat anti-mouse IgG for the following cell surface antibodies, Ly6G, CD11b, 
CD45, CD8, (BD Biosciences), Ly6C, CD4, F4/80, I-A/I-E, CD11c (Biolegend, San 
Diego, CA), and CD4, B220 (eBiosciences, San Diego, CA), or Armenian hamster anti-
mouse IgG for CD80 (BD Biosciences).  
 
4.3.4 Ex vivo peptide restimulation 
Spinal cord leukocytes that were isolated using a Percoll gradient as above were 
stimulated with MOG35-55 peptide or 50ng/mL phorbol myristate acetate (PMA) (Sigma, 
St. Louis, MO) with 2ug/mL Ionomycin (Iono) (Sigma, St. Louis, MO) and BD 
Cytofix/Cytoperm Plus Fixation/Permeabilization Kit (with BD GolgiPlug protein 
transport inhibitor containing brefeldin A) (BD Biosciences, San Jose, CA) and incubated 
at 37°C for 6 hours or 5 hours, respectively. Cells were stained with the surface marker 
CD4 (eBiosciences, San Diego, CA) and for intracellular cytokines including Rat anti-






4.3.5 Quantitative real-time PCR 
Total cDNA from brains and spinal cords of sham and EAE immunized mice at 
day 12 following disease induction was generated via Superscript III (Life Tech., 
Carlsbad, CA) following homogenization in Trizol (Life Tech., Carlsbad, CA). 
Expression of mRNA from defined mouse chemokine and cytokine genes including 
Cxcl1, Cxcl2, Cxcl10, Ccl2, Ccl5, IFN-γ, and IL-17A within the brain of experimental 
mice was determined by qPCR using SYBR Green I Master (Roche) on a LightCycler 
480 (Roche) and normalized to β-actin. (24) 
 
4.3.6 Histology 
Mice were euthanized according to IACUC guidelines and perfused with 20ml of 
4% paraformaldehyde (PFA). Spinal cords were removed, fixed overnight in 4% PFA at 
4°C, and separated into eight 1.5mm sections. Each section was cryoprotected in 30% 
sucrose for 5 days before embedding in OCT; 8 µM thick coronal sections were cut and 
stained with luxol fast blue (LFB) combined with hematoxylin and eosin (H&E). 
Pathology scoring of spinal cord sections was performed using previously described 
methods using 6-8 sections per cord (25).  
 
4.3.7 Immunofluorescence 
Spinal cord sections were processed as described above. For 
immunofluorescence, slides were first desiccated for 2 hours and blocked with 5% 
Normal Donkey Serum with or without 0.3% Triton-X 100. Primary antibodies were 
incubated overnight at 4°C: goat anti-CXCL1 1:50 (R&D Systems, Minneapolis, MN), 
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rabbit anti-GFAP 1:500 (Life Technologies, Carlsbad, CA), and rat anti-Ly-6B.2 1:100 
(Serotec, Raleigh, NC). Images were analyzed using the Image J software (NIH) 
according to previously described methods (26, 27).  
 
4.3.8 Antibody administration 
Rabbit polyclonal antiserum was generated to a 17-amino acid portion of the 
amino-terminus ligand binding domain of CXCR2 (MGEFKVDKFNIEDFFSG) 
(Cocalico Biologicals, Inc., Stevens, PA) and used to target neutrophils as previously 
described (9, 28, 29). Normal rabbit serum (NRS) from pre-immunized rabbits was used 
as controls. Experimental mice were injected i.p. with 0.5 mL with either anti-CXCR2 or 
NRS every 2-3 days starting on day 9 following EAE induction and ending on or before 
day 19. 
 
4.3.9 Statistical analysis 
Flow cytometry data were analyzed using FlowJo, while all graphs were analyzed 
using Prism. Significance was given if the p value was below 0.05 and averages were 
given in ±SEM. 
 
4.4 Results 
4.4.1 Increased clinical disease following Dox-induced  
expression of CXCL1 
Following induction of EAE, CD4+ T cell-derived IL-17 expression in the CNS 
potentiates disease by enhancing expression of the neutrophil chemoattractants CXCL1 
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and CXCL2 (9). The accumulation of neutrophils in the CNS is rapid yet transient and 
reflects the expression kinetics of CXCL1 and CXCL2. To better understand how 
neutrophil infiltration impacts demyelination and disease progression in EAE, tg mice 
were engineered to express CXCL1 within astrocytes upon doxycycline administration, 
as previous studies have shown these cells to be the primary source of CXCL1 in models 
of neuroinflammation (30, 31). Dox responsive double tg mice (pBI-CXCL1-rtTA) or 
single tg controls lacking the rtTA were immunized with MOG35-55 peptide and treated 
daily with Dox (50 mg/kg) i.p. between days 9 through 19 post-immunization (Fig. 
4.1A). Onset of clinical disease was similar between Dox-treated double tg and single tg 
mice (day 9 p.i.), but double tg mice exhibited a significant increase in clinical disease 
severity compared to single tg mice (Fig. 4.1B). Examination of mRNA transcripts 
encoding proinflammatory cytokines indicated a selective >2-fold increase in CXCL1 in 
Dox-treated double tg mice versus single tg mice at day 12 post-immunization, which 
represents a time in which there is a separation in clinical disease between double and 
single tg mice following MOG35-55 immunization. No differences in expression of 
transcripts encoding Cxcl2, Cxcl10, Ccl2, Ccl5, IFN-g, and Il-17A at day 12 between 
Dox-treated double tg and single tg mice were observed (Fig. 4.1C). A significant 
increase in CXCL1 protein was detected only in the spinal cord (Fig. 4.1E) and not in the 
serum (Fig. 4.1D) of double tg mice 12 days post-immunization compared to single tg 
controls . In contrast, we did not detect differences in proteins levels of G-CSF, GM-CSF, 
or IL-17 (data not shown) either prior to or following Dox treatment of double tg or 
single tg EAE mice. Immunofluorescence staining confirmed astrocytes (GFAP+) as the 
primary cellular source of CXCL1 in Dox-treated double tg EAE mice (Fig. 4.1F). 
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Together, these findings indicate that CXCL1 expression was specifically elevated in the 
CNS of Dox-treated double tg mice that correlated with an increase in clinical disease. 
 
4.4.2 Induced expression of CXCL1 does not increase either  
T cell or macrophage infiltration into the CNS 
MOG35-55-induced EAE disease correlates with CNS infiltration of Th1 and Th17 
CD4+ T cells reactive against the encephalitogenic MOG peptide (32). In addition, other 
immune subsets including CD8+ T cells, B cells, and macrophages are also considered 
important in amplifying clinical disease and pathology (32). We determined if 
overexpression of CXCL1 in the CNS of Dox-treated double tg mice immunized with 
MOG35-55 peptide altered the infiltration of inflammatory leukocytes into the CNS. We 
did not detect differences in the frequency or numbers of CD45hi leukocytes (data not 
shown), CD4+ T cells (Fig. 4.2A and B), or CD8+ T cells (Fig. 4.2C and D) in spinal 
cords of Dox-treated double tg mice compared to single tg mice. Moreover, there was no 
difference in intracellular CD4+ T cell cytokine expression of IFN-g, IL-17A, or co-
expressing IFN-g and IL-17A within the spinal cords at day 12 p.i. following 
PMA/ionomycin stimulation (Fig. 4.2E and F). Moreover, we did not observe changes in 
macrophages (CD45hiF4/80+) (Fig. 4.3A), microglia (CD45loF4/80+) (Fig. 4.3B), or 
macrophages or microglia co-expressing MHC class II and CD80 (Fig. 4.3C and D) of 
Dox-treated double and single tg EAE mice. Collectively, these findings argue that the 
increase in clinical disease following Dox-induced CXCL1 expression within the CNS is 
not due to increased infiltration of myelin-reactive CD4+ T cells nor other immune cells 
that are known to contribute to EAE disease severity. 
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4.4.3 Increased neutrophil accumulation within the spinal cord  
in response to Dox-induced expression of CXCL1 
CXCL1 is a potent chemoattractant of neutrophils expressing the chemokine 
receptor CXCR2 and its overexpression from astrocytes enhances the migration and 
accumulation of neutrophils in the white matter tracts of the spinal cords in a model of 
viral-induced encephalomyelitis (21, 28). We next investigated whether Dox-induced 
overexpression of CXCL1 promotes neutrophil accumulation in double tg mice induced 
with EAE. Histopathologic examination of spinal cord sections revealed increased 
localization of inflammatory cells in the anterior median fissure and meninges of the 
spinal cords of Dox-treated double tg mice compared to single tg EAE mice (Fig. 4.4A). 
The majority of inflammatory cells within spinal cords of double tg mice had a multi-
lobed nucleus characteristic of neutrophils (Fig. 4.4B). Immunofluorescence staining 
revealed increased numbers of cells positive for the neutrophil-associated surface antigen 
Ly6B.2 within the spinal cords of Dox-treated double tg EAE mice compared to single tg 
mice treated with Dox (Fig. 4.4C). In addition, flow analysis of spinal cords isolated 
from experimental mice indicated the frequency and numbers of neutrophils 
(CD45hiCD11b+Ly6G+) within the spinal cords of Dox-treated double tg mice were 
significantly (p<0.01) increased compared to single tg mice (Fig. 4.4D and E). 
Importantly, we did not observe an increase in Ly6C+ monocytes in either brain or spinal 
cords of double tg mice treated with Dox (data not shown). Together, these findings 
argue that the Dox-induced increase in CXCL1 expression within the CNS enhances the 
recruitment and accumulation of neutrophils within the spinal cords is associated 
increased with clinical disease severity. 
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4.4.4 Neutrophils increase the severity of demyelination in  
Dox-treated double tg EAE mice 
Using a model of viral-induced demyelination, we have previously shown that 
Dox-induced CXCL1 expression within the CNS increases the severity of white matter 
damage and this was correlated with enhanced neutrophil recruitment into the spinal cord 
(21). Assessment of spinal cord pathology between Dox-treated single tg and double tg 
mice was assessed using H&E/LFB staining at day 21 p.i. (Fig. 4.5A). Pathology scoring 
was evaluated by examining meningeal infiltration, perivascular cuffing, and 
demyelination. An increase in both meningeal infiltration (p<0.05) and demyelination 
(p<0.05) of double tg compared to single tg was observed (Fig. 4.5B). Furthermore, to 
determine whether neutrophils contributed to the enhancement of demyelination, MOG35-
55-immunized double tg mice treated with Dox were administered anti-CXCR2 antisera 
which we have previously shown to effectively target neutrophils (28, 31). Anti-CXCR2 
or NRS was administered to Dox-treated double tg mice at defined times following EAE 
induction (Fig. 4.5C). Administration of anti-CXCR2 antisera to Dox-treated double tg 
mice resulted in a dramatic reduction in clinical disease severity compared to animals 
treated with NRS alone (Fig. 4.5D) and this was correlated with reduced numbers of 
circulating CD45hiCD11b+Ly6C+Ly6G+ neutrophils (Fig. 4.5E). The reduction in clinical 
disease in Dox-treated double tg mice treated with anti-CXCR2 correlated with a 
significant (p<0.01) reduction in the severity of demyelination compared to NRS treated 
mice (Fig. 4.5F and G) and this was associated with reduced numbers of neutrophils 
present within the spinal cords (Fig. 4.5H and I). Together, these findings indicate that 




The pathogenesis of MS is characterized by CNS inflammatory lesions consisting 
of activated lymphocytes and monocyte/macrophages (33, 34). The importance of these 
cells to disease is highlighted in that FDA-approved DMTs used in treatment of 
relapsing-remitting MS limit immune cell infiltration and lesion development (35, 36). 
Nonetheless, there is increasing interest in the potential role of other cell types including 
neutrophils in participating in demyelination. The diverse functions of neutrophils 
include phagocytosis, release of toxic granules, and secretion of reactive oxygen species 
(ROS), nitrogen species, and NETs that can lead to bacterial clearance and tissue damage 
(37-40). In addition, neutrophils can produce many different cytokines and chemokines 
that participate in tailoring the immune response (37-40). Although there is direct 
evidence that neutrophils are important in both disease initiation and progression in EAE 
models, only indirect evidence exists showing these cells also play a role in MS 
pathogenesis (41). Since neutrophils are typically short-lived and have a half-life in 
circulation between 6 and 8 hours in humans (42), direct evidence of neutrophils in MS 
lesions from available autopsy tissue samples has been limited. Nonetheless, recent 
studies from Segal and colleagues (12) have demonstrated increased systemic levels of 
the chemokines CXCL1 and CXCL5 as well as neutrophil elastase that correlated with 
lesion burden and clinical disability in MS patients, arguing for a role for neutrophils in 
augmenting disease. 
The current study was performed to better understand the functional role of 
CXCL1 within the central nervous system following induction of MOG35-55-immunized 
experimental autoimmune encephalomyelitis (EAE) in mice. CXCL1 is a member of the 
68 
 
ELR(+) family of CXC chemokines that bind the chemokine receptor CXCR2 expressed 
on neutrophils that are important in allowing egress of neutrophils out of the bone 
marrow and to sites of inflammation (37). In the context of EAE, the highest expressing 
ELR(+) chemokines within the CNS are CXCL1 and CXCL5 during early stages of 
disease onset (34) and CXCL1 protein levels in the spinal cord were increased prior to 
and following disease onset (12). Mice treated with anti-CXCL1 showed a delayed onset 
of disease and decreased clinical disease, correlating with diminished numbers of Ly6G+ 
neutrophils, yet there was no change in infiltration of CD3+ T cells into the CNS, arguing 
for a role for neutrophils in disease (34). More recently, we have shown that over-
expression of CXCL1 within the CNS following infection with JHMV elevates clinical 
disease severity that correlates with an increase in demyelination; neutrophil ablation 
resulted in diminished white matter disease, highlighting that neutrophils can augment 
demyelination. 
 The successful generation of a Dox-dependent CXCL1 expressing transgenic 
mouse (21) has allowed for selective CXCL1 production from astrocytes and 
subsequently a better understanding of the functional role of this chemokine in MOG35-55-
induced EAE. Previously, Lira and colleagues (43) have shown that chronic 
overexpression of CXCL1 from oligodendrocytes within naïve mice results in a 
neurologic disease associated with microglia and astrocytic reactivity as a result of 
pronounced neutrophil accumulation within the brain. Using the CXCL1 double tg 
animals described in this study, we recently showed that astrocyte-derived 
overexpression of CXCL1 within the CNS was associated with increased clinical disease 
and demyelination in animals infected with the neurotropic JHMV and this was 
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dependent upon neutrophil infiltration into the spinal cords (21). In contrast, Raine and 
colleagues (44) demonstrated that overexpression of CXCL1 by astrocytes protected 
animals from EAE by limiting neuroinflammation as well as increasing numbers of 
oligodendrocytes associated with enhanced remyelination. These differences in clinical 
and histologic most likely reflect that, unlike Raine and colleagues, the Cxcl1 transgene 
employed in our study was lacking the 3’ untranslated region (UTR), resulting in an 
increase in the half-life of CXCL1 mRNA and therefore sustained CXCL1 production 
and subsequently neutrophil accumulation (44). The importance of neutrophils in 
enhancing white matter damage in Dox-treated double tg mice was emphasized by 
demonstrating that blocking neutrophil accumulation within the CNS via anti-CXCR2 
treatment dramatically reduced demyelination.  
Along with our data reported here, increasing evidence has shown that neutrophils 
play a key role in EAE and potentially MS. Ongoing studies are concentrating on 
defining mechanisms by which neutrophils increase demyelination in white matter tracts. 
Our findings demonstrating that the overproduction of CXCL1 in the CNS enhances 
white matter damage by the increase of neutrophil infiltration into the spinal cord, in 
conjunction with others in the EAE model and recent data from MS patients, suggest that 
impeding the production of CXCL1 would be an important target for a prospective 
therapy for neuroinflammatory diseases.  
 
4.6 References 
1. Baker, D., and S. Amor. 2014. Experimental autoimmune encephalomyelitis is a 
good model of multiple sclerosis if used wisely. Mult. Scler. Relat. Disord. 3: 
555-564. 
2. Martin, R., H. F. McFarland, and D. E. McFarlin. 1992. Immunological aspects of 
70 
 
demyelinating diseases. Annu. Rev. Immunol. 10: 153-187. 
3. Rao, P., and B. M. Segal. 2012. Experimental autoimmune encephalomyelitis. 
Methods Mol. Biol. 900: 363-380. 
4. Huseby, E. S., D. Liggitt, T. Brabb, B. Schnabel, C. Ohlen, and J. Goverman. 
2001. A pathogenic role for myelin-specific CD8(+) T cells in a model for 
multiple sclerosis. J. Exp. Med. 194: 669-676. 
5. Zamvil, S., P. Nelson, J. Trotter, D. Mitchell, R. Knobler, R. Fritz, and L. 
Steinman. 1985. T-cell clones specific for myelin basic protein induce chronic 
relapsing paralysis and demyelination. Nature 317: 355-358. 
6. Zamvil, S. S., D. J. Mitchell, A. C. Moore, K. Kitamura, L. Steinman, and J. B. 
Rothbard. 1986. T-cell epitope of the autoantigen myelin basic protein that 
induces encephalomyelitis. Nature 324: 258-260. 
7. Frohman, T. C., S. C. Beh, E. J. Kildebeck, R. Narayan, K. Treadaway, B. 
Greenberg, and E. M. Frohman. 2016. Neurotherapeutic strategies for multiple 
sclerosis. Neurol. Clin. 34: 483-523. 
8. Kroenke, M. A., T. J. Carlson, A. V. Andjelkovic, and B. M. Segal. 2008. IL-12- 
and IL-23-modulated T cells induce distinct types of EAE based on histology, 
CNS chemokine profile, and response to cytokine inhibition. J. Exp. Med. 205: 
1535-1541. 
9. Carlson, T., M. Kroenke, P. Rao, T. E. Lane, and B. Segal. 2008. The Th17-ELR+ 
CXC chemokine pathway is essential for the development of central nervous 
system autoimmune disease. J. Exp. Med. 205: 811-823. 
10. Naegele, M., K. Tillack, S. Reinhardt, S. Schippling, R. Martin, and M. Sospedra. 
2012. Neutrophils in multiple sclerosis are characterized by a primed phenotype. 
J. Neuroimmunol. 242: 60-71. 
11. Pierson, E. R., C. A. Wagner, and J. M. Goverman. 2016. The contribution of 
neutrophils to CNS autoimmunity. Cl. Immunol. S1521-6616: 30143-7. 
12. Rumble, J. M., A. K. Huber, G. Krishnamoorthy, A. Srinivasan, D. A. Giles, X. 
Zhang, L. Wang, and B. M. Segal. 2015. Neutrophil-related factors as biomarkers 
in EAE and MS. J. Exp. Med. 212: 23-35. 
13. Simmons, S. B., D. Liggitt, and J. M. Goverman. 2014. Cytokine-regulated 
neutrophil recruitment is required for brain but not spinal cord inflammation 
during experimental autoimmune encephalomyelitis. J. Immunol. 193: 555-563. 
14. Aube, B., S. A. Levesque, A. Pare, E. Chamma, H. Kebir, R. Gorina, M. A. 
Lecuyer, J. I. Alvarez, Y. De Koninck, B. Engelhardt, A. Prat, D. Cote, and S. 
Lacroix. 2014. Neutrophils mediate blood-spinal cord barrier disruption in 
71 
 
demyelinating neuroinflammatory diseases. J. Immunol. 193: 2438-2454. 
15. Christy, A. L., M. E. Walker, M. J. Hessner, and M. A. Brown. 2013. Mast cell 
activation and neutrophil recruitment promotes early and robust inflammation in 
the meninges in EAE. J. Autoimmun. 42: 50-61. 
16. Levesque, S. A., A. Pare, B. Mailhot, V. Bellver-Landete, H. Kebir, M. A. 
Lecuyer, J. I. Alvarez, A. Prat, J. P. de Rivero Vaccari, R. W. Keane, and S. 
Lacroix. 2016. Myeloid cell transmigration across the CNS vasculature triggers 
IL-1beta-driven neuroinflammation during autoimmune encephalomyelitis in 
mice. J. Exp. Med. 213: 929-949. 
17. Liu, Y., A. T. Holdbrooks, G. P. Meares, J. A. Buckley, E. N. Benveniste, and H. 
Qin. 2015. Preferential recruitment of neutrophils into the cerebellum and 
brainstem contributes to the atypical experimental autoimmune encephalomyelitis 
phenotype. J. Immunol. 195: 841-852. 
18. Miller, N. M., J. Wang, Y. Tan, and B. N. Dittel. 2015. Anti-inflammatory 
mechanisms of IFN-gamma studied in experimental autoimmune 
encephalomyelitis reveal neutrophils as a potential target in multiple sclerosis. 
Front. Neurosci. 9: 287. 
19. Stoolman, J. S., P. C. Duncker, A. K. Huber, and B. M. Segal. 2014. Site-specific 
chemokine expression regulates central nervous system inflammation and 
determines clinical phenotype in autoimmune encephalomyelitis. J. Immunol. 
193: 564-570. 
20. Wu, F., W. Cao, Y. Yang, and A. Liu. 2010. Extensive infiltration of neutrophils 
in the acute phase of experimental autoimmune encephalomyelitis in C57BL/6 
mice. Histochem. Cell Biol. 133: 313-322. 
21. Marro, B. S., J. J. Grist, and T. E. Lane. 2016. Inducible expression of CXCL1 
within the central nervous system amplifies viral-induced demyelination. J. 
Immunol.	196(4):1855-64. 
22. Yu, J., L. Zhang, P. M. Hwang, C. Rago, K. W. Kinzler, and B. Vogelstein. 1999. 
Identification and classification of p53-regulated genes. P. Natl. Acad. Sci. USA 
96: 14517-14522. 
23. Cusick, M. F., J. E. Libbey, L. Oh, S. Jordan, and R. S. Fujinami. 2015. Acthar 
gel treatment suppresses acute exacerbations in a murine model of relapsing-
remitting multiple sclerosis. Autoimmunity 48: 222-230. 
24. Tirotta, E., P. Duncker, J. Oak, S. Klaus, M. R. Tsukamoto, L. Gov, and T. E. 
Lane. 2013. Epstein-Barr virus-induced gene 3 negatively regulates 
neuroinflammation and T cell activation following coronavirus-induced 
encephalomyelitis. J. Neuroimmunol. 254: 110-116. 
72 
 
25. Sato, F., N. E. Martinez, M. Shahid, J. W. Rose, N. G. Carlson, and I. Tsunoda. 
2013. Resveratrol exacerbates both autoimmune and viral models of multiple 
sclerosis. Am. J. Pathol. 183: 1390-1396. 
26. Chen, L., R. Coleman, R. Leang, H. Tran, A. Kopf, C. M. Walsh, I. Sears-
Kraxberger, O. Steward, W. B. Macklin, J. F. Loring, and T. E. Lane. 2014. 
Human neural precursor cells promote neurologic recovery in a viral model of 
multiple sclerosis. Stem Cell Rep. 2: 825-837. 
27. Blanc, C. A., J. J. Grist, H. Rosen, I. Sears-Kraxberger, O. Steward, and T. E. 
Lane. 2015. Sphingosine-1-phosphate receptor antagonism enhances proliferation 
and migration of engrafted neural progenitor cells in a model of viral-induced 
demyelination. Am. J. Pathol. 185: 2819-2832. 
28. Hosking, M. P., L. Liu, R. M. Ransohoff, and T. E. Lane. 2009. A protective role 
for ELR+ chemokines during acute viral encephalomyelitis. PloS Pathog. 5: 
e1000648. 
29. Liu, L., A. Belkadi, L. Darnall, T. Hu, C. Drescher, A. C. Cotleur, D. Padovani-
Claudio, T. He, K. Choi, T. E. Lane, R. H. Miller, and R. M. Ransohoff. 2010. 
CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: 
relevance to multiple sclerosis. Nat. Neurosci. 13: 319-326. 
30.  Lane, T. E., V. C. Asensio, N. Yu, A. D. Paoletti, I. L. Campbell, and M. J. 
Buchmeier. 1998. Dynamic regulation of alpha- and beta-chemokine expression 
in the central nervous system during mouse hepatitis virus-induced demyelinating 
disease. J. Immunol. 160: 970-978. 
31. Hosking, M. P., E. Tirotta, R. M. Ransohoff, and T. E. Lane. 2010. CXCR2 
signaling protects oligodendrocytes and restricts demyelination in a mouse model 
of viral-induced demyelination. PloS One 5: e11340. 
32. Segal, B. M. Th17 cells in autoimmune demyelinating disease. Semin. 
Immunopathol. 32: 71-77. 
33. Compston, A., and A. Coles. 2008. Multiple sclerosis. Lancet 372: 1502-1517. 
34. Roy, M., J. F. Richard, A. Dumas, and L. Vallieres. 2012. CXCL1 can be 
regulated by IL-6 and promotes granulocyte adhesion to brain capillaries during 
bacterial toxin exposure and encephalomyelitis. J. Neuroinflamm. 9: 18. 
35. Hemmer, B., S. Nessler, D. Zhou, B. Kieseier, and H. P. Hartung. 2006. 
Immunopathogenesis and immunotherapy of multiple sclerosis. Nat. Clin. Pract. 
Neuro. 2: 201-211. 
36. Ransohoff, R. M., D. A. Hafler, and C. F. Lucchinetti. 2015. Multiple sclerosis-a 
quiet revolution. Nat. Rev. Neurol. 11: 134-142. 
73 
 
37. Sadik, C. D., N. D. Kim, and A. D. Luster. 2011. Neutrophils cascading their way 
to inflammation. Trends Immunol. 32: 452-460. 
38. Perobelli, S. M., R. G. Galvani, T. Goncalves-Silva, C. R. Xavier, A. Nobrega, 
and A. Bonomo. 2015. Plasticity of neutrophils reveals modulatory capacity. 
Braz. J. Med. Biol. Res. 48: 665-675. 
39. Nathan, C. 2006. Neutrophils and immunity: challenges and opportunities. Nature 
Rev. Immunol. 6: 173-182. 
40. Mantovani, A., M. A. Cassatella, C. Costantini, and S. Jaillon. 2011. Neutrophils 
in the activation and regulation of innate and adaptive immunity. Nat. Rev. 
Immunol. 11: 519-531. 
41. Casserly, C. S., J. C. Nantes, R. F. Whittaker Hawkins, and L. Vallieres. 2017. 
Neutrophil perversion in demyelinating autoimmune diseases: mechanisms to 
medicine. Autoimmun. Rev. 16: 294-307. 
42. Summers, C., S. M. Rankin, A. M. Condliffe, N. Singh, A. M. Peters, and E. R. 
Chilvers. 2010. Neutrophil kinetics in health and disease. Trends Immunol. 31: 
318-324. 
43. Tani, M., M. E. Fuentes, J. W. Peterson, B. D. Trapp, S. K. Durham, J. K. Loy, R. 
Bravo, R. M. Ransohoff, and S. A. Lira. 1996. Neutrophil infiltration, glial 
reaction, and neurological disease in transgenic mice expressing the chemokine 
N51/KC in oligodendrocytes. J. Clin. Invest. 98: 529-539. 
44. Omari, K. M., S. E. Lutz, L. Santambrogio, S. A. Lira, and C. S. Raine. 2009. 
Neuroprotection and remyelination after autoimmune demyelination in mice that 





Figure 4.1. Dox-induced CXCL1 expression increases clinical disease severity 
following MOG35-55-induced EAE. (A) Schematic outline of experimental approach for 
disease induction and Dox administration. (B) Clinical disease is increased in MOG35-55-
immunized double tg mice (n=26) compared to single tg (n=29) following Dox treatment. 
Dox-treated double tg mice had an overall increase in peak clinical disease compared to 
single tg mice. Data represent four independent experiments. (C) Dox-treatment of 
double tg mice (n=2) resulted in an selective 2-fold increase in Cxcl1 mRNA transcripts 
compared to single tg mice (n=2) at day 12 p.i whereas there was no difference in 
expression of transcripts encoding other pro-inflammatory cytokines/chemokines 
between experimental animals. On day 12, ELISA indicates Dox-treatment of either 
double tg or single tg mice did not change CXCL1 levels in serum, (D) yet there was a 
significant (p<0.05) increase in the spinal cords of double tg mice compared to single tg 
mice (E). Data represents a minimum of three independent experiments with between 2-4 
mice for each experiment. Representative immunofluorescence staining (60X) showing 
co-localization of CXCL1 protein (green) with GFAP-positive (red) astrocytes in double 
tg mice at day 12 following Dox treatment (scale bar = 5µm). Statistical analysis 





Figure 4.2. T cell infiltration into the CNS is not altered following Dox-induced 
expression of CXCL1. Spinal cords were removed at day 12 following MOG35-55 
immunization of Dox-treated single and double tg mice and T cell infiltration determined 
by flow cytometry. Increased CXCL1 expression and disease severity in Dox-treated 
double tg (n=10) was not associated with an increase in either CD45+CD4+ T cells (A, 
B) or CD45+CD8a+ T cells (C, D) when compared to single tg mice (n=10). 
Representative contour blots from experimental animals are shown in panels A and C. 
Data in panels B and D are representative of a minimum of two independent experiments 
and data are presented as average+SEM. (E, F) No differences in expression of cytokines 
IL-17A and/or IFN-g between Dox-treated double tg (n=3) or single tg (n=3) following 
PMA/Iono treatment of CD4+ T cells isolated from spinal cords at day 12 following 
MOG35-55 immunization. Data in panel E are representative contour plots showing the 
results of intracellular staining for IL-17A and IFN-g following PMA/Iono treatment of 
CD4+ T cells; data in panel F represent quantification of intracellular cytokine staining. 
Data are presented as average+SEM and statistical analysis employed unpaired two-tailed 




Figure 4.3. Dox-induced CXCL1 within the CNS does not increase 
microglia/macrophage activation. Dox-treated double and single tg mice were 
sacrificed at day 12 following MOG35-55 immunization and spinal cords removed to 
assess macrophage (CD45hi F4/80+) and microglia (CD45loF4/80+) activation via flow 
cytometric staining. Such analysis revealed no differences in either the frequency or 
numbers of either macrophages (A) or microglia (B) between double tg (n=10) or single 
tg (n=10) mice. Surface expression of activation markers MHC class II and CD80 was 
also examined and there were no differences in frequency or numbers of dual-positive 
macrophages (C) or microglia (D) between double tg (n=7) and single tg (n=7) mice. 
Data in panels A and B were derived from three independent experiments; data in panels 
C and D from two independent experiments. Data are presented as average+SEM and 




Figure 4.4. Neutrophil infiltration into the CNS is increased in response to Dox-
induced expression of CXCL1. MOG35-55-immunized double and single tg mice treated 
with Dox were sacrificed at day 12 post-immunization and spinal cords removed to 
assess histopathology and myeloid cell infiltration. (A) Representative H&E/Luxol fast 
blue staining of the spinal cords of experimental mice revealed increased inflammation 
within the anterior median fissure of double tg mice compared to single tg mice, 20X 
magnification. (B) Representative image of a spinal cord of Dox-treated double tg mouse 
showing cells with multilobed nuclei (red arrows) characteristic of neutrophils, 60X 
magnification. (C) Representative immunofluorescent staining for the neutrophil-specific 
surface antigen Ly6B.2 indicates increased expression within the spinal cords of double 
tg mice compared to single tg mice, 20X magnification. (D) Representative contour flow 
graphs showing increase in neutrophils (CD45hi CD11b+ Ly6G+) within the spinal cords 
of double tg mice compared to single tg mice. (E) Quantification of neutrophil flow 
staining revealed a significant increase in both the frequency and numbers of neutrophils 
in the spinal cords of double tg mice (n=10) when compared to single tg mice (n=10) that 
is significant in the percentages and cells/g spinal cord tissue. Data in panel E were 
derived from three independent experiments and data presented as average+SEM. 
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Figure 4.5. Increased neutrophil infiltration augments spinal cord demyelination. 
MOG35-55-immunized double and single tg mice treated with Dox were sacrificed at day 
21 post-immunization and spinal cords removed to assess histopathology and myeloid 
cell infiltration. (A) Representative H&E/LFB stained spinal cord images (4X) (areas of 
demyelination outlined in black) obtained from double tg and single tg mice. (B) 
Quantification of % pathology score at day 21 observing meningeal infiltration, 
perivascular cuffing, and demyelination revealing a significant increase in meningeal 
infiltration and demyelination in double tg mice (n=9) compared to single tg mice (n=9) 
including 3 independent experiments. (C) Schematic outline for experimental design to 
deplete neutrophils in double tg mice via injection of either anti-CXCR2 or NRS control 
antibody. (D) Clinical score analysis of double tg mice given anti-CXCR2 showed a 
significant decrease compared to NRS control double tg mice during MOG35-55 EAE. (E) 
In vivo representation of double tg mice treated with anti-CXCR2 (n=3) showing a 
significant (p<0.01) decrease in neutrophils (CD45hi CD11b+ Ly6C+ Ly6G+) compared to 
double tg mice treated with NRS 3 hours following treatment in the blood at 18 days 
post-immunization in one independent experiment. (F) Representative H&E/LFB 
staining reveals a reduction in the severity of demyelination (outlined in black) in double 
tg mice treated with the neutrophil-depleting anti-CXCR2 antibody compared to the NRS 
control antibody. (G) Quantification of pathology scoring of meningeal infiltration, 
perivascular cuffing, and demyelination in anti-CXCR2 treated double tg mice (n=4) 
compared to NRS treated mice (n=6) including 2 independent experiments at day 21 
indicates that neutrophil depletion significantly decreases demyelination (p<0.01). (H) 
No significant difference in neutrophils (CD45hi CD11b+ Ly6C+ Ly6G+) in the spinal 
cord at day 21, n=3 per group and one experiment. (I) Representative 
immunofluorescence (60X) of the dorsal funiculus in the spinal cord indicating the 
presence of Ly6B.2+ neutrophils within the parenchyma in double tg treated with anti-
CXCR2 that is not present in the double tg NRS treated mice at 21 days post-
immunization. Data presented as average+SEM. Statistical analysis employed unpaired 
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  CHAPTER 5 
 
DISRUPTED CXCR2 SIGNALING IN OLIGODENDROGLIA LINEAGE CELLS 





5.1 Introduction  
MS is a chronic neurodegenerative disease characterized by multifocal regions of 
neuroinflammation, demyelination, and axonal loss that ultimately results in extensive 
neurologic disability (1). Animal models of MS indicate that CNS infiltration of 
neutrophils, monocyte/macrophages, and inflammatory T cells, including those that are 
autoreactive to specific proteins embedded in the myelin sheath, are important in disease 
initiation and maintaining demyelination (2, 3). In support of this is the demonstration 
that drugs designed to limit immune cell infiltration into the CNS impede new lesion 
formation in MS patients (4, 5) and improve clinical outcome, as well as dampen 
demyelination in animal models of MS (6-9). Therefore, understanding the signaling 
events that shape immune cell trafficking into and within the CNS offers new insights for 
identification of novel targets for therapeutic intervention. 
Through use of preclinical mouse models of MS, chemokines and chemokine 
receptors have been implicated as important in attracting activated immune cells into the 
CNS and have been considered relevant targets for clinical intervention for MS patients 
(10-19). CXCR2 is a receptor for ELR(+) CXC chemokines e.g. CXCL1 and CXCL2 and 
is expressed on polymorphonuclear neutrophils (PMN) as well as glia and neurons (20-
24). CXCR2 signaling on neutrophils promotes demyelination in EAE and cuprizone-
induced demyelination (16, 25). CXCR2 has additional roles that extend beyond 
influencing neutrophil activity as it is expressed on immature OPCs as well as mature 
myelinating oligodendrocytes (26). Signaling through CXCR2 influences OPC 
proliferation and differentiation (27), controls the positional migration of OPCs during 
the development of the mouse spinal cord (28), and regulates the numbers of OPCs to 
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ensure the structural integrity of the white matter during CNS development (28). Indeed, 
mice devoid of CXCR2 exhibit a paucity of OPCs and structural misalignments that 
persist into adulthood of the mouse, resulting in reduced numbers of mature 
oligodendrocytes and total myelin within the white matter (29). Moreover, either genetic 
deletion or antibody-mediated targeting of CXCR2 increases myelin synthesis in 
demyelinated cerebellum slice cultures (30). It remains uncertain whether CXCR2 
signaling on oligodendrocyte lineage cells is implicated in the early inflammatory events 
that occur in MS and its models. The answer to this question is consequential, as 
interpretations of results of CXCR2-directed remyelination or oligodendrocyte-injury 
studies are markedly sharpened if a primary effect of oligodendrocyte lineage CXCR2 
can be excluded as a mediator of the initiating inflammatory events.  
The present study was undertaken to better understand how selective deletion of 
Cxcr2 within oligodendroglial lineage cells in adult mice influences CNS disease using 
models of viral-induced and autoimmune-mediated inflammatory demyelinating disease. 
We demonstrate that conditional ablation of Cxcr2 signaling in oligodendroglia did not 
alter the extent of clinical disease severity nor affect neuroinflammation or demyelination 
in either of these preclinical MS models. Therefore, our findings suggest that CXCR2 
signaling on oligodendrocytes does not modulate initial disease in these models of 
neuroinflammation and demyelination. The data indicate that either model can be used 
with confidence, to examine the downstream effects of oligodendrocyte lineage CXCR2 






5.2.1 Mice and tamoxifen treatment 
Plp-Cre-ER(T) :: Cxcr2 fl/fl mice were kindly donated by Dr. Richard Ransohoff 
(Cleveland Clinic). Mice were crossed to the reporter strain B6.Cg-
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J (The Jackson Laboratories, stock 007909) to generate 
Plp-Cre-ER(T) :: Cxcr2 fl/fl :: R26-stop-Td +/- mice (cCxcr2 fl/fl). Tamoxifen was prepared 
by resuspending at 10mg/ml in prewarmed sesame seed oil. The mixture was placed on 
an orbital shaker at 37°C and shaken overnight to completely dissolve solution. Four-
week-old cCxcr2 fl/fl mice received 1mg/ml tamoxifen twice daily for 5 days via i.p. 
injection, rested for 5 weeks and subsequently immunized with MOG35-55 peptide or 
infected intracranially with JHMV (31).  
 
5.2.2 Viral infection 
 Age-matched 5-6-week-old cCxcr2 fl/fl mice were infected i.c. with 250 plaque 
forming units (PFU) of JHMV in 30m l of sterile HBSS. SHAM infected animals received 
30ul HBSS via i.c. injection (32, 33). For viral titer analysis, one half of each brain or 
whole spinal cord was homogenized and used in a plaque assay as previously described 
(34, 35). Clinical disease severity was assessed using a previously described scoring 
system (34, 35). 
 
5.2.3 EAE induction 
CFA was prepared by mixing 10mL incomplete Freund’s adjuvant (Thermo 
Scientific, Rockford, IL) with 40mg M tuberculosis H37 (BD Biosciences, San Jose, CA) 
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to make a 4mg/ml solution of CFA. MOG35-55 peptide was prepared by resuspending in 
PBS at 1 µmol/mL. A 1:1 CFA-MOG emulsification was generating an emulsified by 
homogenization. To induce EAE, mice received two subcutaneous 100 mL injections of 
the CFA-MOG mixture and 100 mL of pertussis toxin (Ptx) (LIST Biological, Campbell, 
CA) via retroorbital injection. Mice received a second injection of Ptx at day 2 post-
immunization (36). Clinical disease was assessed using a previously described scoring 
system (37). 
 
5.2.4 Flow cytometry 
Flow cytometric analysis was performed to assess the composition of 
inflammatory cells entering the CNS using established protocols (38, 39). In brief, single 
cell suspensions were generated from tissue samples by grinding with frosted microscope 
slides. Immune cells were enriched by a 2-step Percoll cushion (90% and 63%) and cells 
were collected at the interface of the two Percoll layers. Before staining with the 
fluorescent antibodies, isolated cells were incubated with anti-CD16/32 Fc block (BD 
Biosciences, CA) at a 1:200 dilution. Immunophenotyping was performed using either rat 
anti-mouse IgG or Armenian hamster anti-mouse IgG antibodies for the following cell 
surface markers: F4/80 (Serotec, Raleigh, NC), MHV S510-tetramer (NIH), MHV M133-
Tetramer (NIH) and CD4, CD8, Ly6g, CD11b, IFN-γ, IL-17A, and CD45 (BD 







Mice were euthanized according to IACUC guidelines and perfused with 20ml of 
4% paraformaldehyde (PFA). Spinal cords were removed, fixed overnight in 4% PFA at 
4°C, and separated into eight 1.5mm sections. Each section was cryoprotected in 30% 
sucrose for 5 days before embedding in OCT. Eight micron thick coronal spinal cord 
sections were cut and stained with LFB as well as H&E from JHMV infected spinal 
cords, while MOG35-55 EAE immunized spinal cords were stained with FluroMyelin 
(Thermo Fisher Scientific, Waltham, MA). The percent demyelination was calculated by 
taking the total average demyelination within the white matter of eight spinal cord 
coronal sections using Image J software (NIH).  
 
5.2.6 Immunofluorescence/Immunocytochemistry 
Spinal cord sections were desiccated at room temperature (RT) for 2 hours before 
beginning the staining process. Slides were then washed in PBS and blocked with 5% 
normal donkey serum (NDS) for 1 hour at RT. Rabbit anti-glutathione S-transferase 
(GST-π) (MBL Life Science, Woburn, MA) was diluted to 1:1000 in 5% NDS and 
stained overnight at 4c. Slides were washed in PBS and Alexa 594-conjugated donkey 
anti-rabbit was added at a 1:500 dilution (Invitrogen, Carlsbad, CA). For cultured 
oligodendrocytes, cells were fixed for 20 mins in 4% PFA before being blocked with 5% 
normal goat serum (NGS). Cells were then stained with mouse anti-mouse O1 at a 
dilution of 1:50 (eBiosciences, San Diego, CA) followed by a secondary stain with Alexa 




5.2.7 Primary oligodendrocyte cultures 
 Cortices from postnatal day 1 cCxcr2 fl/fl mice were dissected and processed 
according to previously published protocols (40). In brief, following removal of the 
meninges, cortical tissue was minced with a razor and placed in pre-warmed DMEM 
containing papain in order to completely dissociate the tissue. Following further 
aspiration through a Pasteur pipette, single cell suspensions were added to Poly-D-Lysine 
coated culture flasks and grown for 9 days in DMEM supplemented with 10% FBS. 
Flasks were then transferred to an orbital shaker in a 5% CO2 tissue culture incubator and 
shaken for approximately 16 hours at 220 rpm in order to remove loosely adherent OPCs. 
Media containing OPCs was transferred to 10 cm dishes for 30 minutes to remove 
strongly adherent astroglial contaminants. OPCs were transferred to a 15ml conical and 
centrifuged at 300xg for 5 minutes. Cells were counted and plated onto matrigel-coated 
NuncTM Lab-Tek II Chamber slides (ThermoFisher Scientific, Waltham, MA) at 50,000 
OPCs per chamber in N2 media supplemented with 3, 3’, 5-Triiodo-L-thyronine sodium 
salt hydrate (T3, Sigma, St. Louis, MO). After 2 days, fresh media was used 
supplemented with (Z)-4-Hydroxytamoxifen (4-OHT, Sigma, St. Louis, MO) at 100nM 
to induce Cre-mediated recombination. Cells were cultured for an additional 6 days.  
  
5.2.8 Western blotting 
Samples were isolated from OPC cultures treated with either 4-OHT or vehicle 
control and separated by SDS-PAGE on a 10% gel (BioRad Mini PROTEAN TGX), 
transferred to a PVDF membrane in a Tris-Glycine buffer containing 20% methanol at 
30V for 3.5 hours, and blocked for 1 hour at room temperature (5% milk in PBS-T). 
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Membranes were then incubated overnight at 4oC in primary antibody diluted in 5% BSA 
in PBS-T. Primary antibodies used were myelin basic protein (MBP) (Rabbit anti-mouse, 
Abcam ab40390 @ 1:1000), cyclic nucleotide phosphodiesterase (CNPase) (Mouse anti-
mouse, Abcam ab6319 @ 1:1000), and b-actin (Rabbit anti-mouse, Abcam ab8227 @ 
1:1000). Primary antibodies were detected using horseradish peroxidase-conjugated 
secondary antibodies (goat anti-rabbit, Abcam ab97051 or goat anti-mouse, Abcam 
ab97023) diluted 1:5000 in 5% milk in PBS-T for 1 hour at room temperature. 
Membranes were developed with Western Lightning Plus-ECL Chemiluminescence 
Substrate (Perkin Elmer, Waltham, MA). 
 
5.2.9 PMA/Ionomycin stimulation assay 
Brains were isolated from experimental mice and processed to generate single cell 
suspensions. A total of 1x106 cells mononuclear cells were added to each well of a 96-
well plate in the presence of 50ng/ml PMA (Sigma, St Louis, MO) + 2ug/ml Iono 
(Sigma, St Louis, MO) for 5 hours. Following the incubation period, cells were stained 
for surface and intracellular antigens.  
 
5.3 Results 
5.3.1 Generation and characterization of Plp-Cre-ER(T); Cxcr2 fl/fl  
(cCxcr2 fl/fl) mice 
We sought to ablate Cxcr2 signaling within oligodendrocytes and their 
progenitors and assess the impact on two well-accepted preclinical mouse models of MS. 
A Plp-Cre-ER(T) :: Cxcr2 fl/fl mouse line (referred as cCxcr2 fl/fl) was employed that 
88 
 
utilizes Cre recombinase to selectively ablate Cxcr2 (41-46). The PLP regulatory element 
promotes expression of Cre-ER(T) (47) and has previously been shown to accurately 
reflect endogenous PLP expression spatially and temporally in oligodendroglia (47). To 
aid in visualizing cells actively expressing Cre recombinase, cCxcr2 fl/fl tg mice were 
crossed to a Cre-inducible Rosa26-Tdtomato red reporter line on the C57BL/6 
background (Figure 5.1A). 
Ablation of Cxcr2 was confirmed within oligodendrocyte-lineage cells following 
ex vivo culture of OPCs generated from the brains of post-natal day 1 (P1) cCxcr2 fl/fl 
mice. Addition of 4-OHT (100nM) induced Cre-mediated recombination at the Cxcr2 
locus as detected by PCR (Figure 5.1B). Further, 4-OHT induced expression of 
Tdtomato red in greater than 90% of OPCs expressing the late stage O1 surface marker 
(Figure 5.1C). Ablation of CXCR2 signaling within cultured cells treated with 4-OHT 
did not alter synthesis of MBP nor CNPase, which are proteins associated with 
oligodendrocyte maturation and myelin synthesis (Figure 5.1D-F). 
To determine the cellular specificity of Cre in vivo, 4-week-old cCxcr2 fl/fl mice 
were treated with 1mg tamoxifen by i.p. administration twice daily for 5 days. 
Recombination at the Cxcr2 locus was detected by PCR in the brain and spinal cord of tg 
mice but not in the spleen, liver, or kidney (Figure 5.2A). Selective expression of 
Tdtomato red was observed in over 70% of GST-π –positive oligodendrocytes within the 
spinal cord (Figure 5.2B). Previous studies (16) have demonstrated that neutrophils 
require CXCR2 to traffic and accumulate within the CNS and promote EAE (16). We 
confirmed that tamoxifen treatment did not induce aberrant Cre activity in neutrophils, as 
no differences were observed in expression of CXCR2 on neutrophils in the spleen at 14 
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days post-tamoxifen treatment (Figure 5.2C). Collectively, these results demonstrate that 
deletion of Cxcr2 is specific to oligodendrocyte-lineage cells. 
 
5.3.2 Disrupted CXCR2 signaling in oligodendroglia does not affect  
susceptibility to EAE 
Tamoxifen has been reported to mute the severity of EAE by dampening immune 
responses to myelin-specific antigens (31). To maximize tamoxifen clearance prior to 
MOG35-55 peptide immunization, cCxcr2 fl/fl mice were rested for 30 days following 
tamoxifen treatment (48) (Figure 5.3A). Enriched expression of Tdtomato red was 
observed within the white matter tracts of the spinal cords of tamoxifen-treated tg mice 
compared to vehicle-treated control mice (Figure 5.3B) and was specific to GST-π 
oligodendrocytes (Figure 5.3C). Tamoxifen-treated tg mice were immunized with 
MOG35-55 peptide with adjuvants (see methods) and the severity of clinical disease was 
monitored. Ablation of Cxcr2 had no effect on clinical disease to at least 35 days post-
immunization (Figures 5.3D). Fluoromyelin staining revealed similar levels of 
demyelination between vehicle and tamoxifen-treated EAE mice (Figure 5.3E) and 
quantification of demyelination by LFB analysis confirmed no difference in white matter 
pathology between groups (Figure 5.3F). These results argue that CXCR2 signaling on 







5.3.3 Silencing of CXCR2 signaling on oligodendroglia does not impair  
immune cell infiltration into the CNS upon EAE induction 
We investigated whether deletion of Cxcr2 in oligodendroglia influenced 
leukocyte infiltration into the CNS, as engagement of CXCR2 on oligodendrocytes in 
culture promotes oligodendroglia-specific autoamplification of ELR-chemokines (49). 
No differences in frequency or numbers of total CD4+ or CD8+ T cells were detected in 
the brain or spinal cord of tamoxifen-treated EAE mice compared to vehicle-treated EAE 
mice at day 20 post-MOG35-55 immunization (Figures 5.4A and B). Ex vivo PMA/Iono 
stimulation of CNS-derived CD4+ T cells isolated from brains of tamoxifen-treated tg 
mice displayed similar expression of IFN-γ+IL17A-, IFN-γ-IL-17A+, and dual-positive 
IFN-γ+IL-17A+ expression compared to vehicle controls (Figures 5.4C and D). No 
differences were detected in CNS infiltration of neutrophils (CD45hiCD11b+Ly6G+) or 
macrophages (CD45hiF480+), and the total numbers of microglia were the same 
(CD45loF480+) between groups (Figures 5.5A and B). 
 
5.3.4 Cxcr2 ablation within oligodendrocytes does not affect  
viral-induced demyelination 
Intracranial instillation of the neuroadapted JHMV results in an acute 
encephalomyelitis followed by a chronic demyelinating disease characterized by viral 
persistence in white matter tracts accompanied by immune-mediated damage (50). The 
JHMV model differs from MOG35-55-induced EAE as it is characterized by transient 
neutrophil accumulation within the CNS and a Th1-mediated pathology whereby virus-
specific IFN-γ-expressing CD4+ T cells and inflammatory macrophages contribute to 
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white matter pathology (3, 51). During chronic JHMV disease, ELR-chemokine signaling 
and the appearance of IL-17A and Th17+ T cells remains minimal and are not considered 
important in contributing to either clinical disease or white matter pathology (52, 53). 
Tamoxifen or vehicle treated cCxcr2 fl/fl mice were infected with 250PFU JHMV and 
clinical disease was monitored. No differences were observed in morbidity or mortality in 
tg mice (Figure 5.6A). Similar frequencies of neutrophils and macrophages were 
observed day 3 p.i. (Figure 5.6B) and the frequency and total numbers of macrophages, 
neutrophils, and T cells were similar between groups at day 6 p.i. (Figure 5.6C). No 
differences were observed in the infiltration of virus-specific CD4+ and CD8+ T cells 
into the CNS of tamoxifen treated tg mice (Figure 5.7A), resulting in similar viral titers 
compared to vehicle treated tg controls (Figure 5.7B). Finally, assessment of the extent 
of demyelination in JHMV-infected mice either treated with tamoxifen or vehicle 
revealed no differences in white matter damage (Figure 5.7C). 
 
5.4 Discussion 
Chemokine signaling networks that are associated with chronic CNS diseases 
such as MS or persistent viral infections are thought to amplify disease severity by 
attracting targeted populations of leukocytes into the CNS (54). One chemokine signaling 
pathway that is emerging as important in chronic CNS disease involves the CXCR2 
receptor and its cognate ELR(+) chemokine ligands CXCL1 -2 -3 and CXCL5 -6 -7 -8. 
CXCR2 is highly expressed on circulating neutrophils, enabling these cells to rapidly 
migrate to the BBB in response to CNS-derived ELR-ligand expression whereby these 
cells participate in degrading components of the BBB. Evidence for a proinflammatory 
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role of neutrophils in chronic neurologic disease is supported by Segal and colleagues 
(16) who have shown that genetic silencing or antibody-mediated blockade of CXCR2 in 
mice following PLP-induced EAE resulted in reduced clinical disease and relapses as a 
result of limiting BBB permeability. Within the context of acute viral infection of the 
CNS, we have previously reported that antibody-mediated neutralization of CXCR2 
during JHMV-infection enhanced disease (55). This outcome was a result of reduced 
neutrophil and monocyte trafficking, as these cells are critical in permeabilizing the BBB 
that subsequently allows penetration of virus-specific T cells in the parenchyma to 
combat viral replication.  
In addition to being expressed on circulating myeloid cells, CXCR2 is also 
expressed on neurons as well as resident glial cells including oligodendroglia. With 
regards to a putative functional role for CXCR2 signaling during chronic JHMV-induced 
neuroinflammation and demyelination, administration of a CXCR2-specific blocking 
antibody to infected mice increased clinical disease and correlated with a significant 
increase in oligodendrocyte apoptosis and demyelination (56). Further, addition of IFN-γ 
to cultured OPCs derived from mouse neural progenitor cells results in apoptosis, while 
inclusion of CXCL1 protein blocks OPC apoptotic death (22).  
CXCR2 is believed to influence OPC proliferation and differentiation (27) as well 
as controlling migration of spinal cord OPCs during development (28). Ablation of Cxcr2 
results in a paucity of OPC numbers and structural misalignments that persist into 
adulthood of the mouse, and manifest as reduced numbers of mature oligodendrocytes 
and total myelin within the white matter (29). The functional role of CXCR2 signaling in 
mouse models of demyelination within the CNS is somewhat enigmatic. Some findings 
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suggest that the CXCR2 signaling axis downregulates myelin production by 
oligodendrocytes (57), while others have reported that CXCR2 signaling is a survival 
mechanism for OPCs needed to halt apoptosis induced by cytotoxic factors secreted 
during an inflammatory response (22, 56, 58, 59). Liu and colleagues (30) used bone 
marrow chimeric mice to partition the contribution of CXCR2 expression on either 
hematopoietic or CNS derived cells. Adoptive transfer of hematopoietic cells derived 
from the bone-marrow of Cxcr2 +/+ mice into Cxcr2 -/- mice led to increased 
oligodendrocyte differentiation in both EAE and cuprizone models of demyelination 
suggesting that CXCR2 may be an inhibitory signaling cue for myelin repair (30). Using 
CXCR2 antagonism via a neutralizing antibody therapy resulted in enhanced 
oligodendrocyte differentiation and clinical recovery during EAE, further supporting a 
detrimental role for CXCR2 signaling within the CNS in mouse models of chronic 
inflammatory demyelinating disease (60). Conversely, inducible overproduction of 
CXCL1 by astrocytes reduced EAE clinical disease; although it is unclear whether 
increased levels of CXCL1 directly impacted oligodendrocyte biology or modulated 
immune cell recruitment into the CNS (58). Previous work from our laboratory 
employing antibody-mediated targeting of CXCR2 shows that blocking signaling in 
JHMV-infected mice increases the severity of demyelination arguing for a protective role 
for CXCR2 in a model of viral-induced demyelination as previously discussed (49). 
However, whether this is a direct effect of blocking CXCR2 signaling on oligodendroglia 
and/or other CNS resident cells is unknown. 
Our present study built upon these studies to further our understanding of how 
CXCR2 signaling on oligodendrocytes affects experimental models of 
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neuroinflammatory demyelination. Using both the MOG35-55-induced EAE and the 
JHMV model of viral-induced demyelination, we provide evidence that tamoxifen-
induced silencing of CXCR2 on oligodendroglia did not affect clinical disease. More 
importantly, we did not observe any changes in the extent of neuroinflammation in either 
model, suggesting that muting CXCR2 on oligodendroglia alone did not influence 
proinflammatory gene expression within the CNS. This notion is supported by evidence 
indicating that neither generation of antigen-specific T lymphocytes was impacted nor 
was recruitment of T cells, neutrophils, or macrophages affected following tamoxifen 
treatment of experimental cCxcr2 fl/fl mice compared to mice treated with vehicle control. 
These findings argue that CXCR2 signaling on oligodendroglia has no effect on 
proinflammatory gene signatures responsible for recruiting either EAE-associated 
Th1/Th17 cells nor JHMV-associated Th1 cells. This is interesting in light of a recent 
report demonstrating that NG2-positive glia, precursors to glial cells including 
oligodendroglia, respond to the cytokine IL-17, and mediate the effector phase of Th17-
mediated EAE (61). In addition, IL-17 impairs maturation of oligodendroglia and reduces 
their survival (61). Therefore, oligodendroglia are responsive to the cytokine/chemokine 
milieu within the CNS microenvironment during neuroinflammatory disease. 
Nonetheless, our findings clearly indicate typical neuroinflammation occurs in the 
absence of CXCR2 signaling on oligodendroglia.  
In vitro treatment of oligodendroglia isolated from cCxcr2 fl/fl mice with 4-OHT 
did not increase or decrease synthesis of myelin-associated proteins MBP and CNPase. 
These findings contrast with reports suggesting that blocking CXCR2 increases myelin 
formation (30, 62, 63). These studies were performed using either small molecule 
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antagonists for CXCR2 or Cxcr2 germline knock-out mice that would lack specificity for 
selectively targeting CXCR2 signaling to oligodendroglia lineage cells. More recently, 
Ransohoff and colleagues generated mice in which Cxcr2 was selectively ablated in 
oligodendrocytes (64). Similar to the animals we have generated, Cxcr2 is silenced within 
oligodendroglia in adult mice upon tamoxifen treatment (64). Employing toxin models of 
demyelination, the authors clearly show enhanced remyelination in animals in which 
CXCR2 signaling in oligodendrocytes is inhibited arguing for an important role for this 
chemokine receptor in influencing oligodendrocyte biology. Our findings showing that 
silencing of CXCR2 did not improve clinical disease in either autoimmune or viral-
induced neuroinflammatory demyelination argues that remyelination was not occurring. 
These results highly suggest that the effect of CXCR2 on remyelination may be model 
dependent. In the non-inflammatory toxin models of demyelination, blocking CXCR2 
enhances OPC maturation and increases remyelination whereas in neuroinflammatory 
models, selective ablation of CXCR2 does not have any appreciable effects on 
remyelination. Whether this is the result of the inflammatory microenvironment on 
masking the potentially protective effect of targeting CXCR2 on oligodendroglia is 
unknown at this time and is the focus of ongoing studies. 
 
5.5 Conclusions 
This study demonstrates that targeted silencing of Cxcr2 expression within 
oligodendroglia did not impact neuroinflammation nor demyelination using either a viral 
or autoimmune model of MS. These findings argue that signaling through CXCR2 on 
oligodendroglia is not a key factor in amplifying proinflammatory gene expression and 
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immune cell infiltration into the CNS. Nonetheless, compelling evidence indicate that 
CXCR2 plays an important role in OPC maturation and subsequent remyelination. 
Therefore, within the context of oligodendroglia, CXCR2 is not important in disease 
initiation yet has an important role in repair. 
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Figure 5.1: Cre-mediated recombination is detected in vitro. (A) Schematic diagram 
showing genetic strategy to generate tamoxifen-inducible knock-out of Cxcr2 within 
oligodendroglia. (B) Cre-mediated recombination at Cxcr2 locus was detected by PCR 
from oligodendrocyte-enriched cultures derived from P1 cCxcr2 fl/fl mice following 
addition of 4-OHT. (C) Treatment with 4-OHT induced expression of Tdtomato red in 
>90% O1-positive oligodentrocytes derived from P1 cCxcr2 fl/fl mice. (D) Western blot of 
CNPase and MBP from 4-OHT treated oligodendrocyte cultures. (E) Normalized 
expression of MBP or (F) CNPase following 4-OHT treatment. Quantification of 
Tdtomato red-positive O1-positive oligodendrocytes in panel C represents 4 independent 
OPC cultures derived from cCxcr2 fl/fl mice; data presented as average+SEM. DIV, days 
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Figure 5.2: Cxcr2 is ablated in vivo following tamoxifen treatment. (A) Detection of 
Cre-mediated recombination at the Cxcr2 locus in the brain and spinal cord of cCxcr2 fl/fl 
mice 2 weeks following tamoxifen treatment. (B) Quantification revealed ~75% of GST-
π-positive oligodendrocytes expressed Tdtomato following tamoxifen treatment. (C) 
CXCR2 expression on splenic neutrophils following tamoxifen-treated cCxcr2 fl/fl mice. 
Panel B is representative of 8 separate coronal spinal cord sections from 4 mice and 
presented as average+SEM. Panel C represents 2 independent experiments with a 





Figure 5.3: Clinical and histologic disease is not affected following MOG35-55-induced 
EAE in cCxcr2 fl/fl mice. (A) Schematic depicting tamoxifen injections and MOG35-55 
immunization in cCxcr2 fl/fl mice. (B) Representative spinal cord images of MOG35-55-
immunized treated with vehicle (control) or tamoxifen at day 21 following MOG35-55 
immunization. (C) Representative immunofluorescent staining for GST-p confirmed that 
Tdtomato red expression is restricted to oligodendrocytes. (D) Clinical disease scoring of 
tamoxifen-treated cCxcr2 fl/fl mice (n=15) compared with control-treated mice (n=16) 
immunized with MOG35-55 peptide. (E) Representative fluoromyelin staining of spinal 
cords from control (n=5) and tamoxifen-treated cCxcr2 fl/fl mice (n=7); areas of 
demyelination are outlined by red lines and (F) quantification on total demyelination in 
spinal cord sections. Clinical scoring data are derived from two independent experiments. 
Fluoromyelin staining represents 2 independent experiments including 8 spinal cord 





Figure 5.4: MOG35-55-specific CD4+ T cell responses are intact following tamoxifen 
treatment. MOG35-55-immunized cCxcr2 fl/fl mice were treated with either tamoxifen 
(n=8) or vehicle control (n=6) including 2 independent experiments and spinal cords 
removed at day 20-21 post-immunization to measure the frequency and number of (A) 
Percent and numbers of CD4+ T cells and (B) CD8+ T cells in spinal cords. (C-D) On 
day 20 post-immunization, isolated brain leukocytes were stimulated PMA/Iono for 5 
hours and intracellular cytokine production of IFN-g and/or IL-17A was measured in 
CD4+ T cells. (D) Data are derived from one independent experiment n=3 per group and 





Figure 5.5: EAE neuroinflammation is not affected in response to tamoxifen 
treatment. MOG35-55-immunized cCxcr2 fl/fl mice were treated with either tamoxifen 
(n=8) or vehicle control (n=6) and spinal cords removed at day 20-21 following peptide 
injection to measure the frequency and numbers of (A) neutrophils 
(CD45hiCD11b+Ly6G+), (B) macrophages (CD45hiF4/80+) and microglia (CD45hiF4/80-). 



























































































































































































Figure 5.6: Tamoxifen-mediated ablation of Cxcr2 does not affect 
neuroinflammation in response to JHMV infection of the CNS. cCxcr2 fl/fl mice were 
treated with tamoxifen or vehicle control and infected with 250 PFU JHMV. (A) Clinical 
disease severity and mortality was recorded following JHMV infection. (B) Flow 
cytometric analysis of the frequency leukocytes (CD45hi), neutrophils 
(CD45hiCD11b+Ly6G+), and macrophages (CD45hiF4/80+) in the brains at day 3 p.i. or 
(C) day 6 p.i.. Also included are the numbers of infiltrating leukocytes, neutrophils, 
macrophages, CD4+ T cells, and CD8+ T cells in the brain at day 6 p.i.. Clinical disease 
and mortality is representative of 10 vehicle treated and 22 tamoxifen treated cCxcr2 fl/fl 





Figure 5.7: Cxcr2 ablation does not alter antiviral immune responses nor 
demyelination. JHMV-infected cCxcr2 fl/fl mice treated with either tamoxifen or vehicle 
control and infected with 250 PFU JHMV. (A) M133-specific CD4+ T cells or S510-
specific CD8+ cell frequencies were determined in by tetramer staining from cells 
derived from the brains of mice at day 6 p.i. (B) Viral titers in brain and spinal cord of 
mice were measured at day 7 p.i. (C) Representative (left) spinal cord sections showing 
demyelination within the white matter tracts of mice was measured by H&E in 
conjunction with LFB staining. Percent demyelination was quantified (right). Data in 
panel A, B, and C represent at least 4 mice per group and 6-8 spinal cord sections per 
















6.1 Overexpression of CXCL1 in models of MS 
The ELR(+) CXC chemokines bind to the receptor CXCR2 that is expressed on 
neutrophils and is important in their ability to traffic to sites of inflammation (1). In the 
context of a model of viral-induced demyelination e.g. JHMV-infection of the CNS of 
susceptible mice, the ELR(+) CXC chemokine CXCL1 as well as others are increased 
early following infection. In EAE, the autoimmune model of MS, expression of ELR(+) 
chemokines are also increased near onset of disease (2-4). During acute JHMV, treatment 
with anti-CXCR2 depleted neutrophils in the brain, showing that the release of MMP-9 
by neutrophils early during disease is important in aiding the breakdown of the BBB 
resulting in decreased immune cell recruitment to the CNS, unimpaired viral replication, 
and increased mortality in the mice (2). Blocked neutrophil trafficking in EAE models via 
anti-Ly6G, anti-CXCL1, or anti-CXCR2 treatment resulted in a delay in clinical disease 
onset (4-6). Conversely, in transgenic mice in which CXCL1 is constitutively expressed 
from oligodendroglia resulted in increased neutrophil accumulation within the CNS and 
enhanced microglial and astrocyte activation that correlated with pronounced ataxia and 
decreased lifespan (7). Astrocytes express the chemokine CXCL1 and we wanted to 
better understand how overexpression of CXCL1 influenced disease in two preclinical 
mouse models of MS and if neutrophils participated in demyelination (4, 8, 9).  
  Dox-dependent overexpression of CXCL1 from astrocytes in JHMV-infected 
mice and MOG35-55-induced EAE resulted in a significant increase in clinical disease 
correlating with an increase in spinal cord neutrophil infiltration. In both models, there is 
an increase in demyelination when CXCL1 is overproduced; either depletion of 
neutrophils via anti-Ly6G treatment or blocking neutrophil trafficking via anti-CXCR2 
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decreased the severity of spinal cord demyelination. In the JHMV model, increased 
neutrophil accumulation in the CNS correlated with an increase in mortality independent 
of changes in BBB permeability, alterations in other proinflammatory cytokine levels, or 
infiltration of virus-specific T cells or monocyte/macrophages. Similar results appeared 
in the MOG35-55 EAE model in which the increase in disease was associated with 
increased neutrophil infiltration, while myelin-reactive T cells as well as other leukocyte 
were not affected. Together, these findings suggest that the increase in CXCL1 in the 
CNS during mouse models of MS contributes to increased disease severity mediated by 
neutrophils. Overexpression of CXCL1 within astrocytes showed an increase in 
macrophages/microglia within the spinal cords of experimental mice, but we do not think 
that these cells are contributing to the increase in morbidity since there was no increase in 
the activation state as determined by measuring MHC class II and CD80/86 expression. 
In addition, previous studies have suggested that Ly6C+ myeloid precursor cells can also 
contribute to disease severity in EAE (10).  
 
6.2 Oligodendrocyte expression of CXCR2 role in MS models 
The role of CXCR2 on neutrophils has been mainly studied in mouse models of 
MS, either by antibody blockage, antagonist administration, or use of whole-body Cxcr2 
-/- mice (2, 5, 11, 12). During acute JHMV infection, antibody neutralization of CXCR2 
increased morbidity and mortality in mice by an inability to breakdown the BBB due to 
the decrease in neutrophil recruitment and mice succumb to viral infection (2). In a toxin 
model of demyelination, CXCR2+ neutrophils contribute to white matter damage (11). In 
both the lysolecithin (LPC) and MOG35-55 EAE model, CXCR2 antagonist administration 
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resulted in a decrease in demyelination and increase in remyelination, although the 
specific cell type/types involved were not deduced (12). In the PLP139-151 EAE and 
cuprizone model of demyelination, CXCR2 expression in nonhematopoietic cells 
impeded the ability for myelin repair, indicating that CXCR2 in resident cells of the CNS 
are involved in myelin repair (11). During the chronic stage of JHMV infection, anti-
CXCR2 treatment increased clinical disease and this was associated with oligodendrocyte 
apoptosis and demyelination, suggesting a protective role of CXCR2 on oligodendrocytes 
in the late stages of this model (3). In addition, OPCs administered CXCL1 impedes 
apoptosis in response to viral infection by inhibiting cleavage of caspase 3 (13). 
While the role of CXCR2 in neutrophil recruitment to sites of inflammation has 
been studied more extensively, CXCR2 expressed in resident cells within the CNS 
including neurons, OPCs, oligodendrocytes, activated astrocytes, and microglia has not 
been analyzed (8, 14-19). Previous studies have indicated that CXCR2 is important in 
OPC proliferation and migration during development and Cxcr2 -/- mice show spatial 
alterations in OPC levels in the CNS and a decrease in white matter and myelin thickness 
in the spinal cord of adult mice (20, 21). Since CXCR2 is important in OLCs during 
development, we wanted to better understand its role in PLP+ OLCs during 
demyelination/remyelination in MS mouse models. As such, we developed mice in which 
we could selectively ablate Cxcr2 within oligodendroglia upon tamoxifen treatment and 
this allowed us to better understand the functional role of this receptor in disease and 
repair in JHMV-infected mice as well as animals with EAE.  
Our findings argue that genetic ablation of CXCR2 in oligodendroglia was not 
important in the clinical course of both MOG35-55 EAE and JHMV-infected mice. No 
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differences in the recruitment of T cells, neutrophils, or macrophages into the CNS 
during either JHMV or MOG35-55 EAE were observed. Nor was there a difference in Th1, 
Th17, or Th1/Th17 cells in EAE or viral specific T cells during JHMV infection. In vitro 
deletion of CXCR2 from oligodendroglia did not alter myelin protein alterations, MBP 
and CNPase (12, 21, 22). Collectively, these findings would argue that CXCR2 signaling 
in oligodendroglia does not influence either demyelination or remyelination in 
neuroinflammatory models of demyelination yet is important in positional migration of 
OPCs and myelination during development. 
 
6.3 Future directions 
The FDA-approved drugs for MS patients have focused on the adaptive immune 
response, although none completely subside symptoms or relapse, thus designing drugs 
that modulate the innate immune system need to be tested. There has been limited direct 
evidence for neutrophils in MS patients due to limited autopsy tissue samples and due to 
the short-lived nature (6-8 hours in humans) of these cells (23, 24). Neutrophils can 
release toxic factors including microbicidal granules such as cathepsin G, reactive oxygen 
and nitrogen species, neutrophil extracellular traps (NETs), MMPs, and many cytokines 
and chemokines, as well as their ability to phagocytize pathogens (1, 25-28). Although 
neutrophils are short-lived, bystander destruction of host cells and tissue including axons 
and oligodendrocytes can occur through NADPH oxidase producing both nitric oxide 
(NO) and reactive oxygen species (ROS), which has been shown to increase oxidative 
stress, inflammation, and ischemia-reperfusion damage in the brain in a mouse model of 
ischemic injury has been observed (29-32). Neutrophils have been shown to enhance 
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spinal cord lesions in patients with NMO and blocking neutrophil elastase in a mouse 
model of NMO decreased neuroinflammation and demyelination (33-35). Neutrophils 
and nitric oxide synthase production enhanced glial cell death in the brains of virally 
infected mice (36). It has been proposed that neutrophils may augment macrophage 
recruitment as well as antigen presentation (6). In the MOG35-55 EAE model, it was 
observed that neutrophils activate macrophages and microglia express MHC class II and 
subsequently antigen presentation (6). CNS infiltrating neutrophils also contribute to 
disease by the production of many proinflammatory cytokines (6). During EAE, there is a 
distinct difference in cytokine expression between neutrophils in the CNS compared to 
the bone marrow and during JHMV infection neutrophils have been shown to produce 
MMP9 to aid in the breakdown of the BBB early during infection (2, 6) 
In MOG35-55 EAE, it has been shown that neutrophils within the CNS produce 
many proinflammatory cytokines including TNF-α, IL-6, IL-12/23p40, and IFN-γ, but 
not IL-10 or IL-17 (6). In vitro studies showed that CNS neutrophils are important in 
enhancing MHC class II, CD80, and CD86 on bone marrow dendritic cells, but could not 
pinpoint the cytokine or other mechanism of how neutrophils accomplished this feat (6). 
In addition, neutrophils do not present MHC class II, although they reportedly increase 
the APC capacity of microglia/macrophages, but without altering levels of antigen-
specific CD4+ T cells (6). This article was the first to show a specific role for neutrophils 
in MOG35-55 EAE, although it did not determine a mechanism. It was found that 
myeloperoxidase and neutrophil elastase did not alter overall clinical score in MOG35-55 
EAE mice, suggesting is not important in pathogenesis of disease (6). In JHMV infection, 
we now know that neutrophils express MMP-9 and aid in breakdown of the BBB (2). The 
116 
 
observation that neutrophils increasing morbidity viral and autoimmune models of MS 
combined with from Segal and colleagues reporting an increase in CXCL1, CXCL5, and 
neutrophil elastase in MS patient’s serum correlating with MS lesion burden suggests that 
targeting ELR(+) CXC chemokines or its receptor may be used as novel therapies to treat 
MS (37). Therefore, future studies will require understanding specifically how 
neutrophils contribute to neurologic disease and specifically demyelination. 
We know that expression of CXCR2 on OPCs are important in proliferation and 
migration during development and adult mice that are Cxcr2 -/- show an altered spatial 
formation of OPCs, decreased myelin thickness in the spinal cord, and impaired 
remyelination (20-22). To understand the mechanism of impaired remyelination by 
CXCR2 within the CNS, the first CNS resident cell types to look at were OLCs. The 
recent article by Ransohoff and colleagues demonstrated that genetic ablation of CXCR2 
in oligodendroglia enhanced remyelination arguing that CXCR2 signaling may impede 
OPC maturation and/or myelin synthesis in non-inflammatory models of demyelination 
(38). We are currently analyzing remyelination in both of these mouse models to see if 
CXCR2 on OLCs impedes myelin repair. To better understand the mechanism of CXCR2 
in myelin repair, future studies will require the ablation of CXCR2 from other resident 
glial cell populations that have been shown to express CXCR2 including astrocytes, 
microglia, and neurons followed by observations of alterations in the 
pathogenesis/myelin repair in mouse models of demyelination. Overall, these studies all 
suggest that the development of drugs to block CXCR2 may aid in decreasing clinical 
symptoms in MS patients either by impeding neutrophil recruitment to the CNS or 
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The oral drug FTY720 affects sphingosine-1-phosphate (S1P) signaling on targeted cells that bear the
S1P receptors S1P1, S1P3, S1P4, and S1P5. We examined the effect of FTY720 treatment on the biology
of mouse neural progenitor cells (NPCs) after transplantation in a viral model of demyelination.
Intracerebral infection with the neurotropic JHM strain of mouse hepatitis virus (JHMV) resulted in an
acute encephalomyelitis, followed by demyelination similar in pathology to the human demyelinating
disease, multiple sclerosis. We have previously reported that intraspinal transplantation of mouse NPCs
into JHMV-infected animals resulted in selective colonization of demyelinated lesions, preferential
differentiation into oligodendroglia accompanied by axonal preservation, and increased remyelination.
Cultured NPCs expressed transcripts for S1P receptors S1P1, S1P2, S1P3, S1P4, and S1P5. FTY720
treatment of cultured NPCs resulted in increased mitogen-activated protein kinase phosphorylation and
migration after exposure to the chemokine CXCL12. Administration of FTY720 to JHMV-infected mice
resulted in enhanced migration and increased proliferation of transplanted NPCs after spinal cord
engraftment. FTY720 treatment did not improve clinical disease, diminish neuroinﬂammation or the
severity of demyelination, nor increase remyelination. These ﬁndings argue that FTY720 treatment
selectively increases NPC proliferation and migration but does not either improve clinical outcome or
enhance remyelination after transplantation into animals in which immune-mediated demyelination is
initiated by the viral infection of the central nervous system. (Am J Pathol 2015, 185: 2819e2832;
http://dx.doi.org/10.1016/j.ajpath.2015.06.009)
Intracranial infection with the neurotropic JHM strain of
mouse hepatitis virus (JHMV) results in an acute encepha-
lomyelitis, followed by chronic demyelination characterized
by viral persistence within the central nervous system
(CNS), axonal damage, and demyelination.1e7 Previous
studies from our laboratory have used the JHMV model of
neuroinﬂammation-mediated demyelination to evaluate
the therapeutic beneﬁt of mouse neural progenitor cell
(NPC) engraftment on remyelination.8e10 Transplantation
of mouse NPCs into the spinal cords of JHMV-infected
mice results in extensive migration and colonization
of areas of white matter damage and preferential
differentiation into oligodendroglia.8e10 Engrafted NPCs
physically engage damaged axons, and this ultimately
leads to increased axonal integrity that correlates with
remyelination.8,11 These ﬁndings, along with others,12e14
argue that engraftment of NPCs may provide an important
unmet clinical need for treatment of human demyelinating
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diseases, including multiple sclerosis (MS), by facilitating
sustained remyelination that can restore motor function
and ameliorate clinical symptoms.
After engraftment of NPCs into the spinal cords of
JHMV-infected mice, transplanted cells migrate both rostral
and caudal from the implantation site.8,9 The chemokine
ligand CXCL12 is enriched within areas of demyelination,
and transplanted NPCs express the signaling receptor
CXCR4, resulting in colonization of areas of white matter
damage. Blocking CXCR4 signaling on NPC trans-
plantation impaired NPC migration, arguing for an impor-
tant role for this chemokine signaling pathway in
contributing to repair by mediating trafﬁcking to sites of
myelin damage.9 However, the molecular mechanisms
governing positional migration of NPCs are likely complex
and consist of additional soluble factors that affect the
ability of NPCs to effectively congregate within areas of
white matter pathology.
Among potential molecules that may inﬂuence migration
is the lysophospholipid sphingosine-1-phosphate (S1P) that
is well documented in controlling proliferation and migra-
tion of numerous cell types.15e18 Although the importance
of S1P signaling in controlling lymphocyte homing and
egress from lymphatic tissues is well documented,19e21
increasing evidence indicates a functional role within the
CNS as glia and neurons express different combinations of
speciﬁc signaling receptors S1P1, S1P2, S1P3, S1P4, and
S1P5.22,23 Activation of these receptors yields different ef-
fects on migration and survival of astrocytes, microglia, and
oligodendrocytes.24e26 In addition, NPCs express S1P re-
ceptors, and signaling has previously been reported to in-
ﬂuence in vitro differentiation.27 Moreover, Kimura et al28
demonstrated an important role for S1P signaling in con-
trolling migration of transplanted NPCs to an injury site in a
model of spinal cord injury.
We examined the functional role of S1P signaling after NPC
transplantation into the spinal cords of JHMV-infected mice.
FTY720 is a U.S. Food and Drug Administrationeapproved
oral drug for treatment of patients with relapsing
MS.22,23,29e31 FTY720 exerts immunomodulatory effects that
reduce acute relapses, new lesion formation, and disability
progression and brain volume loss in MS patients.32 The
mechanism(s) behind FTY720 functions are not yet deﬁned;
however, the phosphorylated active form of FTY720
(FTY720P) is an S1P receptormodulator that inhibits egress of
lymphocytes from lymph nodes. FTY720 is a functional
antagonist of S1P1 on lymphocytes,20 yet also can act as a
nonselective agonist of S1P1, S1P3, S1P4, and S1P5.33
Therefore, the available evidence suggests that cellular
source and receptor expression proﬁle are critical in terms of
how FTY720 affects S1P signaling, and likely lead to a
dampening of autoreactive T cells speciﬁc for myelin antigens
inﬁltrating into the CNS.More important, FTY720, because of
its lipophilic nature, penetrates the blood-brain barrier and
readily enters the CNS parenchyma. Furthermore, FTY720P is
detected in situ, suggesting that it may inﬂuence the biology of
resident cells of the CNS. Our ﬁndings reveal that treatment of
cultured NPCs with FTY720P led to an active signaling
response, as determined by phosphorylation of mitogen-
activated protein (MAP) kinase, yet did not inﬂuence lineage
fate commitment. FTY720 treatment of JHMV-infected mice,
transplanted with NPCs, demonstrated enhanced migration
associated with increased numbers of NPCs compared with
vehicle-treated control animals. FTY720 treatment did not
affect the accumulation of T cells or macrophages within the
CNS. Finally, after treatment in animals in which demyelin-
ation is established, FTY720 did not augment the effects of
NPCs on inﬂuencing remyelination, indicating a selective




Age-matched (5 to 7 weeks) S1P1 enhanced green ﬂuo-
rescent protein (eGFP) knock-in mice (C57BL/6 back-
ground)34 and C57BL/6 mice were anesthetized with an i.p.
injection of 150 mL of a mixture of ketamine (Western
Medical Supply, Arcadia, CA) and xylazine (Phoenix
Pharmaceutical, Saint Joseph, MO) in Hanks’ balanced salt
solution. Mice were injected intracranially with 150 plaque-
forming units of JHMV (strain V2.2-1) suspended in 30 mL
saline.9 Clinical severity was assessed by blinded in-
vestigators (T.E.L. and C.A.B.) using a previously described
four-point scoring scale.35 FTY720 (2-amino-2-[2-(4-
octylphenyl) ethyl]-1,3-propanediol, hydrochloride) and
FTY720P (2-amino-2 [2-(4-octylphenyl) ethyl]-1,3-
propanediol, mono dihydrogen phosphate ester) were
purchased from Cayman Chemical Co (Ann Arbor, MI).
FTY720 or the vehicle was administered by daily i.p.
injections of 100 mL, starting at day 13 postinfection
(p.i.). Experiments for all animal studies were reviewed
and approved by the University of Utah (Salt Lake City)
and the University of California (Irvine) Institutional
Animal Care and Use Committees.
NPC Isolation and Culture
Neurosphere cultures were prepared from brains of perinatal
S1P1 eGFP knock-in mice, as previously described.8,36
Brieﬂy, dissected striata were razor minced and triturated
in 0.05% trypsin for 10 minutes, followed by anti-trypsin to
inactivate the digestion. Single cells were resuspended in
Dulbecco’s modiﬁed Eagle’s medium:F12 (Invitrogen,
Carlsbad, CA) supplemented with B27 (Invitrogen), insulin-
transferrin-selenium-X (Invitrogen), penicillin-streptomycin
(Invitrogen), 40 ng/mL T3 (T67407; Sigma, St. Louis,
MO), and 20 ng/mL human recombinant epidermal growth
factor (E9644; Sigma). Cells were cultured for 6 days with
replacement of media every other day, at which point
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mature neurospheres were isolated and GFP expression was
visualized by ﬂuorescence microscopy.
PCR
Total RNA was extracted from neurospheres, DNase treated,
and puriﬁed via phenol-chloroform extraction. cDNA was
synthesized with a reverse transcription kit superscript VILO
(Invitrogen), according to the manufacturer’s instructions.
The following primers were used to identify S1P1-S1P5
mRNA expression: S1P1, 50-TTTCCATCGCCATCCTC-
TAC-30 (forward) and 50-GCAGGCAATGAAGACAC-
TCA-30 (reverse); S1P2, 50-TCTCAGGGCATGTCACTC-





(reverse); and S1P5, 50-GATCCCTTCCTGGGTCTAGC-
30 (forward) and 50-TAGAGCTGCGATCCAAGGTT-30
(reverse). Primers were purchased from Invitrogen.
Sequencing of PCR amplicons conﬁrmed primer speciﬁcity.
Western Blot Analysis
NPCs were plated on Matrigel-coated 6-well plates and treated
with either 100 nmol/L FTY720 phosphate or vehicle for 5
minutes, 30 minutes, 1 hour, 2 hours, and 4 hours. The cells
were then lysed using radioimmunoprecipitation assay buffer
[50 mmol/L Tris-HCL (pH 7.4), 175 mmol/L NaCl, 5 mmol/L
EDTA, 1% NP-40, 0.1% SDS, and 0.5% deoxycholic acid]
supplemented in protease and phosphatase inhibitors (Roche).
P44/42 MAP kinase (1:2000; Cell Signaling, Danvers, MA)
and phosphorylated p44/42 MAP kinase (1:15,000; Cell
Signaling) were detected by Western blot analysis using
horseradish peroxidaseeconjugated secondary antibodies
(1:25,000; Jackson ImmunoResearch Laboratory, West Grove,
PA) and exposed to Supersignal West-Femto chemilumines-
cent reagent (Pierce, Rockford, IL).
NPC Differentiation
To assess differentiation potential, NPCs expressing
GFP8,9,11,37 were grown on Matrigel-coated chamber slides
with epidermal growth factor for 24 hours, at which point
growth factor was removed and NPCs were allowed to
differentiate for up to 7 days.8 Cells were treated daily with
100 nmol/L FTY720P or vehicle subsequently ﬁxed in 4%
paraformaldehyde for 20 minutes at room temperature.
Immunoﬂuorescence was performed using established
protocols: rabbiteanti-mouse Olig 2 (1:200; Millipore,
Darmstadt, Germany), rabbiteanti-mouse glial ﬁbrillary
acidic protein (1:1000; Invitrogen), mouseeanti-mouse Map2
(1:750; Sigma), Alexa-594 anti-rabbit (1:500; Invitrogen), and
anti-mouse (1:1000; Invitrogen) were used as secondary an-
tibodies. Samples were then washed in phosphate-buffered
saline (PBS), and coverslip was mounted with DAPI Vecta-
shield Mounting Medium (Vector Laboratories, Burlingame,
CA). The percentage of immunopositive cells for each stain
was determined by dividing the total number of immuno-
positive cells by the total number of DAPI-positive cells.
NPC Transplantation
Transplantation was performed on day 14 p.i. with JHMV, at
which point infected mice have established demyelin-
ation.8,9,11 Mice were anesthetized with an i.p. injection of
150 mL of a mixture of ketamine (Western Medical Supply,
Arcadia, CA) and xylazine (Phoenix Pharmaceutical, Saint
Joseph, MO) in Hanks’ balanced salt solution, a laminectomy
was performed at T9, and 2.5! 105 NPCs resuspended in 2.5
mL solution were injected into the spinal cord using a 10-mL
Hamilton syringe, as previously described.8,38e40 Recipient
mice also received daily i.p. injections of 3 mg/kg FTY720
starting at day 13 p.i., whereas a control group received
vehicle starting at day 13 p.i.
NPC Chemotaxis
In vitro chemotaxis assays were performed using aNeuroProbe
ChemoTx system, according to the manufacturer’s protocol.
Brieﬂy, GFP-NPCs treated with 100 nmol/L, 10 nmol/L, and 1
mmol/L FTY720P or vehicle control were allowed to migrate in
response to recombinant mouse CXCL12 (Peprotech, Rocky
Hill, NJ). Migration after 16 hours of culture was assessed by a
ﬂuorescent microplate reader (Synergy H1; BioTek, Winooski,
VT), according to manufacturer’s speciﬁcations.
Histology
Spinal cords were isolated at deﬁned time points and ﬁxed
overnight with 4% paraformaldehyde at 4"C. Individual
spinal cords were divided into sections, and twelve coronal
sections (1 mm thick) were cryoprotected in 20% sucrose
and embedded in OCT (VWR, Radnor, PA). Coronal sec-
tions (8 mm thick) were cut, and sections were stained with
luxol fast blue. Areas of total white matter and demyelinated
white matter were determined with ImageJ software version
1.48 (NIH, Bethesda, MD; http://imagej.nih.gov/ij).41
Demyelination was scored as a percentage of total demye-
lination along the entire length of the spinal cord. The total
numbers of GFP-positive cells were determined in each of
the twelve spinal cord sections surrounding the transplant
site by counting GFP-positive cells colocalized with DAPI-
positive nuclei. Determination of both the severity of
demyelination and numbers of GFP-positive cells was per-
formed blinded (T.E.L. and C.A.B.).
Electron Microscopy
Mice were perfused with 0.1 mol/L cacodylate buffer con-
taining 2% paraformaldehyde/2% glutaraldehyde, and spinal
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cords were isolated, and then embedded in Epon (Danbury,
CT) epoxy resin. Serial ultrathin sections were stained with
uranyl acetateelead citrate and analyzed as previously
described. Images at !1200 magniﬁcation were analyzed for
g-ratio using ImageJ software.42 A minimum of 150 axons
were analyzed per mouse, and the g-ratio was calculated by
dividing the axon diameter by the total ﬁber diameter.
Immunoﬂuorescence
For immunophenotyping of glial cells, ﬁxed spinal cord sec-
tions were incubated in 10% normal goat serum (Jackson
ImmunoResearch, West Grove, PA) and 1% bovine serum
albumin for 1 hour at room temperature. This was followed by
an overnight incubation at 4"C with the following primary
antibodies in 1% bovine serum albumin: rabbit anti-mouse
glutathione S-transferase (GST)-p (1:1000; MBL, Interna-
tional Corporation, Woburn MA), rabbiteanti-mouse glial
ﬁbrillary acidic protein (GFAP; 1:1000; Invitrogen), and
rabbiteanti-mouse Ki-67 (1:300; Abcam, Cambridge, MA).
Sections were then washed in PBS and incubated for 1 hour
at room temperature with Alexa ﬂuorescent-conjugated
secondary antibodies (goateanti-rabbit Alexa 594 or
goateanti-mouse Alexa 594; 1:1000 in PBS; Invitrogen).
Next, sections were washed in PBS and coverslip mounted
using DAPI Vectashield Mounting Medium (Vector Labo-
ratories). The percentage of immunopositive cells for each
stain was determined by dividing the total number of
immunopositive cells by the total number of DAPI-positive
cells.
Cell Isolation and Flow Cytometry
Brain, spinal cords, and blood were isolated at day 21 or 28
p.i. from infected mice treated with 3 mg/kg FTY720 or
vehicle, starting at day 13 p.i. and transplanted with GFP-
labeled NPCs. By using previously described protocols,41
tissues were then homogenized and immunophenotyped
by ﬂow cytometry using the following antibodies: rateanti-
mouse CD4-allophycocyanin (1:50; Biolegend, San Diego,
CA), rateanti-mouse CD8-allophycocyanin (1:50; Biolegend),
S510 to S518 tetramer-phosphatidylethanolamine (1:300;
NIH), and M133 to M147 tetramer-phosphatidylethanolamine
(1:150; NIH). Blood was collected by cardiac heart punc-
ture, and cells were stained with rateanti-mouse CD4-
allophycocyanin and CD8-phosphatidylethanolamine after
red blood cell lysis. Samples were analyzed using a
BD-Fortessa X-20 Flow Cytometer (BD Biosciences,
Franklin Lakes, NJ).
Results
FTY720 Treatment Activates Cultured NPCs
FTY720 functions as both an antagonist and agonist for
members of the S1P receptor family whose natural ligand
is S1P. Previous studies have demonstrated that FTY720
preferentially binds S1P1, S1P3, S1P4, and S1P5 re-
ceptors, including lower afﬁnity for S1P4, but does not
bind to S1P2.19 We tested whether mouse NPCs expressed
S1P receptors and if FTY720 treatment affected deﬁned
responses. Neurospheres were isolated from the subventricular
zone of day 1 old eGFP-S1P1 knock-in mice,8,36 and
immunoﬂuorescence conﬁrmed that NPCs express S1P1,
as evidenced by GFP expression (Figure 1A). Subsequent
analysis of additional S1P receptor expression by RT-PCR
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Figure 1 FTY720 treatment activates cultured neural progenitor cells
(NPCs). Neurospheres were isolated from the subventricular zone of
sphingosine-1-phosphate receptor 1 (S1P1) enhanced green ﬂuorescent
protein (eGFP) neonatal pups. A: Representative immunoﬂuorescence
images conﬁrm that neurospheres express S1P1, as evidenced by GFP
expression. B: Analysis of S1P receptor expression by NPCs at the mRNA
level demonstrates expression of transcripts speciﬁc for S1P1 to S1P5; the
sequence of amplicons conﬁrmed primer speciﬁcity. C: Western blot
analysis of cultured NPCs treated with either vehicle or 100 nmol/L
phosphorylated active form of FTY720 (FTY720P) reveals increased
phosphorylation over time. D: Quantitative analysis of Western blot data
conﬁrms increased phosphorylation of mitogen-activated protein kinase
(MAPK). Analyses of band intensity on ﬁlms are presented as the relative
ratio of phosphorylated MAPK/actin. BF, brightﬁeld microscopy; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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S1P receptors (Figure 1B). Previous studies have
demonstrated that FTY720 treatment activates several
intracellular signaling cascades, including phosphoryla-
tion of MAP kinase.43,44 Treatment of cultured NPCs
with the activated FTY720P (100 nmol/L) resulted in
phosphorylation of MAP kinase in a time-dependent
manner, indicating receptor binding and activation
(Figure 1, C and D). These ﬁndings support earlier
studies15 demonstrating that NPCs express S1P receptors
and FTY720 treatment initiates activation of intracellular
signaling pathways.
FTY720 Does Not Affect NPC Differentiation
We next tested whether exposure of cultured NPCs to
FTY720 inﬂuenced lineage fate commitment. Under deﬁned
conditions, cultured NPCs will preferentially differentiate




















































Figure 2 FTY720 does not affect neural progenitor cell (NPC) differentiation. Exposure of cultured NPCs to daily 100 nmol/L phosphorylated active form of
FTY720 (FTY720P) for 5 days does not inﬂuence lineage fate commitment to either oligodendroglia (Olig2; A), neurons [mitogen-activated protein (Map) 2; B],
and astrocytes [glial ﬁbrillary acidic protein (GFAP); C] compared with vehicle-controletreated cultures. D: Quantiﬁcation of immunocytochemical staining for
deﬁned cell lineages indicates similar frequencies of Olig2-, MAP2-, and GFAP-positive cells after treatment of cultured NPCs with either vehicle or FTY720P.
Data were presented as means ! SEM (D). n Z 3 independent experiments (D).
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Figure 3 FTY720 treatment enhances migration of engrafted green ﬂuorescent protein (GFP)eneural progenitor cells (NPCs). JHMV-infected mice were
treated with FTY720 (3 mg/kg daily via i.p. injection) or vehicle control beginning at day 13 postinfection (p.i.). GFP-expressing NPCs were transplanted into
the spinal cords at day 14 p.i., and migration of transplanted cells rostral and caudal to the implantation site was assessed 3 weeks posttransplant (p.t.). A:
Transplanted GFP-NPCs migrate both rostral and caudal from the implantation site in both control and FTY720-treated mice. Images represent spinal cord
sections rostral (1 to 4) and caudal (5 to 8) from the transplantation site. B: Transplanted GFP-NPCs congregate within areas of demyelination located in the
anterior and lateral funiculus in both FTY720-treated mice and vehicle control. C: Quantiﬁcation of GFP-NPC cell numbers at deﬁned spinal cord sections rostral
and caudal to the implantation site in vehicle control and FTY720-treated animals. D: Representative images depicting Ki-67 staining by transplanted GFP-NPCs
in vehicle control and FTY720-treated mice. Arrowheads represent Ki-67þ transplanted GFP-NPCs. E: Quantiﬁcation of GFP-NPCs expressing Ki-67. Data
are presented as means " SEM (C and E). n Z 2 or more independent experiments with n Z 4 or more mice per group (C and E). *P < 0.05,
**P < 0.01.
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also present.8,9 Exposure of NPCs to 100 nmol/L FTY720P
did not inﬂuence differentiation because we detected similar
frequencies of oligodendroglia (Olig2 positive), astrocytes
(GFAP), and neurons (Map2) when compared with vehicle-
controletreated cultures (Figure 2, AeD). Therefore, S1P
receptor antagonism does not affect NPC differentiation.
FTY720 Treatment Enhances Migration of Engrafted
GFP-NPCs
To test if FTY720 affects migration of engrafted NPCs, JHMV
and GFP-expressing NPCs (GFP-NPCs) were transplanted into
the spinal cord at day 14 p.i.,8,11,37,39 and FTY720 treatment
(3 mg/kg, daily, via i.p. injection) was initiated at day 13 p.i.
Control groups consisted of JHMV-infected mice transplanted
with GFP-NPCs treated with vehicle only.Mice were sacriﬁced
at 3 weeks posttransplant, and GFP-NPC distribution was
assessed histologically in spinal cord cross sections. In both
FTY720 and vehicle-treated control mice, GFP-NPCs were
distributed rostral and caudal from the implantation site and
colonized areas of demyelination within the ventral funiculus
and lateral white matter columns (Figure 3, A and B). Quanti-
ﬁcation of GFP-NPCs in deﬁned spinal cord sections rostral and
caudal to the implantation site indicated a signiﬁcant (P< 0.05)
increase in numbers of GFP-NPCs in FTY720-treated animals
when compared with vehicle-treated mice (Figure 3C).
Immunostaining for Ki-67 revealed increased numbers of
Ki-67epositive GFP-NPCs throughout the spinal cord in
FTY720-treated mice, consistent with increased proliferation
(Figure 3, D and E).
These ﬁndings suggest a role in S1P receptor antagonism in
controlling proliferation and/or migration of NPCs engrafted
into the spinal cord.We have previously shown that CXCL12 is
critical in controlling the positional migration of engrafted
NPCs by signaling through CXCR4 expressed on the surface of
NPCs.9 Furthermore, Kimura et al45 have reported that FTY720
treatment promotes migration of human CD34þ hematopoietic
progenitor cells by enhancing CXCR4 function. CulturedNPCs
were treated with increasing concentrations of FTY720P (10
nmol/L, 100 nmol/L, and 1 mmol/L), and the in vitromigration
in response to 200 ng/mL recombinant mouse CXCL12
resulted in a dose-dependent migration response (Figure 4A).
Flow analysis revealed that FTY720 treatment did not affect
surface expression of CXCR4 at any concentration tested
(Figure 4, B and C). Therefore, administration of FTY720 en-
hances migration of NPCs potentially by enhancing CXCR4
function, consistent with earlier studies.45
FTY720 Treatment of NPC-Transplanted Mice Does Not
Affect NPC Differentiation or Demyelination
FTY720 did not affect clinical disease in JHMV-infected
mice, regardless if transplanted with GFP-NPCs or treated
with vehicle (data not shown). We next examined if FTY720
treatment inﬂuenced the ability of engrafted NPCs to differ-
entiate into oligodendroglia, because our previous studies have
shown that most transplanted cells preferentially differentiate
into these cells.8,9 By 14 days posttransplant, FTY720 did not
affect lineage fate commitment of NPCs because similar fre-
quencies of GST-pepositive cells (a marker for mature
myelin-producing oligodendrocytes) were observed in
FTY720 versus vehicle-treated mice (Figure 5, A and B). The
severity of spinal cord demyelination in transplanted mice
treated with FTY720 was examined by staining serial coronal
sections rostral and caudal to the implantation site with luxol
fast blue and quantifying the percentage of white matter
damage.41,42 By day 14 posttransplant, the severity of demy-
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Figure 4 FTY720 does not affect CXCR4 expression by neural progenitor cells (NPCs). A: Cultured NPCs were treated with increasing concentrations of
phosphorylated active form of FTY720 (FTY720P; 10 nmol/L, 100 nmol/L, and 1 mmol/L), and migration in response to 200 ng/mL recombinant mouse CXCL12
was determined after 16 hours. Exposure to FTY720P results in a dose-dependent migration response. B: Representative ﬂow analysis reveals that FTY720
treatment does not affect surface expression of CXCR4 by cultured NPCs at a deﬁned concentration. C: This is conﬁrmed by quantiﬁcation of mean ﬂuorescence
intensity of CXCR4 expression of cultured cells under experimental conditions. Data are given as means " SEM (A and C). nZ 2 independent experiments (A);
n Z 3 independent experiments (C). ***P < 0.001. Max, maximum.
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FTY720 when compared with control animals (Figure 5, C
and D). Electron microscopic analysis of spinal cords from
experimental mice was performed to better assess whether
FTY720 treatment of mice promoted remyelination. Deter-
mination of the g-ratio, the ratio of the inner axonal diameter/
the total outer ﬁber diameter, is an established structural index
of remyelination, with lower ratios indicating more extensive
remyelination.42 Regions of spinal cord ventral and lateral
white matter tracts of JHMV-infected mice, transplanted with
GFP-NPCs and treated with FTY720 or vehicle, and JHMV-
infected mice treated with vehicle or FTY720 alone were
analyzed (Figure 6A).
We ﬁrst determined whether FTY720 treatment alone
increased remyelination in JHMV-infected mice. Our ﬁndings
indicate that, although there was an overall trend toward
remyelination after FTY720 treatment compared with control
mice, this did not reach signiﬁcance (Figure 6, B, C, and F).
Increased remyelination was observed in JHMV-infected mice
that were transplanted with GFP-NPCs compared with vehicle
treatment alone (Figure 6, B, D, and F). However, FTY720 did
not result in a signiﬁcant increase in remyelination in GFP-
NPCetreated animals compared with transplanted animals
treated with vehicle alone (Figure 6, B, E, and F). Therefore,
these ﬁndings argue that FTY720 treatment does not enhance
remyelination in JHMV-infectedmice regardless if transplanted
with GFP-NPCs.
Treatment with FTY720 Does Not Affect
Neuroinﬂammation in JHMV-Infected Mice
We have previously determined that FTY720 treatment of
JHMV-infected mice during acute disease results in
A






















Figure 5 FTY720 does not decrease the severity of demyelination. Mice were infected with 150 plaque-forming units of JHMV and 3 mg/kg FTY720 or
control vehicle treatment initiated at day 13 postinfection (p.i.) and transplanted with green ﬂuorescent protein (GFP)eneural progenitor cells (NPCs) at day
14 p.i. In addition, JHMV-infected mice treated with FTY720 or vehicle alone served as an additional control. A: Representative glutathione S-transferase
(GST)-p immunoﬂuorescence staining of spinal cords isolated at day 14 posttransplant (p.t.) from JHMV-infected mice engrafted with GFP-NPCs at day 14 p.i.
and treated with either FTY720 or control at day 13 p.i. Arrowheads represent GST-pepositive transplanted GFP-NPCs. B: Similar frequencies of GFP-positive
mature oligodendrocytes in GFP-NPCetransplanted mice treated with either FTY720 or vehicle. Twelve spinal cord sections per mouse were counted to
determine the frequency of transplanted GFP-NPCs that differentiated into GST-pepositive cells. C: Representative luxol fast blueestained spinal cord sections
from NPC-transplanted mice treated with either FTY720 or control vehicle, or nontransplanted mice treated with FTY720 or control vehicle at day 14 p.t. D:
Quantiﬁcation of demyelination indicates no differences in the severity of white matter damage in experimental groups of mice at day 14 p.t. Data are
presented as means ! SEM (B and D). nZ 2 independent experiments with nZ 4 or more mice per experimental group (B); nZ 2 independent experiments
with n Z 5 or more mice per experimental group (D). Scale bar Z 50 mm (A).
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increased mortality and limited inﬁltration of T cells into
the CNS, which correlated with impaired ability to control
viral replication within the CNS.41 We next examined
whether FTY720 treatment affected T-cell inﬁltration into
the CNS of mice either infected with JHMV or infected
and transplanted with GFP-NPCs. Mice were infected
intracranially with JHMV, and mice received daily i.p.
injections of FTY720 beginning at day 13 p.i. Flow anal-
ysis of T-cell inﬁltration into the spinal cords of infected
mice isolated at day 28 p.i. indicated no differences in
CD4þ or CD8þ T cells within the spinal cords of mice
treated with either FTY720 or vehicle alone (Figure 7, A
and B). Moreover, inﬁltration of virus-speciﬁc CD4þ and
CD8þ T cells was not affected after FTY720 treatment
(Figure 7, A and B).
Transplantation of GFP-NPCs into JHMV-infected mice
did not affect inﬁltration of total CD4þ and CD8þ T cells nor
virus-speciﬁc T cells into the spinal cord (Figure 7, C and D),
and this is consistent with our previously published studies.46
Similarly, administration of FTY720 to infected mice trans-
planted with GFP-NPCs did not prevent total T-cell or virus-
speciﬁc T-cell entry into the CNS (Figure 7, C and D). In
addition, FTY720 did not affect T-cell inﬁltration into the
brains of mice infected with JHMV alone or transplanted
with GFP-NPCs (data not shown). We conﬁrmed the bio-
logical activity of FTY720 during chronic disease by
examining levels of circulating T cells within the blood.
FTY720 signiﬁcantly (P< 0.05) diminished the frequency of
both CD4þ (Figure 8A) and CD8þ (Figure 8C) T cells within
the blood compared with control mice. In addition, by using
S1P1 eGFP knock-in mice, we determined that surface
expression of S1P1, measured by eGFP expression, was also
decreased (P < 0.05) on circulating CD4þ (Figure 8B) and
CD8þ T cells (Figure 8D) in FTY720-treated mice when
compared with control animals. Therefore, FTY720 treat-
ment of JHMV-infected mice results in diminished levels of
circulating lymphocytes that correlates with decreased S1P1
expression, and this is consistent with our earlier ﬁndings.41
These results indicate that FTY720 does not affect T-cell
migration into the CNS during chronic disease in animals,
regardless of whether transplanted with GFP-NPCs or
vehicle alone.
Discussion
The use of stem cells for treatment of human demyelinating
diseases, such as MS, to induce tissue repair offers an
attractive therapy for promoting remyelination and poten-
tially sustained clinical recovery.11,42,47e50 After spinal
cord engraftment of mouse NPCs into JHMV-infected mice,
NPCs preferentially migrate to sites of demyelination by
responding to the chemokine CXCL12 via expression of the
receptor CXCR4.9 However, it is likely that other signaling
cues are present within this inﬂammatory demyelinating
environment that inﬂuence NPC migration. The S1P/S1P1
axis has been shown to be involved in NPC migration to
sites of damage in a model of spinal cord injury highlighting
the importance of S1P receptors in mediating positional
migration of NPCs.28 Treatment of mice with FTY720
Figure 6 FTY720 treatment does not promote remyelination. A: Representative transverse spinal cord section; boxed areas indicate the regions in which
demyelinated and remyelinated axons were determined. Representative electron microscopic (EM) images of spinal cords of JHMVeinfected mice treated with
vehicle (VEH) alone (B), FTY720 (C), green ﬂuorescent protein (GFP)eneural progenitor cells (NPCs) and vehicle (D), and GFP-NPCs and FTY720 (E). Black
arrows indicate myelinated axons; white arrows, demyelinated axons; asterisks, remyelinated axons. F: Calculation of g-ratio, as a measurement of axonal
remyelination, shows no signiﬁcant differences between experimental mice. Data are presented as means " SEM (F). nZ 3 per group with nZ 150 or more
axons per mouse analyzed (F). Original magniﬁcation, #1200 (BeE).
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augments CXCR4 signaling and potentiates migration of
hematopoietic stem cells.45 Moreover, FTY720 readily
penetrates the CNS,19,24,33,51,52 arguing that it can modulate
the biology of transplanted NPCs by binding to S1P re-
ceptors. Indeed, Gonzalez-Cabrera et al53 have shown that
chronic FTY720 degrades and down modulates the receptor
in the CNS. FTY720 has a 17:1 brain/plasma ratio and is
accumulated in the brain, providing long-term steady-state
levels that drive complete receptor occupancy and degra-
dation. Therefore, we investigated the effects of FTY720
treatment in conjunction with NPC therapy in a viral model
of MS.
Herein, we show that FTY720 treatment of JHMV-
infected mice transplanted with GFP-NPCs results in
enhanced migration of transplanted cells when compared
with transplanted animals treated with vehicle control
(Figure 3, A and C). FTY720 treatment did not alter po-
sitional migration of transplanted NPCs because these cells
efﬁciently congregated within areas of demyelination
(Figure 3, A and B). The in vivo migration data support our
in vitro experimental results showing that FTY720
treatment of cultured NPCs increases migration after
exposure to recombinant mouse CXCL12, and this was
independent of elevated surface expression of CXCR4 on
NPCs (Figure 4, A and B). These ﬁndings argue that a
mechanism underlying enhanced NPC migration could
involve an effect on CXCR4 function and/or the down-
stream signaling cascade, such as calcium mobilization or
cytoskeleton rearrangement.
Previous studies have shown that FTY720 activates the
phosphorylation of CXCR4 through S1P3 activation, fol-
lowed by downstream cascade activation of Src kinase and
Janus-activating kinase 2 in progenitor cells,54 and affects
CXCR4-mediated migration in hematopoietic stem cells
after exposure to CXCL12.45
Future work focusing on deﬁning the speciﬁc S1P re-
ceptor(s) involved in elevated CXCR4 function will be
critical to better understand the molecular mechanisms
governing how receptor agonists/antagonists inﬂuence NPC
migration mediated by CXCR4.
Our ﬁndings also indicated increased numbers of GFP-














































































































































































































































































































Figure 7 Treatment with FTY720 does not affect neuroinﬂammation in JHMV infected mice. The effect of FTY720 treatment on T-cell inﬁltration into the
spinal cord after either JHMV infection alone or GFP-NPCs transplantation was examined. Spinal cords were removed at day 28 postinfection [p.i.; day 14
posttransplant (p.t.) of GFP-NPCs], and the frequency of total T-cell subsets and virus-speciﬁc T cells was determined. There is no difference in frequencies of
CD4þ (A) or CD8þ (B) T cells and virus-speciﬁc CD4þ (A) or CD8þ (B) T cells in JHMV-infected mice treated with either vehicle control or FTY720. FTY720 does
not reduce overall frequencies of inﬁltrating CD4þ (C) or CD8þ (D) T cells compared with vehicle-treated control mice nor are there differences in the fre-
quencies of virus-speciﬁc CD4þ (C) and CD8þ (D) T cells following spinal cord transplantation of GFP-NPCs. Data represent means " SEM (AeD). nZ 4 mice or
more per group (AeD).
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in JHMV-infected mice treated with FTY720 when
compared with transplanted mice treated with vehicle con-
trol, suggesting proliferation is increased in vivo. Collec-
tively, these results argue that FTY720 treatment increased
NPC migration and proliferation following engraftment.
We have recently shown that FTY720 treatment of
JHMV-infected mice during acute disease results in
increased mortality that is associated with impaired migra-
tion of virus-speciﬁc T cells into the CNS and elevated viral
titers within the CNS.41 Dampened neuroinﬂammation
correlated with increased cellularity of draining cervical
lymph nodes, consistent with previous reports indicating
that S1P antagonism impairs lymphocyte egress from
lymphatic tissue.19,20,51,52 More important, administration of
FTY720 to JHMV-infected mice during acute disease was
associated with diminished severity of demyelination. These
ﬁndings highlight an important role for S1P signaling in
host defense during acute viral-induced neurological dis-
ease, most likely by enhancing T cells to efﬁciently migrate
from lymphatic tissue into the CNS. In marked contrast, the
present study indicates that when FTY720 treatment is
initiated at day 13 p.i. with JHMV, there is no effect on
T-cell accumulation within the CNS, and the severity of
demyelination is not affected. We believe these differences
in outcomes with regard to neuroinﬂammation reﬂect the
stage of disease at which point FTY720 is administered. As
indicated above, FTY720 treatment during acute disease
limited egress of virus-speciﬁc T cells from draining cer-
vical lymph nodes, thereby reducing the severity of neuro-
inﬂammation and demyelination. By day 13 p.i., surviving
Figure 8 FTY720 induces lymphopenia and
down-regulates sphingosine-1-phosphate receptor
1 (S1P1) on T cells. Frequencies of CD4þ and CD8þ
T cells in the blood day 7 posttransplant with GFP-
NPCs into JHMV-infected S1P1 eGFP mice treated
daily with FTY720 or control starting at day 13
postinfection. FTY720 signiﬁcantly diminishes the
frequency of both CD4þ (A) and CD8þ (C) T cells
and S1P1 expression measured by GFP expression
on CD4þ (B) and CD8þ (D) T cells. Data are pre-
sented as means " SEM (AeD). n Z 2 or
more experiments with a minimum n Z 4 per
group (AeD). *P < 0.05. FSC, forward scatter.
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mice have reduced viral titers below the level of detection as
a result of inﬁltration of virus-speciﬁc T cells into the CNS
that can effectively control viral replication. Correspond-
ingly, treatment with FTY720 would have limited-to-no
effect on disease progression at this stage of disease
because the bulk of virus-speciﬁc lymphocytes have already
expanded and exited the draining cervical lymph nodes and
subsequently inﬁltrated the CNS. In addition, these data also
indicate that T cells do not rely on S1P signaling for T-cell
migration to the CNS during chronic disease but rather use
other inﬂammatory signaling cues (eg, chemokines) to gain
access to the CNS of JHMV-infected mice.2,55
Although FTY720 treatment of cultured NPCs resulted in
activation, increased proliferation, and enhanced migration in
response to CXCL12, there was no effect on lineage fate
commitment because similar frequencies of oligodendroglia,
astrocytes, and neurons were observed compared with
NPCs treated with control vehicle. Similar frequencies of
GFP-positive oligodendroglia expressing GST-p were detec-
ted within spinal cords of GFP-NPCetransplanted mice
treated with either FTY720 or vehicle control. Although there
were increased numbers of GFP-NPCs within areas of
demyelination in FTY720-treated mice, we did not observe
any discernable increase in remyelination. Whether this is
because of functional deﬁcits in these cells is currently
unknown and is the focus of ongoing studies.
We have previously shown that engrafted NPCs can
remyelinate demyelinated axons,11 and these ﬁndings
would argue that FTY720 does not increase the remyeli-
nation potential of engrafted NPCs in our model of viral-
induced demyelination. This is similar to previous
studies that determined that FTY720 does not induce
remyelination in either the cuprizone or lysophosphatidyl
choline models of demyelination.56 However, Miron et al57
have demonstrated that FTY720 treatment resulted in
increased remyelination in organotypic cerebral slices
where demyelination was induced by lysolecithin. These
ﬁndings support other studies demonstrating FTY720
treatment in augmenting neurogenesis and repair in models
of CNS injury, possibly by activating endogenous NPCs
and/or oligodendrocyte progenitor cells.58e62 We are
currently examining whether FTY720 activates endoge-
nous progenitor cells within the CNS of JHMV-infected
mice. The conﬂicting reports on the effects of FTY720
on remyelination highlight differences in model systems
used, emphasizing the potential importance of targeting
speciﬁc receptors for promoting OPC maturation and
myelin synthesis. For example, by using a lysophospha-
tidyl cholineeinduced model of demyelination, adminis-
tration of S1P5 agonist has been reported to have a greater
effect on remyelination compared with S1P1 agonists.63
FTY720 treatment of MS patients with the relapsing-
remitting form of disease reduced the risk of disability
progression; yet, it is not clear if this is because of an in-
crease in remyelination.64 The fact that we did not observe
any increase in remyelination in JHMV-infected mice
treated with FTY720 alone would argue additional studies
in preclinical models of MS with more selective S1P
receptor agonists or antagonists to better understand the
effects on both endogenous glial cells and transplanted
NPCs with regard to promoting remyelination.
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